BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//PULSENMORE | Home Ultrasound - ECPv6.16.4//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:PULSENMORE | Home Ultrasound
X-ORIGINAL-URL:https://pulsenmore.com
X-WR-CALDESC:Events for PULSENMORE | Home Ultrasound
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Asia/Jerusalem
BEGIN:DAYLIGHT
TZOFFSETFROM:+0200
TZOFFSETTO:+0300
TZNAME:IDT
DTSTART:20240329T000000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0300
TZOFFSETTO:+0200
TZNAME:IST
DTSTART:20241026T230000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0200
TZOFFSETTO:+0300
TZNAME:IDT
DTSTART:20250328T000000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0300
TZOFFSETTO:+0200
TZNAME:IST
DTSTART:20251025T230000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0200
TZOFFSETTO:+0300
TZNAME:IDT
DTSTART:20260327T000000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0300
TZOFFSETTO:+0200
TZNAME:IST
DTSTART:20261024T230000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0200
TZOFFSETTO:+0300
TZNAME:IDT
DTSTART:20270326T000000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0300
TZOFFSETTO:+0200
TZNAME:IST
DTSTART:20271030T230000
END:STANDARD
END:VTIMEZONE
BEGIN:VTIMEZONE
TZID:Europe/Moscow
BEGIN:STANDARD
TZOFFSETFROM:+0300
TZOFFSETTO:+0300
TZNAME:MSK
DTSTART:20240101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=Asia/Jerusalem:20260615T080000
DTEND;TZID=Asia/Jerusalem:20260618T170000
DTSTAMP:20260625T173159
CREATED:20260517T113814Z
LAST-MODIFIED:20260517T113814Z
UID:59354-1781510400-1781802000@pulsenmore.com
SUMMARY:HLTH Europe 2026
DESCRIPTION:Pulsenmore Announces Strategic Partnership with Ouma Health to Expand Access to Remote Prenatal Care Across the United States  \nFDA-authorized home ultrasound technology to be integrated into Ouma Health’s virtual maternity care model\, creating a scalable pathway to expand the adoption of home ultrasound in prenatal care across the United States  \nRamat Gan\, Israel\, June 24\, 2026 /PRNewswire/ Pulsenmore Ltd. (NASDAQ\, TASE: PLSM)\, a pioneer in home ultrasound technology\, today announced a strategic partnership with Ouma Health\, a leading provider of virtual maternity care solutions in the United States.  \nThrough the collaboration\, Ouma Health will incorporate Pulsenmore’s FDA-authorized home ultrasound platform as part of its virtual maternity care platform\, enabling clinicians to extend prenatal ultrasound monitoring beyond the clinic and into patients’ homes while maintaining continuous connection between expectant mothers and their care teams throughout pregnancy.  \nFor Pulsenmore\, the agreement represents a significant expansion of its presence in the U.S. maternal health market and an opportunity to integrate its home ultrasound platform into an established virtual care model serving expectant mothers nationwide.  \n“Maternal healthcare is undergoing a fundamental transformation toward more connected\, patient-centered care models\,” said Dr. Elazar Sonnenschein\, Founder and CEO of Pulsenmore. “By partnering with Ouma Health\, we have an opportunity to bring ultrasound beyond the walls of the clinic and into established virtual maternity care pathways\, helping healthcare professionals expand access to prenatal monitoring while keeping patients at the center of care. With 35% of U.S. counties classified as maternal care deserts\, virtual care models combined with home ultrasound technology will play an important role in closing critical access gaps for expectant mothers.”  \n“At Ouma\, we care for patients who often face significant geographic and logistical barriers to prenatal care\, including those living in maternity deserts and underserved communities\,” said Dr. Sina Haeri\, CEO of Ouma Health. “Pulsenmore’s technology gives us a way to bring more of the prenatal monitoring experience into the home\, while keeping patients connected to a clinical team that can review the information and guide next steps. This partnership helps us make virtual maternity care more clinically complete\, especially for patients who cannot easily access specialty care in person.  \nMaternal health remains one of the most critical areas of healthcare delivery in the United States. As healthcare organizations look for ways to improve access\, patient engagement\, and care coordination\, home ultrasound is emerging as a meaningful component of virtual and hybrid prenatal care models.  \nThe collaboration aims to deliver transformative care for the most underserved patients and establish insights and experience to support future expansion opportunities with healthcare systems\, maternity care providers\, and payer organizations seeking innovative approaches for maternal health delivery. Home ultrasound has the potential to become an important part of the next generation of prenatal care\, helping healthcare providers expand access\, improve patient engagement\, and deliver more connected pregnancy care beyond traditional clinical settings.  \nAbout Pulsenmore  \nPulsenmore Ltd. is dedicated to revolutionizing maternal health through home-use ultrasound technology that connects mothers and healthcare providers remotely. By leveraging advanced imaging and telemedicine\, Pulsenmore makes prenatal care patient-centric\, expanding access and improving continuity of care. For more information\, visit www.pulsenmore.com  \n  \nAbout Ouma Health  \nOuma Health is the nation’s largest independent maternity telemedicine company\, providing comprehensive care from preconception through postpartum. Founded and run by maternal-fetal medicine specialists\, Ouma is committed to equity\, innovation\, and outcomes\, serving patients in all 50 states through partnerships with major payors\, health systems\, OB groups\, FQHCs\, reproductive agencies\, and employers. For more information\, visit www.oumahealth.com.  \n  \nThis press release contains forward-looking statements. In particular\, statements using words such as “may\,” “seek\,” “will\,” “consider\,” “likely\,” “assume\,” “estimate\,” “expect\,” “anticipate\,” “intend\,” “believe\,” “contemplate\,” “do not believe\,” “aim\,” “goal\,” “due\,” “predict\,” “plan\,” “project\,” “continue\,” “potential\,” “positioned\,” “guidance\,” “objective\,” “outlook\,” “trends\,” “future\,” “could\,” “would\,” “should\,” “target\,” “on track” or their negatives or variations\, and similar terminology and words of similar import\, generally involve future or forward-looking statements. Such forward-looking statements include\, but are not limited to\, statements relating to the expected outcome of Pulsenmore’s engagement with OUMA. Forward-looking statements reflect Pulsenmore’s current views\, plans\, or expectations with respect to future events or financial performance. They are inherently subject to significant business\, economic\, competitive\, and other risks\, uncertainties\, and contingencies. Forward-looking statements are based on Pulsenmore’s current expectations and are subject to inherent uncertainties\, risks and assumptions that are difficult to predict\, including\, but not limited to\, the following: the Company’s lack of operating history; the Company’s current and future capital requirements and the Company’s belief that its existing cash will be sufficient to fund its operations for more than one year from the date that the financial statements are issued; the Company’s ability to manufacture\, market and sell its products and to generate revenues; the Company’s ability to maintain its relationships with key partners and grow relationships with new partners; the Company’s ability to maintain or protect the validity of its U.S. and other patents and other intellectual property; the Company’s ability to launch and penetrate markets in new locations and new market segments; the Company’s ability to retain key executive members and hire additional personnel; the Company’s ability to maintain and expand intellectual property rights; interpretations of current laws and the passages of future laws; the Company’s ability to achieve greater regulatory compliance needed in existing and new markets; the Company’s ability to achieve key performance milestones in its planned operational testing; the Company’s ability to establish adequate sales\, marketing and distribution channels; security\, political and economic instability in the Middle East that could harm its business; and acceptance of the Company’s business model by investors. Further\, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. For a more detailed description of the risks and uncertainties affecting the Company\, reference is made to the Company’s reports filed from time to time with the SEC\, including\, but not limited to\, the risks\, uncertainties and other factors included in the Company’s Form 20-F (SEC File No. 001-43033)\, filed with the SEC on December 29\, 2025. The inclusion of forward-looking statements in this or any other communication should not be considered as a representation by Pulsenmore or any other person that current plans or expectations will be achieved. Forward-looking statements speak only as of the date on which they are made\, and Pulsenmore undertakes no obligation to publicly update or revise any forward-looking statement\, whether as a result of new information\, future developments\, or otherwise\, except as otherwise required by law.  \n  \nInvestor Contact:  \n  \nMiri Segal-Scharia  \nMS-IR LLC  \nmsegal@ms-ir.com 
URL:https://pulsenmore.com/event/hlth-europe-2026/
ATTACH;FMTTYPE=image/png:https://pulsenmore.com/wp-content/uploads/2026/05/Screenshot-2026-05-17-143638.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Asia/Jerusalem:20260527T080000
DTEND;TZID=Asia/Jerusalem:20260528T170000
DTSTAMP:20260625T173159
CREATED:20260519T113514Z
LAST-MODIFIED:20260519T113514Z
UID:59652-1779868800-1779987600@pulsenmore.com
SUMMARY:Medtech Summit
DESCRIPTION:Pulsenmore Announces Strategic Partnership with Ouma Health to Expand Access to Remote Prenatal Care Across the United States  \nFDA-authorized home ultrasound technology to be integrated into Ouma Health’s virtual maternity care model\, creating a scalable pathway to expand the adoption of home ultrasound in prenatal care across the United States  \nRamat Gan\, Israel\, June 24\, 2026 /PRNewswire/ Pulsenmore Ltd. (NASDAQ\, TASE: PLSM)\, a pioneer in home ultrasound technology\, today announced a strategic partnership with Ouma Health\, a leading provider of virtual maternity care solutions in the United States.  \nThrough the collaboration\, Ouma Health will incorporate Pulsenmore’s FDA-authorized home ultrasound platform as part of its virtual maternity care platform\, enabling clinicians to extend prenatal ultrasound monitoring beyond the clinic and into patients’ homes while maintaining continuous connection between expectant mothers and their care teams throughout pregnancy.  \nFor Pulsenmore\, the agreement represents a significant expansion of its presence in the U.S. maternal health market and an opportunity to integrate its home ultrasound platform into an established virtual care model serving expectant mothers nationwide.  \n“Maternal healthcare is undergoing a fundamental transformation toward more connected\, patient-centered care models\,” said Dr. Elazar Sonnenschein\, Founder and CEO of Pulsenmore. “By partnering with Ouma Health\, we have an opportunity to bring ultrasound beyond the walls of the clinic and into established virtual maternity care pathways\, helping healthcare professionals expand access to prenatal monitoring while keeping patients at the center of care. With 35% of U.S. counties classified as maternal care deserts\, virtual care models combined with home ultrasound technology will play an important role in closing critical access gaps for expectant mothers.”  \n“At Ouma\, we care for patients who often face significant geographic and logistical barriers to prenatal care\, including those living in maternity deserts and underserved communities\,” said Dr. Sina Haeri\, CEO of Ouma Health. “Pulsenmore’s technology gives us a way to bring more of the prenatal monitoring experience into the home\, while keeping patients connected to a clinical team that can review the information and guide next steps. This partnership helps us make virtual maternity care more clinically complete\, especially for patients who cannot easily access specialty care in person.  \nMaternal health remains one of the most critical areas of healthcare delivery in the United States. As healthcare organizations look for ways to improve access\, patient engagement\, and care coordination\, home ultrasound is emerging as a meaningful component of virtual and hybrid prenatal care models.  \nThe collaboration aims to deliver transformative care for the most underserved patients and establish insights and experience to support future expansion opportunities with healthcare systems\, maternity care providers\, and payer organizations seeking innovative approaches for maternal health delivery. Home ultrasound has the potential to become an important part of the next generation of prenatal care\, helping healthcare providers expand access\, improve patient engagement\, and deliver more connected pregnancy care beyond traditional clinical settings.  \nAbout Pulsenmore  \nPulsenmore Ltd. is dedicated to revolutionizing maternal health through home-use ultrasound technology that connects mothers and healthcare providers remotely. By leveraging advanced imaging and telemedicine\, Pulsenmore makes prenatal care patient-centric\, expanding access and improving continuity of care. For more information\, visit www.pulsenmore.com  \n  \nAbout Ouma Health  \nOuma Health is the nation’s largest independent maternity telemedicine company\, providing comprehensive care from preconception through postpartum. Founded and run by maternal-fetal medicine specialists\, Ouma is committed to equity\, innovation\, and outcomes\, serving patients in all 50 states through partnerships with major payors\, health systems\, OB groups\, FQHCs\, reproductive agencies\, and employers. For more information\, visit www.oumahealth.com.  \n  \nThis press release contains forward-looking statements. In particular\, statements using words such as “may\,” “seek\,” “will\,” “consider\,” “likely\,” “assume\,” “estimate\,” “expect\,” “anticipate\,” “intend\,” “believe\,” “contemplate\,” “do not believe\,” “aim\,” “goal\,” “due\,” “predict\,” “plan\,” “project\,” “continue\,” “potential\,” “positioned\,” “guidance\,” “objective\,” “outlook\,” “trends\,” “future\,” “could\,” “would\,” “should\,” “target\,” “on track” or their negatives or variations\, and similar terminology and words of similar import\, generally involve future or forward-looking statements. Such forward-looking statements include\, but are not limited to\, statements relating to the expected outcome of Pulsenmore’s engagement with OUMA. Forward-looking statements reflect Pulsenmore’s current views\, plans\, or expectations with respect to future events or financial performance. They are inherently subject to significant business\, economic\, competitive\, and other risks\, uncertainties\, and contingencies. Forward-looking statements are based on Pulsenmore’s current expectations and are subject to inherent uncertainties\, risks and assumptions that are difficult to predict\, including\, but not limited to\, the following: the Company’s lack of operating history; the Company’s current and future capital requirements and the Company’s belief that its existing cash will be sufficient to fund its operations for more than one year from the date that the financial statements are issued; the Company’s ability to manufacture\, market and sell its products and to generate revenues; the Company’s ability to maintain its relationships with key partners and grow relationships with new partners; the Company’s ability to maintain or protect the validity of its U.S. and other patents and other intellectual property; the Company’s ability to launch and penetrate markets in new locations and new market segments; the Company’s ability to retain key executive members and hire additional personnel; the Company’s ability to maintain and expand intellectual property rights; interpretations of current laws and the passages of future laws; the Company’s ability to achieve greater regulatory compliance needed in existing and new markets; the Company’s ability to achieve key performance milestones in its planned operational testing; the Company’s ability to establish adequate sales\, marketing and distribution channels; security\, political and economic instability in the Middle East that could harm its business; and acceptance of the Company’s business model by investors. Further\, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. For a more detailed description of the risks and uncertainties affecting the Company\, reference is made to the Company’s reports filed from time to time with the SEC\, including\, but not limited to\, the risks\, uncertainties and other factors included in the Company’s Form 20-F (SEC File No. 001-43033)\, filed with the SEC on December 29\, 2025. The inclusion of forward-looking statements in this or any other communication should not be considered as a representation by Pulsenmore or any other person that current plans or expectations will be achieved. Forward-looking statements speak only as of the date on which they are made\, and Pulsenmore undertakes no obligation to publicly update or revise any forward-looking statement\, whether as a result of new information\, future developments\, or otherwise\, except as otherwise required by law.  \n  \nInvestor Contact:  \n  \nMiri Segal-Scharia  \nMS-IR LLC  \nmsegal@ms-ir.com 
URL:https://pulsenmore.com/event/medtech-summit/
ATTACH;FMTTYPE=image/png:https://pulsenmore.com/wp-content/uploads/2026/05/Screenshot-2026-05-19-143236.png
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20260527
DTEND;VALUE=DATE:20260531
DTSTAMP:20260625T173159
CREATED:20260517T113509Z
LAST-MODIFIED:20260517T113509Z
UID:59329-1779840000-1780185599@pulsenmore.com
SUMMARY:AIUM 2026
DESCRIPTION:Pulsenmore Announces Strategic Partnership with Ouma Health to Expand Access to Remote Prenatal Care Across the United States  \nFDA-authorized home ultrasound technology to be integrated into Ouma Health’s virtual maternity care model\, creating a scalable pathway to expand the adoption of home ultrasound in prenatal care across the United States  \nRamat Gan\, Israel\, June 24\, 2026 /PRNewswire/ Pulsenmore Ltd. (NASDAQ\, TASE: PLSM)\, a pioneer in home ultrasound technology\, today announced a strategic partnership with Ouma Health\, a leading provider of virtual maternity care solutions in the United States.  \nThrough the collaboration\, Ouma Health will incorporate Pulsenmore’s FDA-authorized home ultrasound platform as part of its virtual maternity care platform\, enabling clinicians to extend prenatal ultrasound monitoring beyond the clinic and into patients’ homes while maintaining continuous connection between expectant mothers and their care teams throughout pregnancy.  \nFor Pulsenmore\, the agreement represents a significant expansion of its presence in the U.S. maternal health market and an opportunity to integrate its home ultrasound platform into an established virtual care model serving expectant mothers nationwide.  \n“Maternal healthcare is undergoing a fundamental transformation toward more connected\, patient-centered care models\,” said Dr. Elazar Sonnenschein\, Founder and CEO of Pulsenmore. “By partnering with Ouma Health\, we have an opportunity to bring ultrasound beyond the walls of the clinic and into established virtual maternity care pathways\, helping healthcare professionals expand access to prenatal monitoring while keeping patients at the center of care. With 35% of U.S. counties classified as maternal care deserts\, virtual care models combined with home ultrasound technology will play an important role in closing critical access gaps for expectant mothers.”  \n“At Ouma\, we care for patients who often face significant geographic and logistical barriers to prenatal care\, including those living in maternity deserts and underserved communities\,” said Dr. Sina Haeri\, CEO of Ouma Health. “Pulsenmore’s technology gives us a way to bring more of the prenatal monitoring experience into the home\, while keeping patients connected to a clinical team that can review the information and guide next steps. This partnership helps us make virtual maternity care more clinically complete\, especially for patients who cannot easily access specialty care in person.  \nMaternal health remains one of the most critical areas of healthcare delivery in the United States. As healthcare organizations look for ways to improve access\, patient engagement\, and care coordination\, home ultrasound is emerging as a meaningful component of virtual and hybrid prenatal care models.  \nThe collaboration aims to deliver transformative care for the most underserved patients and establish insights and experience to support future expansion opportunities with healthcare systems\, maternity care providers\, and payer organizations seeking innovative approaches for maternal health delivery. Home ultrasound has the potential to become an important part of the next generation of prenatal care\, helping healthcare providers expand access\, improve patient engagement\, and deliver more connected pregnancy care beyond traditional clinical settings.  \nAbout Pulsenmore  \nPulsenmore Ltd. is dedicated to revolutionizing maternal health through home-use ultrasound technology that connects mothers and healthcare providers remotely. By leveraging advanced imaging and telemedicine\, Pulsenmore makes prenatal care patient-centric\, expanding access and improving continuity of care. For more information\, visit www.pulsenmore.com  \n  \nAbout Ouma Health  \nOuma Health is the nation’s largest independent maternity telemedicine company\, providing comprehensive care from preconception through postpartum. Founded and run by maternal-fetal medicine specialists\, Ouma is committed to equity\, innovation\, and outcomes\, serving patients in all 50 states through partnerships with major payors\, health systems\, OB groups\, FQHCs\, reproductive agencies\, and employers. For more information\, visit www.oumahealth.com.  \n  \nThis press release contains forward-looking statements. In particular\, statements using words such as “may\,” “seek\,” “will\,” “consider\,” “likely\,” “assume\,” “estimate\,” “expect\,” “anticipate\,” “intend\,” “believe\,” “contemplate\,” “do not believe\,” “aim\,” “goal\,” “due\,” “predict\,” “plan\,” “project\,” “continue\,” “potential\,” “positioned\,” “guidance\,” “objective\,” “outlook\,” “trends\,” “future\,” “could\,” “would\,” “should\,” “target\,” “on track” or their negatives or variations\, and similar terminology and words of similar import\, generally involve future or forward-looking statements. Such forward-looking statements include\, but are not limited to\, statements relating to the expected outcome of Pulsenmore’s engagement with OUMA. Forward-looking statements reflect Pulsenmore’s current views\, plans\, or expectations with respect to future events or financial performance. They are inherently subject to significant business\, economic\, competitive\, and other risks\, uncertainties\, and contingencies. Forward-looking statements are based on Pulsenmore’s current expectations and are subject to inherent uncertainties\, risks and assumptions that are difficult to predict\, including\, but not limited to\, the following: the Company’s lack of operating history; the Company’s current and future capital requirements and the Company’s belief that its existing cash will be sufficient to fund its operations for more than one year from the date that the financial statements are issued; the Company’s ability to manufacture\, market and sell its products and to generate revenues; the Company’s ability to maintain its relationships with key partners and grow relationships with new partners; the Company’s ability to maintain or protect the validity of its U.S. and other patents and other intellectual property; the Company’s ability to launch and penetrate markets in new locations and new market segments; the Company’s ability to retain key executive members and hire additional personnel; the Company’s ability to maintain and expand intellectual property rights; interpretations of current laws and the passages of future laws; the Company’s ability to achieve greater regulatory compliance needed in existing and new markets; the Company’s ability to achieve key performance milestones in its planned operational testing; the Company’s ability to establish adequate sales\, marketing and distribution channels; security\, political and economic instability in the Middle East that could harm its business; and acceptance of the Company’s business model by investors. Further\, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. For a more detailed description of the risks and uncertainties affecting the Company\, reference is made to the Company’s reports filed from time to time with the SEC\, including\, but not limited to\, the risks\, uncertainties and other factors included in the Company’s Form 20-F (SEC File No. 001-43033)\, filed with the SEC on December 29\, 2025. The inclusion of forward-looking statements in this or any other communication should not be considered as a representation by Pulsenmore or any other person that current plans or expectations will be achieved. Forward-looking statements speak only as of the date on which they are made\, and Pulsenmore undertakes no obligation to publicly update or revise any forward-looking statement\, whether as a result of new information\, future developments\, or otherwise\, except as otherwise required by law.  \n  \nInvestor Contact:  \n  \nMiri Segal-Scharia  \nMS-IR LLC  \nmsegal@ms-ir.com 
URL:https://pulsenmore.com/event/aium-2026/
ATTACH;FMTTYPE=image/png:https://pulsenmore.com/wp-content/uploads/2026/05/Screenshot-2026-05-17-143440.png
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20260326
DTEND;VALUE=DATE:20260328
DTSTAMP:20260625T173159
CREATED:20251123T123831Z
LAST-MODIFIED:20251123T123945Z
UID:51295-1774483200-1774655999@pulsenmore.com
SUMMARY:BMFMS 2026
DESCRIPTION:Pulsenmore Announces Strategic Partnership with Ouma Health to Expand Access to Remote Prenatal Care Across the United States  \nFDA-authorized home ultrasound technology to be integrated into Ouma Health’s virtual maternity care model\, creating a scalable pathway to expand the adoption of home ultrasound in prenatal care across the United States  \nRamat Gan\, Israel\, June 24\, 2026 /PRNewswire/ Pulsenmore Ltd. (NASDAQ\, TASE: PLSM)\, a pioneer in home ultrasound technology\, today announced a strategic partnership with Ouma Health\, a leading provider of virtual maternity care solutions in the United States.  \nThrough the collaboration\, Ouma Health will incorporate Pulsenmore’s FDA-authorized home ultrasound platform as part of its virtual maternity care platform\, enabling clinicians to extend prenatal ultrasound monitoring beyond the clinic and into patients’ homes while maintaining continuous connection between expectant mothers and their care teams throughout pregnancy.  \nFor Pulsenmore\, the agreement represents a significant expansion of its presence in the U.S. maternal health market and an opportunity to integrate its home ultrasound platform into an established virtual care model serving expectant mothers nationwide.  \n“Maternal healthcare is undergoing a fundamental transformation toward more connected\, patient-centered care models\,” said Dr. Elazar Sonnenschein\, Founder and CEO of Pulsenmore. “By partnering with Ouma Health\, we have an opportunity to bring ultrasound beyond the walls of the clinic and into established virtual maternity care pathways\, helping healthcare professionals expand access to prenatal monitoring while keeping patients at the center of care. With 35% of U.S. counties classified as maternal care deserts\, virtual care models combined with home ultrasound technology will play an important role in closing critical access gaps for expectant mothers.”  \n“At Ouma\, we care for patients who often face significant geographic and logistical barriers to prenatal care\, including those living in maternity deserts and underserved communities\,” said Dr. Sina Haeri\, CEO of Ouma Health. “Pulsenmore’s technology gives us a way to bring more of the prenatal monitoring experience into the home\, while keeping patients connected to a clinical team that can review the information and guide next steps. This partnership helps us make virtual maternity care more clinically complete\, especially for patients who cannot easily access specialty care in person.  \nMaternal health remains one of the most critical areas of healthcare delivery in the United States. As healthcare organizations look for ways to improve access\, patient engagement\, and care coordination\, home ultrasound is emerging as a meaningful component of virtual and hybrid prenatal care models.  \nThe collaboration aims to deliver transformative care for the most underserved patients and establish insights and experience to support future expansion opportunities with healthcare systems\, maternity care providers\, and payer organizations seeking innovative approaches for maternal health delivery. Home ultrasound has the potential to become an important part of the next generation of prenatal care\, helping healthcare providers expand access\, improve patient engagement\, and deliver more connected pregnancy care beyond traditional clinical settings.  \nAbout Pulsenmore  \nPulsenmore Ltd. is dedicated to revolutionizing maternal health through home-use ultrasound technology that connects mothers and healthcare providers remotely. By leveraging advanced imaging and telemedicine\, Pulsenmore makes prenatal care patient-centric\, expanding access and improving continuity of care. For more information\, visit www.pulsenmore.com  \n  \nAbout Ouma Health  \nOuma Health is the nation’s largest independent maternity telemedicine company\, providing comprehensive care from preconception through postpartum. Founded and run by maternal-fetal medicine specialists\, Ouma is committed to equity\, innovation\, and outcomes\, serving patients in all 50 states through partnerships with major payors\, health systems\, OB groups\, FQHCs\, reproductive agencies\, and employers. For more information\, visit www.oumahealth.com.  \n  \nThis press release contains forward-looking statements. In particular\, statements using words such as “may\,” “seek\,” “will\,” “consider\,” “likely\,” “assume\,” “estimate\,” “expect\,” “anticipate\,” “intend\,” “believe\,” “contemplate\,” “do not believe\,” “aim\,” “goal\,” “due\,” “predict\,” “plan\,” “project\,” “continue\,” “potential\,” “positioned\,” “guidance\,” “objective\,” “outlook\,” “trends\,” “future\,” “could\,” “would\,” “should\,” “target\,” “on track” or their negatives or variations\, and similar terminology and words of similar import\, generally involve future or forward-looking statements. Such forward-looking statements include\, but are not limited to\, statements relating to the expected outcome of Pulsenmore’s engagement with OUMA. Forward-looking statements reflect Pulsenmore’s current views\, plans\, or expectations with respect to future events or financial performance. They are inherently subject to significant business\, economic\, competitive\, and other risks\, uncertainties\, and contingencies. Forward-looking statements are based on Pulsenmore’s current expectations and are subject to inherent uncertainties\, risks and assumptions that are difficult to predict\, including\, but not limited to\, the following: the Company’s lack of operating history; the Company’s current and future capital requirements and the Company’s belief that its existing cash will be sufficient to fund its operations for more than one year from the date that the financial statements are issued; the Company’s ability to manufacture\, market and sell its products and to generate revenues; the Company’s ability to maintain its relationships with key partners and grow relationships with new partners; the Company’s ability to maintain or protect the validity of its U.S. and other patents and other intellectual property; the Company’s ability to launch and penetrate markets in new locations and new market segments; the Company’s ability to retain key executive members and hire additional personnel; the Company’s ability to maintain and expand intellectual property rights; interpretations of current laws and the passages of future laws; the Company’s ability to achieve greater regulatory compliance needed in existing and new markets; the Company’s ability to achieve key performance milestones in its planned operational testing; the Company’s ability to establish adequate sales\, marketing and distribution channels; security\, political and economic instability in the Middle East that could harm its business; and acceptance of the Company’s business model by investors. Further\, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. For a more detailed description of the risks and uncertainties affecting the Company\, reference is made to the Company’s reports filed from time to time with the SEC\, including\, but not limited to\, the risks\, uncertainties and other factors included in the Company’s Form 20-F (SEC File No. 001-43033)\, filed with the SEC on December 29\, 2025. The inclusion of forward-looking statements in this or any other communication should not be considered as a representation by Pulsenmore or any other person that current plans or expectations will be achieved. Forward-looking statements speak only as of the date on which they are made\, and Pulsenmore undertakes no obligation to publicly update or revise any forward-looking statement\, whether as a result of new information\, future developments\, or otherwise\, except as otherwise required by law.  \n  \nInvestor Contact:  \n  \nMiri Segal-Scharia  \nMS-IR LLC  \nmsegal@ms-ir.com 
URL:https://pulsenmore.com/event/bmfms-2026/
ATTACH;FMTTYPE=image/png:https://pulsenmore.com/wp-content/uploads/2025/11/Screenshot-2025-11-23-143714.png
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20260322
DTEND;VALUE=DATE:20260326
DTSTAMP:20260625T173159
CREATED:20251123T123250Z
LAST-MODIFIED:20251123T123250Z
UID:51264-1774137600-1774483199@pulsenmore.com
SUMMARY:PSANZ + FAOPS Congress
DESCRIPTION:Pulsenmore Announces Strategic Partnership with Ouma Health to Expand Access to Remote Prenatal Care Across the United States  \nFDA-authorized home ultrasound technology to be integrated into Ouma Health’s virtual maternity care model\, creating a scalable pathway to expand the adoption of home ultrasound in prenatal care across the United States  \nRamat Gan\, Israel\, June 24\, 2026 /PRNewswire/ Pulsenmore Ltd. (NASDAQ\, TASE: PLSM)\, a pioneer in home ultrasound technology\, today announced a strategic partnership with Ouma Health\, a leading provider of virtual maternity care solutions in the United States.  \nThrough the collaboration\, Ouma Health will incorporate Pulsenmore’s FDA-authorized home ultrasound platform as part of its virtual maternity care platform\, enabling clinicians to extend prenatal ultrasound monitoring beyond the clinic and into patients’ homes while maintaining continuous connection between expectant mothers and their care teams throughout pregnancy.  \nFor Pulsenmore\, the agreement represents a significant expansion of its presence in the U.S. maternal health market and an opportunity to integrate its home ultrasound platform into an established virtual care model serving expectant mothers nationwide.  \n“Maternal healthcare is undergoing a fundamental transformation toward more connected\, patient-centered care models\,” said Dr. Elazar Sonnenschein\, Founder and CEO of Pulsenmore. “By partnering with Ouma Health\, we have an opportunity to bring ultrasound beyond the walls of the clinic and into established virtual maternity care pathways\, helping healthcare professionals expand access to prenatal monitoring while keeping patients at the center of care. With 35% of U.S. counties classified as maternal care deserts\, virtual care models combined with home ultrasound technology will play an important role in closing critical access gaps for expectant mothers.”  \n“At Ouma\, we care for patients who often face significant geographic and logistical barriers to prenatal care\, including those living in maternity deserts and underserved communities\,” said Dr. Sina Haeri\, CEO of Ouma Health. “Pulsenmore’s technology gives us a way to bring more of the prenatal monitoring experience into the home\, while keeping patients connected to a clinical team that can review the information and guide next steps. This partnership helps us make virtual maternity care more clinically complete\, especially for patients who cannot easily access specialty care in person.  \nMaternal health remains one of the most critical areas of healthcare delivery in the United States. As healthcare organizations look for ways to improve access\, patient engagement\, and care coordination\, home ultrasound is emerging as a meaningful component of virtual and hybrid prenatal care models.  \nThe collaboration aims to deliver transformative care for the most underserved patients and establish insights and experience to support future expansion opportunities with healthcare systems\, maternity care providers\, and payer organizations seeking innovative approaches for maternal health delivery. Home ultrasound has the potential to become an important part of the next generation of prenatal care\, helping healthcare providers expand access\, improve patient engagement\, and deliver more connected pregnancy care beyond traditional clinical settings.  \nAbout Pulsenmore  \nPulsenmore Ltd. is dedicated to revolutionizing maternal health through home-use ultrasound technology that connects mothers and healthcare providers remotely. By leveraging advanced imaging and telemedicine\, Pulsenmore makes prenatal care patient-centric\, expanding access and improving continuity of care. For more information\, visit www.pulsenmore.com  \n  \nAbout Ouma Health  \nOuma Health is the nation’s largest independent maternity telemedicine company\, providing comprehensive care from preconception through postpartum. Founded and run by maternal-fetal medicine specialists\, Ouma is committed to equity\, innovation\, and outcomes\, serving patients in all 50 states through partnerships with major payors\, health systems\, OB groups\, FQHCs\, reproductive agencies\, and employers. For more information\, visit www.oumahealth.com.  \n  \nThis press release contains forward-looking statements. In particular\, statements using words such as “may\,” “seek\,” “will\,” “consider\,” “likely\,” “assume\,” “estimate\,” “expect\,” “anticipate\,” “intend\,” “believe\,” “contemplate\,” “do not believe\,” “aim\,” “goal\,” “due\,” “predict\,” “plan\,” “project\,” “continue\,” “potential\,” “positioned\,” “guidance\,” “objective\,” “outlook\,” “trends\,” “future\,” “could\,” “would\,” “should\,” “target\,” “on track” or their negatives or variations\, and similar terminology and words of similar import\, generally involve future or forward-looking statements. Such forward-looking statements include\, but are not limited to\, statements relating to the expected outcome of Pulsenmore’s engagement with OUMA. Forward-looking statements reflect Pulsenmore’s current views\, plans\, or expectations with respect to future events or financial performance. They are inherently subject to significant business\, economic\, competitive\, and other risks\, uncertainties\, and contingencies. Forward-looking statements are based on Pulsenmore’s current expectations and are subject to inherent uncertainties\, risks and assumptions that are difficult to predict\, including\, but not limited to\, the following: the Company’s lack of operating history; the Company’s current and future capital requirements and the Company’s belief that its existing cash will be sufficient to fund its operations for more than one year from the date that the financial statements are issued; the Company’s ability to manufacture\, market and sell its products and to generate revenues; the Company’s ability to maintain its relationships with key partners and grow relationships with new partners; the Company’s ability to maintain or protect the validity of its U.S. and other patents and other intellectual property; the Company’s ability to launch and penetrate markets in new locations and new market segments; the Company’s ability to retain key executive members and hire additional personnel; the Company’s ability to maintain and expand intellectual property rights; interpretations of current laws and the passages of future laws; the Company’s ability to achieve greater regulatory compliance needed in existing and new markets; the Company’s ability to achieve key performance milestones in its planned operational testing; the Company’s ability to establish adequate sales\, marketing and distribution channels; security\, political and economic instability in the Middle East that could harm its business; and acceptance of the Company’s business model by investors. Further\, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. For a more detailed description of the risks and uncertainties affecting the Company\, reference is made to the Company’s reports filed from time to time with the SEC\, including\, but not limited to\, the risks\, uncertainties and other factors included in the Company’s Form 20-F (SEC File No. 001-43033)\, filed with the SEC on December 29\, 2025. The inclusion of forward-looking statements in this or any other communication should not be considered as a representation by Pulsenmore or any other person that current plans or expectations will be achieved. Forward-looking statements speak only as of the date on which they are made\, and Pulsenmore undertakes no obligation to publicly update or revise any forward-looking statement\, whether as a result of new information\, future developments\, or otherwise\, except as otherwise required by law.  \n  \nInvestor Contact:  \n  \nMiri Segal-Scharia  \nMS-IR LLC  \nmsegal@ms-ir.com 
URL:https://pulsenmore.com/event/psanz-faops-congress/
ATTACH;FMTTYPE=image/png:https://pulsenmore.com/wp-content/uploads/2025/11/Screenshot-2025-11-23-143157.png
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20260317
DTEND;VALUE=DATE:20260319
DTSTAMP:20260625T173159
CREATED:20251123T122918Z
LAST-MODIFIED:20251123T122918Z
UID:51253-1773705600-1773878399@pulsenmore.com
SUMMARY:MIXiii Health-Tech.IL
DESCRIPTION:Pulsenmore Announces Strategic Partnership with Ouma Health to Expand Access to Remote Prenatal Care Across the United States  \nFDA-authorized home ultrasound technology to be integrated into Ouma Health’s virtual maternity care model\, creating a scalable pathway to expand the adoption of home ultrasound in prenatal care across the United States  \nRamat Gan\, Israel\, June 24\, 2026 /PRNewswire/ Pulsenmore Ltd. (NASDAQ\, TASE: PLSM)\, a pioneer in home ultrasound technology\, today announced a strategic partnership with Ouma Health\, a leading provider of virtual maternity care solutions in the United States.  \nThrough the collaboration\, Ouma Health will incorporate Pulsenmore’s FDA-authorized home ultrasound platform as part of its virtual maternity care platform\, enabling clinicians to extend prenatal ultrasound monitoring beyond the clinic and into patients’ homes while maintaining continuous connection between expectant mothers and their care teams throughout pregnancy.  \nFor Pulsenmore\, the agreement represents a significant expansion of its presence in the U.S. maternal health market and an opportunity to integrate its home ultrasound platform into an established virtual care model serving expectant mothers nationwide.  \n“Maternal healthcare is undergoing a fundamental transformation toward more connected\, patient-centered care models\,” said Dr. Elazar Sonnenschein\, Founder and CEO of Pulsenmore. “By partnering with Ouma Health\, we have an opportunity to bring ultrasound beyond the walls of the clinic and into established virtual maternity care pathways\, helping healthcare professionals expand access to prenatal monitoring while keeping patients at the center of care. With 35% of U.S. counties classified as maternal care deserts\, virtual care models combined with home ultrasound technology will play an important role in closing critical access gaps for expectant mothers.”  \n“At Ouma\, we care for patients who often face significant geographic and logistical barriers to prenatal care\, including those living in maternity deserts and underserved communities\,” said Dr. Sina Haeri\, CEO of Ouma Health. “Pulsenmore’s technology gives us a way to bring more of the prenatal monitoring experience into the home\, while keeping patients connected to a clinical team that can review the information and guide next steps. This partnership helps us make virtual maternity care more clinically complete\, especially for patients who cannot easily access specialty care in person.  \nMaternal health remains one of the most critical areas of healthcare delivery in the United States. As healthcare organizations look for ways to improve access\, patient engagement\, and care coordination\, home ultrasound is emerging as a meaningful component of virtual and hybrid prenatal care models.  \nThe collaboration aims to deliver transformative care for the most underserved patients and establish insights and experience to support future expansion opportunities with healthcare systems\, maternity care providers\, and payer organizations seeking innovative approaches for maternal health delivery. Home ultrasound has the potential to become an important part of the next generation of prenatal care\, helping healthcare providers expand access\, improve patient engagement\, and deliver more connected pregnancy care beyond traditional clinical settings.  \nAbout Pulsenmore  \nPulsenmore Ltd. is dedicated to revolutionizing maternal health through home-use ultrasound technology that connects mothers and healthcare providers remotely. By leveraging advanced imaging and telemedicine\, Pulsenmore makes prenatal care patient-centric\, expanding access and improving continuity of care. For more information\, visit www.pulsenmore.com  \n  \nAbout Ouma Health  \nOuma Health is the nation’s largest independent maternity telemedicine company\, providing comprehensive care from preconception through postpartum. Founded and run by maternal-fetal medicine specialists\, Ouma is committed to equity\, innovation\, and outcomes\, serving patients in all 50 states through partnerships with major payors\, health systems\, OB groups\, FQHCs\, reproductive agencies\, and employers. For more information\, visit www.oumahealth.com.  \n  \nThis press release contains forward-looking statements. In particular\, statements using words such as “may\,” “seek\,” “will\,” “consider\,” “likely\,” “assume\,” “estimate\,” “expect\,” “anticipate\,” “intend\,” “believe\,” “contemplate\,” “do not believe\,” “aim\,” “goal\,” “due\,” “predict\,” “plan\,” “project\,” “continue\,” “potential\,” “positioned\,” “guidance\,” “objective\,” “outlook\,” “trends\,” “future\,” “could\,” “would\,” “should\,” “target\,” “on track” or their negatives or variations\, and similar terminology and words of similar import\, generally involve future or forward-looking statements. Such forward-looking statements include\, but are not limited to\, statements relating to the expected outcome of Pulsenmore’s engagement with OUMA. Forward-looking statements reflect Pulsenmore’s current views\, plans\, or expectations with respect to future events or financial performance. They are inherently subject to significant business\, economic\, competitive\, and other risks\, uncertainties\, and contingencies. Forward-looking statements are based on Pulsenmore’s current expectations and are subject to inherent uncertainties\, risks and assumptions that are difficult to predict\, including\, but not limited to\, the following: the Company’s lack of operating history; the Company’s current and future capital requirements and the Company’s belief that its existing cash will be sufficient to fund its operations for more than one year from the date that the financial statements are issued; the Company’s ability to manufacture\, market and sell its products and to generate revenues; the Company’s ability to maintain its relationships with key partners and grow relationships with new partners; the Company’s ability to maintain or protect the validity of its U.S. and other patents and other intellectual property; the Company’s ability to launch and penetrate markets in new locations and new market segments; the Company’s ability to retain key executive members and hire additional personnel; the Company’s ability to maintain and expand intellectual property rights; interpretations of current laws and the passages of future laws; the Company’s ability to achieve greater regulatory compliance needed in existing and new markets; the Company’s ability to achieve key performance milestones in its planned operational testing; the Company’s ability to establish adequate sales\, marketing and distribution channels; security\, political and economic instability in the Middle East that could harm its business; and acceptance of the Company’s business model by investors. Further\, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. For a more detailed description of the risks and uncertainties affecting the Company\, reference is made to the Company’s reports filed from time to time with the SEC\, including\, but not limited to\, the risks\, uncertainties and other factors included in the Company’s Form 20-F (SEC File No. 001-43033)\, filed with the SEC on December 29\, 2025. The inclusion of forward-looking statements in this or any other communication should not be considered as a representation by Pulsenmore or any other person that current plans or expectations will be achieved. Forward-looking statements speak only as of the date on which they are made\, and Pulsenmore undertakes no obligation to publicly update or revise any forward-looking statement\, whether as a result of new information\, future developments\, or otherwise\, except as otherwise required by law.  \n  \nInvestor Contact:  \n  \nMiri Segal-Scharia  \nMS-IR LLC  \nmsegal@ms-ir.com 
URL:https://pulsenmore.com/event/mixiii-health-tech-il/
ATTACH;FMTTYPE=image/png:https://pulsenmore.com/wp-content/uploads/2025/11/Screenshot-2025-11-23-142644.png
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20260309
DTEND;VALUE=DATE:20260311
DTSTAMP:20260625T173159
CREATED:20251123T123630Z
LAST-MODIFIED:20251123T123630Z
UID:51283-1773014400-1773187199@pulsenmore.com
SUMMARY:MedInTechs 2026
DESCRIPTION:Pulsenmore Announces Strategic Partnership with Ouma Health to Expand Access to Remote Prenatal Care Across the United States  \nFDA-authorized home ultrasound technology to be integrated into Ouma Health’s virtual maternity care model\, creating a scalable pathway to expand the adoption of home ultrasound in prenatal care across the United States  \nRamat Gan\, Israel\, June 24\, 2026 /PRNewswire/ Pulsenmore Ltd. (NASDAQ\, TASE: PLSM)\, a pioneer in home ultrasound technology\, today announced a strategic partnership with Ouma Health\, a leading provider of virtual maternity care solutions in the United States.  \nThrough the collaboration\, Ouma Health will incorporate Pulsenmore’s FDA-authorized home ultrasound platform as part of its virtual maternity care platform\, enabling clinicians to extend prenatal ultrasound monitoring beyond the clinic and into patients’ homes while maintaining continuous connection between expectant mothers and their care teams throughout pregnancy.  \nFor Pulsenmore\, the agreement represents a significant expansion of its presence in the U.S. maternal health market and an opportunity to integrate its home ultrasound platform into an established virtual care model serving expectant mothers nationwide.  \n“Maternal healthcare is undergoing a fundamental transformation toward more connected\, patient-centered care models\,” said Dr. Elazar Sonnenschein\, Founder and CEO of Pulsenmore. “By partnering with Ouma Health\, we have an opportunity to bring ultrasound beyond the walls of the clinic and into established virtual maternity care pathways\, helping healthcare professionals expand access to prenatal monitoring while keeping patients at the center of care. With 35% of U.S. counties classified as maternal care deserts\, virtual care models combined with home ultrasound technology will play an important role in closing critical access gaps for expectant mothers.”  \n“At Ouma\, we care for patients who often face significant geographic and logistical barriers to prenatal care\, including those living in maternity deserts and underserved communities\,” said Dr. Sina Haeri\, CEO of Ouma Health. “Pulsenmore’s technology gives us a way to bring more of the prenatal monitoring experience into the home\, while keeping patients connected to a clinical team that can review the information and guide next steps. This partnership helps us make virtual maternity care more clinically complete\, especially for patients who cannot easily access specialty care in person.  \nMaternal health remains one of the most critical areas of healthcare delivery in the United States. As healthcare organizations look for ways to improve access\, patient engagement\, and care coordination\, home ultrasound is emerging as a meaningful component of virtual and hybrid prenatal care models.  \nThe collaboration aims to deliver transformative care for the most underserved patients and establish insights and experience to support future expansion opportunities with healthcare systems\, maternity care providers\, and payer organizations seeking innovative approaches for maternal health delivery. Home ultrasound has the potential to become an important part of the next generation of prenatal care\, helping healthcare providers expand access\, improve patient engagement\, and deliver more connected pregnancy care beyond traditional clinical settings.  \nAbout Pulsenmore  \nPulsenmore Ltd. is dedicated to revolutionizing maternal health through home-use ultrasound technology that connects mothers and healthcare providers remotely. By leveraging advanced imaging and telemedicine\, Pulsenmore makes prenatal care patient-centric\, expanding access and improving continuity of care. For more information\, visit www.pulsenmore.com  \n  \nAbout Ouma Health  \nOuma Health is the nation’s largest independent maternity telemedicine company\, providing comprehensive care from preconception through postpartum. Founded and run by maternal-fetal medicine specialists\, Ouma is committed to equity\, innovation\, and outcomes\, serving patients in all 50 states through partnerships with major payors\, health systems\, OB groups\, FQHCs\, reproductive agencies\, and employers. For more information\, visit www.oumahealth.com.  \n  \nThis press release contains forward-looking statements. In particular\, statements using words such as “may\,” “seek\,” “will\,” “consider\,” “likely\,” “assume\,” “estimate\,” “expect\,” “anticipate\,” “intend\,” “believe\,” “contemplate\,” “do not believe\,” “aim\,” “goal\,” “due\,” “predict\,” “plan\,” “project\,” “continue\,” “potential\,” “positioned\,” “guidance\,” “objective\,” “outlook\,” “trends\,” “future\,” “could\,” “would\,” “should\,” “target\,” “on track” or their negatives or variations\, and similar terminology and words of similar import\, generally involve future or forward-looking statements. Such forward-looking statements include\, but are not limited to\, statements relating to the expected outcome of Pulsenmore’s engagement with OUMA. Forward-looking statements reflect Pulsenmore’s current views\, plans\, or expectations with respect to future events or financial performance. They are inherently subject to significant business\, economic\, competitive\, and other risks\, uncertainties\, and contingencies. Forward-looking statements are based on Pulsenmore’s current expectations and are subject to inherent uncertainties\, risks and assumptions that are difficult to predict\, including\, but not limited to\, the following: the Company’s lack of operating history; the Company’s current and future capital requirements and the Company’s belief that its existing cash will be sufficient to fund its operations for more than one year from the date that the financial statements are issued; the Company’s ability to manufacture\, market and sell its products and to generate revenues; the Company’s ability to maintain its relationships with key partners and grow relationships with new partners; the Company’s ability to maintain or protect the validity of its U.S. and other patents and other intellectual property; the Company’s ability to launch and penetrate markets in new locations and new market segments; the Company’s ability to retain key executive members and hire additional personnel; the Company’s ability to maintain and expand intellectual property rights; interpretations of current laws and the passages of future laws; the Company’s ability to achieve greater regulatory compliance needed in existing and new markets; the Company’s ability to achieve key performance milestones in its planned operational testing; the Company’s ability to establish adequate sales\, marketing and distribution channels; security\, political and economic instability in the Middle East that could harm its business; and acceptance of the Company’s business model by investors. Further\, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. For a more detailed description of the risks and uncertainties affecting the Company\, reference is made to the Company’s reports filed from time to time with the SEC\, including\, but not limited to\, the risks\, uncertainties and other factors included in the Company’s Form 20-F (SEC File No. 001-43033)\, filed with the SEC on December 29\, 2025. The inclusion of forward-looking statements in this or any other communication should not be considered as a representation by Pulsenmore or any other person that current plans or expectations will be achieved. Forward-looking statements speak only as of the date on which they are made\, and Pulsenmore undertakes no obligation to publicly update or revise any forward-looking statement\, whether as a result of new information\, future developments\, or otherwise\, except as otherwise required by law.  \n  \nInvestor Contact:  \n  \nMiri Segal-Scharia  \nMS-IR LLC  \nmsegal@ms-ir.com 
URL:https://pulsenmore.com/event/medintechs-2026/
ATTACH;FMTTYPE=image/png:https://pulsenmore.com/wp-content/uploads/2025/11/Screenshot-2025-11-23-143340.png
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20260208
DTEND;VALUE=DATE:20260214
DTSTAMP:20260625T173159
CREATED:20251123T122308Z
LAST-MODIFIED:20251123T122457Z
UID:51225-1770508800-1771027199@pulsenmore.com
SUMMARY:SMFM 2026
DESCRIPTION:Pulsenmore Announces Strategic Partnership with Ouma Health to Expand Access to Remote Prenatal Care Across the United States  \nFDA-authorized home ultrasound technology to be integrated into Ouma Health’s virtual maternity care model\, creating a scalable pathway to expand the adoption of home ultrasound in prenatal care across the United States  \nRamat Gan\, Israel\, June 24\, 2026 /PRNewswire/ Pulsenmore Ltd. (NASDAQ\, TASE: PLSM)\, a pioneer in home ultrasound technology\, today announced a strategic partnership with Ouma Health\, a leading provider of virtual maternity care solutions in the United States.  \nThrough the collaboration\, Ouma Health will incorporate Pulsenmore’s FDA-authorized home ultrasound platform as part of its virtual maternity care platform\, enabling clinicians to extend prenatal ultrasound monitoring beyond the clinic and into patients’ homes while maintaining continuous connection between expectant mothers and their care teams throughout pregnancy.  \nFor Pulsenmore\, the agreement represents a significant expansion of its presence in the U.S. maternal health market and an opportunity to integrate its home ultrasound platform into an established virtual care model serving expectant mothers nationwide.  \n“Maternal healthcare is undergoing a fundamental transformation toward more connected\, patient-centered care models\,” said Dr. Elazar Sonnenschein\, Founder and CEO of Pulsenmore. “By partnering with Ouma Health\, we have an opportunity to bring ultrasound beyond the walls of the clinic and into established virtual maternity care pathways\, helping healthcare professionals expand access to prenatal monitoring while keeping patients at the center of care. With 35% of U.S. counties classified as maternal care deserts\, virtual care models combined with home ultrasound technology will play an important role in closing critical access gaps for expectant mothers.”  \n“At Ouma\, we care for patients who often face significant geographic and logistical barriers to prenatal care\, including those living in maternity deserts and underserved communities\,” said Dr. Sina Haeri\, CEO of Ouma Health. “Pulsenmore’s technology gives us a way to bring more of the prenatal monitoring experience into the home\, while keeping patients connected to a clinical team that can review the information and guide next steps. This partnership helps us make virtual maternity care more clinically complete\, especially for patients who cannot easily access specialty care in person.  \nMaternal health remains one of the most critical areas of healthcare delivery in the United States. As healthcare organizations look for ways to improve access\, patient engagement\, and care coordination\, home ultrasound is emerging as a meaningful component of virtual and hybrid prenatal care models.  \nThe collaboration aims to deliver transformative care for the most underserved patients and establish insights and experience to support future expansion opportunities with healthcare systems\, maternity care providers\, and payer organizations seeking innovative approaches for maternal health delivery. Home ultrasound has the potential to become an important part of the next generation of prenatal care\, helping healthcare providers expand access\, improve patient engagement\, and deliver more connected pregnancy care beyond traditional clinical settings.  \nAbout Pulsenmore  \nPulsenmore Ltd. is dedicated to revolutionizing maternal health through home-use ultrasound technology that connects mothers and healthcare providers remotely. By leveraging advanced imaging and telemedicine\, Pulsenmore makes prenatal care patient-centric\, expanding access and improving continuity of care. For more information\, visit www.pulsenmore.com  \n  \nAbout Ouma Health  \nOuma Health is the nation’s largest independent maternity telemedicine company\, providing comprehensive care from preconception through postpartum. Founded and run by maternal-fetal medicine specialists\, Ouma is committed to equity\, innovation\, and outcomes\, serving patients in all 50 states through partnerships with major payors\, health systems\, OB groups\, FQHCs\, reproductive agencies\, and employers. For more information\, visit www.oumahealth.com.  \n  \nThis press release contains forward-looking statements. In particular\, statements using words such as “may\,” “seek\,” “will\,” “consider\,” “likely\,” “assume\,” “estimate\,” “expect\,” “anticipate\,” “intend\,” “believe\,” “contemplate\,” “do not believe\,” “aim\,” “goal\,” “due\,” “predict\,” “plan\,” “project\,” “continue\,” “potential\,” “positioned\,” “guidance\,” “objective\,” “outlook\,” “trends\,” “future\,” “could\,” “would\,” “should\,” “target\,” “on track” or their negatives or variations\, and similar terminology and words of similar import\, generally involve future or forward-looking statements. Such forward-looking statements include\, but are not limited to\, statements relating to the expected outcome of Pulsenmore’s engagement with OUMA. Forward-looking statements reflect Pulsenmore’s current views\, plans\, or expectations with respect to future events or financial performance. They are inherently subject to significant business\, economic\, competitive\, and other risks\, uncertainties\, and contingencies. Forward-looking statements are based on Pulsenmore’s current expectations and are subject to inherent uncertainties\, risks and assumptions that are difficult to predict\, including\, but not limited to\, the following: the Company’s lack of operating history; the Company’s current and future capital requirements and the Company’s belief that its existing cash will be sufficient to fund its operations for more than one year from the date that the financial statements are issued; the Company’s ability to manufacture\, market and sell its products and to generate revenues; the Company’s ability to maintain its relationships with key partners and grow relationships with new partners; the Company’s ability to maintain or protect the validity of its U.S. and other patents and other intellectual property; the Company’s ability to launch and penetrate markets in new locations and new market segments; the Company’s ability to retain key executive members and hire additional personnel; the Company’s ability to maintain and expand intellectual property rights; interpretations of current laws and the passages of future laws; the Company’s ability to achieve greater regulatory compliance needed in existing and new markets; the Company’s ability to achieve key performance milestones in its planned operational testing; the Company’s ability to establish adequate sales\, marketing and distribution channels; security\, political and economic instability in the Middle East that could harm its business; and acceptance of the Company’s business model by investors. Further\, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. For a more detailed description of the risks and uncertainties affecting the Company\, reference is made to the Company’s reports filed from time to time with the SEC\, including\, but not limited to\, the risks\, uncertainties and other factors included in the Company’s Form 20-F (SEC File No. 001-43033)\, filed with the SEC on December 29\, 2025. The inclusion of forward-looking statements in this or any other communication should not be considered as a representation by Pulsenmore or any other person that current plans or expectations will be achieved. Forward-looking statements speak only as of the date on which they are made\, and Pulsenmore undertakes no obligation to publicly update or revise any forward-looking statement\, whether as a result of new information\, future developments\, or otherwise\, except as otherwise required by law.  \n  \nInvestor Contact:  \n  \nMiri Segal-Scharia  \nMS-IR LLC  \nmsegal@ms-ir.com 
URL:https://pulsenmore.com/event/smfm-2026/
ATTACH;FMTTYPE=image/png:https://pulsenmore.com/wp-content/uploads/2025/11/Screenshot-2025-11-23-141903.png
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20260123
DTEND;VALUE=DATE:20260126
DTSTAMP:20260625T173159
CREATED:20251012T113930Z
LAST-MODIFIED:20251012T113930Z
UID:47822-1769126400-1769385599@pulsenmore.com
SUMMARY:12e édition des Nouvelles Journées d'Echographie Fœtale (NJEF)
DESCRIPTION:Pulsenmore Announces Strategic Partnership with Ouma Health to Expand Access to Remote Prenatal Care Across the United States  \nFDA-authorized home ultrasound technology to be integrated into Ouma Health’s virtual maternity care model\, creating a scalable pathway to expand the adoption of home ultrasound in prenatal care across the United States  \nRamat Gan\, Israel\, June 24\, 2026 /PRNewswire/ Pulsenmore Ltd. (NASDAQ\, TASE: PLSM)\, a pioneer in home ultrasound technology\, today announced a strategic partnership with Ouma Health\, a leading provider of virtual maternity care solutions in the United States.  \nThrough the collaboration\, Ouma Health will incorporate Pulsenmore’s FDA-authorized home ultrasound platform as part of its virtual maternity care platform\, enabling clinicians to extend prenatal ultrasound monitoring beyond the clinic and into patients’ homes while maintaining continuous connection between expectant mothers and their care teams throughout pregnancy.  \nFor Pulsenmore\, the agreement represents a significant expansion of its presence in the U.S. maternal health market and an opportunity to integrate its home ultrasound platform into an established virtual care model serving expectant mothers nationwide.  \n“Maternal healthcare is undergoing a fundamental transformation toward more connected\, patient-centered care models\,” said Dr. Elazar Sonnenschein\, Founder and CEO of Pulsenmore. “By partnering with Ouma Health\, we have an opportunity to bring ultrasound beyond the walls of the clinic and into established virtual maternity care pathways\, helping healthcare professionals expand access to prenatal monitoring while keeping patients at the center of care. With 35% of U.S. counties classified as maternal care deserts\, virtual care models combined with home ultrasound technology will play an important role in closing critical access gaps for expectant mothers.”  \n“At Ouma\, we care for patients who often face significant geographic and logistical barriers to prenatal care\, including those living in maternity deserts and underserved communities\,” said Dr. Sina Haeri\, CEO of Ouma Health. “Pulsenmore’s technology gives us a way to bring more of the prenatal monitoring experience into the home\, while keeping patients connected to a clinical team that can review the information and guide next steps. This partnership helps us make virtual maternity care more clinically complete\, especially for patients who cannot easily access specialty care in person.  \nMaternal health remains one of the most critical areas of healthcare delivery in the United States. As healthcare organizations look for ways to improve access\, patient engagement\, and care coordination\, home ultrasound is emerging as a meaningful component of virtual and hybrid prenatal care models.  \nThe collaboration aims to deliver transformative care for the most underserved patients and establish insights and experience to support future expansion opportunities with healthcare systems\, maternity care providers\, and payer organizations seeking innovative approaches for maternal health delivery. Home ultrasound has the potential to become an important part of the next generation of prenatal care\, helping healthcare providers expand access\, improve patient engagement\, and deliver more connected pregnancy care beyond traditional clinical settings.  \nAbout Pulsenmore  \nPulsenmore Ltd. is dedicated to revolutionizing maternal health through home-use ultrasound technology that connects mothers and healthcare providers remotely. By leveraging advanced imaging and telemedicine\, Pulsenmore makes prenatal care patient-centric\, expanding access and improving continuity of care. For more information\, visit www.pulsenmore.com  \n  \nAbout Ouma Health  \nOuma Health is the nation’s largest independent maternity telemedicine company\, providing comprehensive care from preconception through postpartum. Founded and run by maternal-fetal medicine specialists\, Ouma is committed to equity\, innovation\, and outcomes\, serving patients in all 50 states through partnerships with major payors\, health systems\, OB groups\, FQHCs\, reproductive agencies\, and employers. For more information\, visit www.oumahealth.com.  \n  \nThis press release contains forward-looking statements. In particular\, statements using words such as “may\,” “seek\,” “will\,” “consider\,” “likely\,” “assume\,” “estimate\,” “expect\,” “anticipate\,” “intend\,” “believe\,” “contemplate\,” “do not believe\,” “aim\,” “goal\,” “due\,” “predict\,” “plan\,” “project\,” “continue\,” “potential\,” “positioned\,” “guidance\,” “objective\,” “outlook\,” “trends\,” “future\,” “could\,” “would\,” “should\,” “target\,” “on track” or their negatives or variations\, and similar terminology and words of similar import\, generally involve future or forward-looking statements. Such forward-looking statements include\, but are not limited to\, statements relating to the expected outcome of Pulsenmore’s engagement with OUMA. Forward-looking statements reflect Pulsenmore’s current views\, plans\, or expectations with respect to future events or financial performance. They are inherently subject to significant business\, economic\, competitive\, and other risks\, uncertainties\, and contingencies. Forward-looking statements are based on Pulsenmore’s current expectations and are subject to inherent uncertainties\, risks and assumptions that are difficult to predict\, including\, but not limited to\, the following: the Company’s lack of operating history; the Company’s current and future capital requirements and the Company’s belief that its existing cash will be sufficient to fund its operations for more than one year from the date that the financial statements are issued; the Company’s ability to manufacture\, market and sell its products and to generate revenues; the Company’s ability to maintain its relationships with key partners and grow relationships with new partners; the Company’s ability to maintain or protect the validity of its U.S. and other patents and other intellectual property; the Company’s ability to launch and penetrate markets in new locations and new market segments; the Company’s ability to retain key executive members and hire additional personnel; the Company’s ability to maintain and expand intellectual property rights; interpretations of current laws and the passages of future laws; the Company’s ability to achieve greater regulatory compliance needed in existing and new markets; the Company’s ability to achieve key performance milestones in its planned operational testing; the Company’s ability to establish adequate sales\, marketing and distribution channels; security\, political and economic instability in the Middle East that could harm its business; and acceptance of the Company’s business model by investors. Further\, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. For a more detailed description of the risks and uncertainties affecting the Company\, reference is made to the Company’s reports filed from time to time with the SEC\, including\, but not limited to\, the risks\, uncertainties and other factors included in the Company’s Form 20-F (SEC File No. 001-43033)\, filed with the SEC on December 29\, 2025. The inclusion of forward-looking statements in this or any other communication should not be considered as a representation by Pulsenmore or any other person that current plans or expectations will be achieved. Forward-looking statements speak only as of the date on which they are made\, and Pulsenmore undertakes no obligation to publicly update or revise any forward-looking statement\, whether as a result of new information\, future developments\, or otherwise\, except as otherwise required by law.  \n  \nInvestor Contact:  \n  \nMiri Segal-Scharia  \nMS-IR LLC  \nmsegal@ms-ir.com 
URL:https://pulsenmore.com/event/12e-edition-des-nouvelles-journees-dechographie-foetale-njef/
ATTACH;FMTTYPE=image/png:https://pulsenmore.com/wp-content/uploads/2025/10/Screenshot-2025-10-12-143646.png
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20260113
DTEND;VALUE=DATE:20260117
DTSTAMP:20260625T173159
CREATED:20251011T210043Z
LAST-MODIFIED:20251012T105220Z
UID:47803-1768262400-1768607999@pulsenmore.com
SUMMARY:43rd Annual J.P. Morgan Healthcare Conference
DESCRIPTION:Pulsenmore Announces Strategic Partnership with Ouma Health to Expand Access to Remote Prenatal Care Across the United States  \nFDA-authorized home ultrasound technology to be integrated into Ouma Health’s virtual maternity care model\, creating a scalable pathway to expand the adoption of home ultrasound in prenatal care across the United States  \nRamat Gan\, Israel\, June 24\, 2026 /PRNewswire/ Pulsenmore Ltd. (NASDAQ\, TASE: PLSM)\, a pioneer in home ultrasound technology\, today announced a strategic partnership with Ouma Health\, a leading provider of virtual maternity care solutions in the United States.  \nThrough the collaboration\, Ouma Health will incorporate Pulsenmore’s FDA-authorized home ultrasound platform as part of its virtual maternity care platform\, enabling clinicians to extend prenatal ultrasound monitoring beyond the clinic and into patients’ homes while maintaining continuous connection between expectant mothers and their care teams throughout pregnancy.  \nFor Pulsenmore\, the agreement represents a significant expansion of its presence in the U.S. maternal health market and an opportunity to integrate its home ultrasound platform into an established virtual care model serving expectant mothers nationwide.  \n“Maternal healthcare is undergoing a fundamental transformation toward more connected\, patient-centered care models\,” said Dr. Elazar Sonnenschein\, Founder and CEO of Pulsenmore. “By partnering with Ouma Health\, we have an opportunity to bring ultrasound beyond the walls of the clinic and into established virtual maternity care pathways\, helping healthcare professionals expand access to prenatal monitoring while keeping patients at the center of care. With 35% of U.S. counties classified as maternal care deserts\, virtual care models combined with home ultrasound technology will play an important role in closing critical access gaps for expectant mothers.”  \n“At Ouma\, we care for patients who often face significant geographic and logistical barriers to prenatal care\, including those living in maternity deserts and underserved communities\,” said Dr. Sina Haeri\, CEO of Ouma Health. “Pulsenmore’s technology gives us a way to bring more of the prenatal monitoring experience into the home\, while keeping patients connected to a clinical team that can review the information and guide next steps. This partnership helps us make virtual maternity care more clinically complete\, especially for patients who cannot easily access specialty care in person.  \nMaternal health remains one of the most critical areas of healthcare delivery in the United States. As healthcare organizations look for ways to improve access\, patient engagement\, and care coordination\, home ultrasound is emerging as a meaningful component of virtual and hybrid prenatal care models.  \nThe collaboration aims to deliver transformative care for the most underserved patients and establish insights and experience to support future expansion opportunities with healthcare systems\, maternity care providers\, and payer organizations seeking innovative approaches for maternal health delivery. Home ultrasound has the potential to become an important part of the next generation of prenatal care\, helping healthcare providers expand access\, improve patient engagement\, and deliver more connected pregnancy care beyond traditional clinical settings.  \nAbout Pulsenmore  \nPulsenmore Ltd. is dedicated to revolutionizing maternal health through home-use ultrasound technology that connects mothers and healthcare providers remotely. By leveraging advanced imaging and telemedicine\, Pulsenmore makes prenatal care patient-centric\, expanding access and improving continuity of care. For more information\, visit www.pulsenmore.com  \n  \nAbout Ouma Health  \nOuma Health is the nation’s largest independent maternity telemedicine company\, providing comprehensive care from preconception through postpartum. Founded and run by maternal-fetal medicine specialists\, Ouma is committed to equity\, innovation\, and outcomes\, serving patients in all 50 states through partnerships with major payors\, health systems\, OB groups\, FQHCs\, reproductive agencies\, and employers. For more information\, visit www.oumahealth.com.  \n  \nThis press release contains forward-looking statements. In particular\, statements using words such as “may\,” “seek\,” “will\,” “consider\,” “likely\,” “assume\,” “estimate\,” “expect\,” “anticipate\,” “intend\,” “believe\,” “contemplate\,” “do not believe\,” “aim\,” “goal\,” “due\,” “predict\,” “plan\,” “project\,” “continue\,” “potential\,” “positioned\,” “guidance\,” “objective\,” “outlook\,” “trends\,” “future\,” “could\,” “would\,” “should\,” “target\,” “on track” or their negatives or variations\, and similar terminology and words of similar import\, generally involve future or forward-looking statements. Such forward-looking statements include\, but are not limited to\, statements relating to the expected outcome of Pulsenmore’s engagement with OUMA. Forward-looking statements reflect Pulsenmore’s current views\, plans\, or expectations with respect to future events or financial performance. They are inherently subject to significant business\, economic\, competitive\, and other risks\, uncertainties\, and contingencies. Forward-looking statements are based on Pulsenmore’s current expectations and are subject to inherent uncertainties\, risks and assumptions that are difficult to predict\, including\, but not limited to\, the following: the Company’s lack of operating history; the Company’s current and future capital requirements and the Company’s belief that its existing cash will be sufficient to fund its operations for more than one year from the date that the financial statements are issued; the Company’s ability to manufacture\, market and sell its products and to generate revenues; the Company’s ability to maintain its relationships with key partners and grow relationships with new partners; the Company’s ability to maintain or protect the validity of its U.S. and other patents and other intellectual property; the Company’s ability to launch and penetrate markets in new locations and new market segments; the Company’s ability to retain key executive members and hire additional personnel; the Company’s ability to maintain and expand intellectual property rights; interpretations of current laws and the passages of future laws; the Company’s ability to achieve greater regulatory compliance needed in existing and new markets; the Company’s ability to achieve key performance milestones in its planned operational testing; the Company’s ability to establish adequate sales\, marketing and distribution channels; security\, political and economic instability in the Middle East that could harm its business; and acceptance of the Company’s business model by investors. Further\, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. For a more detailed description of the risks and uncertainties affecting the Company\, reference is made to the Company’s reports filed from time to time with the SEC\, including\, but not limited to\, the risks\, uncertainties and other factors included in the Company’s Form 20-F (SEC File No. 001-43033)\, filed with the SEC on December 29\, 2025. The inclusion of forward-looking statements in this or any other communication should not be considered as a representation by Pulsenmore or any other person that current plans or expectations will be achieved. Forward-looking statements speak only as of the date on which they are made\, and Pulsenmore undertakes no obligation to publicly update or revise any forward-looking statement\, whether as a result of new information\, future developments\, or otherwise\, except as otherwise required by law.  \n  \nInvestor Contact:  \n  \nMiri Segal-Scharia  \nMS-IR LLC  \nmsegal@ms-ir.com 
URL:https://pulsenmore.com/event/43rd-annual-j-p-morgan-healthcare-conference/
ATTACH;FMTTYPE=image/png:https://pulsenmore.com/wp-content/uploads/2025/10/Screenshot-2025-10-12-134714.png
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20251208
DTEND;VALUE=DATE:20251210
DTSTAMP:20260625T173159
CREATED:20251123T121721Z
LAST-MODIFIED:20251123T122500Z
UID:51195-1765152000-1765324799@pulsenmore.com
SUMMARY:The GIANT Health Event\, 2025
DESCRIPTION:Pulsenmore Announces Strategic Partnership with Ouma Health to Expand Access to Remote Prenatal Care Across the United States  \nFDA-authorized home ultrasound technology to be integrated into Ouma Health’s virtual maternity care model\, creating a scalable pathway to expand the adoption of home ultrasound in prenatal care across the United States  \nRamat Gan\, Israel\, June 24\, 2026 /PRNewswire/ Pulsenmore Ltd. (NASDAQ\, TASE: PLSM)\, a pioneer in home ultrasound technology\, today announced a strategic partnership with Ouma Health\, a leading provider of virtual maternity care solutions in the United States.  \nThrough the collaboration\, Ouma Health will incorporate Pulsenmore’s FDA-authorized home ultrasound platform as part of its virtual maternity care platform\, enabling clinicians to extend prenatal ultrasound monitoring beyond the clinic and into patients’ homes while maintaining continuous connection between expectant mothers and their care teams throughout pregnancy.  \nFor Pulsenmore\, the agreement represents a significant expansion of its presence in the U.S. maternal health market and an opportunity to integrate its home ultrasound platform into an established virtual care model serving expectant mothers nationwide.  \n“Maternal healthcare is undergoing a fundamental transformation toward more connected\, patient-centered care models\,” said Dr. Elazar Sonnenschein\, Founder and CEO of Pulsenmore. “By partnering with Ouma Health\, we have an opportunity to bring ultrasound beyond the walls of the clinic and into established virtual maternity care pathways\, helping healthcare professionals expand access to prenatal monitoring while keeping patients at the center of care. With 35% of U.S. counties classified as maternal care deserts\, virtual care models combined with home ultrasound technology will play an important role in closing critical access gaps for expectant mothers.”  \n“At Ouma\, we care for patients who often face significant geographic and logistical barriers to prenatal care\, including those living in maternity deserts and underserved communities\,” said Dr. Sina Haeri\, CEO of Ouma Health. “Pulsenmore’s technology gives us a way to bring more of the prenatal monitoring experience into the home\, while keeping patients connected to a clinical team that can review the information and guide next steps. This partnership helps us make virtual maternity care more clinically complete\, especially for patients who cannot easily access specialty care in person.  \nMaternal health remains one of the most critical areas of healthcare delivery in the United States. As healthcare organizations look for ways to improve access\, patient engagement\, and care coordination\, home ultrasound is emerging as a meaningful component of virtual and hybrid prenatal care models.  \nThe collaboration aims to deliver transformative care for the most underserved patients and establish insights and experience to support future expansion opportunities with healthcare systems\, maternity care providers\, and payer organizations seeking innovative approaches for maternal health delivery. Home ultrasound has the potential to become an important part of the next generation of prenatal care\, helping healthcare providers expand access\, improve patient engagement\, and deliver more connected pregnancy care beyond traditional clinical settings.  \nAbout Pulsenmore  \nPulsenmore Ltd. is dedicated to revolutionizing maternal health through home-use ultrasound technology that connects mothers and healthcare providers remotely. By leveraging advanced imaging and telemedicine\, Pulsenmore makes prenatal care patient-centric\, expanding access and improving continuity of care. For more information\, visit www.pulsenmore.com  \n  \nAbout Ouma Health  \nOuma Health is the nation’s largest independent maternity telemedicine company\, providing comprehensive care from preconception through postpartum. Founded and run by maternal-fetal medicine specialists\, Ouma is committed to equity\, innovation\, and outcomes\, serving patients in all 50 states through partnerships with major payors\, health systems\, OB groups\, FQHCs\, reproductive agencies\, and employers. For more information\, visit www.oumahealth.com.  \n  \nThis press release contains forward-looking statements. In particular\, statements using words such as “may\,” “seek\,” “will\,” “consider\,” “likely\,” “assume\,” “estimate\,” “expect\,” “anticipate\,” “intend\,” “believe\,” “contemplate\,” “do not believe\,” “aim\,” “goal\,” “due\,” “predict\,” “plan\,” “project\,” “continue\,” “potential\,” “positioned\,” “guidance\,” “objective\,” “outlook\,” “trends\,” “future\,” “could\,” “would\,” “should\,” “target\,” “on track” or their negatives or variations\, and similar terminology and words of similar import\, generally involve future or forward-looking statements. Such forward-looking statements include\, but are not limited to\, statements relating to the expected outcome of Pulsenmore’s engagement with OUMA. Forward-looking statements reflect Pulsenmore’s current views\, plans\, or expectations with respect to future events or financial performance. They are inherently subject to significant business\, economic\, competitive\, and other risks\, uncertainties\, and contingencies. Forward-looking statements are based on Pulsenmore’s current expectations and are subject to inherent uncertainties\, risks and assumptions that are difficult to predict\, including\, but not limited to\, the following: the Company’s lack of operating history; the Company’s current and future capital requirements and the Company’s belief that its existing cash will be sufficient to fund its operations for more than one year from the date that the financial statements are issued; the Company’s ability to manufacture\, market and sell its products and to generate revenues; the Company’s ability to maintain its relationships with key partners and grow relationships with new partners; the Company’s ability to maintain or protect the validity of its U.S. and other patents and other intellectual property; the Company’s ability to launch and penetrate markets in new locations and new market segments; the Company’s ability to retain key executive members and hire additional personnel; the Company’s ability to maintain and expand intellectual property rights; interpretations of current laws and the passages of future laws; the Company’s ability to achieve greater regulatory compliance needed in existing and new markets; the Company’s ability to achieve key performance milestones in its planned operational testing; the Company’s ability to establish adequate sales\, marketing and distribution channels; security\, political and economic instability in the Middle East that could harm its business; and acceptance of the Company’s business model by investors. Further\, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. For a more detailed description of the risks and uncertainties affecting the Company\, reference is made to the Company’s reports filed from time to time with the SEC\, including\, but not limited to\, the risks\, uncertainties and other factors included in the Company’s Form 20-F (SEC File No. 001-43033)\, filed with the SEC on December 29\, 2025. The inclusion of forward-looking statements in this or any other communication should not be considered as a representation by Pulsenmore or any other person that current plans or expectations will be achieved. Forward-looking statements speak only as of the date on which they are made\, and Pulsenmore undertakes no obligation to publicly update or revise any forward-looking statement\, whether as a result of new information\, future developments\, or otherwise\, except as otherwise required by law.  \n  \nInvestor Contact:  \n  \nMiri Segal-Scharia  \nMS-IR LLC  \nmsegal@ms-ir.com 
URL:https://pulsenmore.com/event/the-giant-health-event-2025/
ATTACH;FMTTYPE=image/png:https://pulsenmore.com/wp-content/uploads/2025/11/Screenshot-2025-11-23-141647.png
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20251204
DTEND;VALUE=DATE:20251207
DTSTAMP:20260625T173159
CREATED:20251126T112406Z
LAST-MODIFIED:20251126T112406Z
UID:51422-1764806400-1765065599@pulsenmore.com
SUMMARY:CMO\, Santa Joana
DESCRIPTION:Pulsenmore Announces Strategic Partnership with Ouma Health to Expand Access to Remote Prenatal Care Across the United States  \nFDA-authorized home ultrasound technology to be integrated into Ouma Health’s virtual maternity care model\, creating a scalable pathway to expand the adoption of home ultrasound in prenatal care across the United States  \nRamat Gan\, Israel\, June 24\, 2026 /PRNewswire/ Pulsenmore Ltd. (NASDAQ\, TASE: PLSM)\, a pioneer in home ultrasound technology\, today announced a strategic partnership with Ouma Health\, a leading provider of virtual maternity care solutions in the United States.  \nThrough the collaboration\, Ouma Health will incorporate Pulsenmore’s FDA-authorized home ultrasound platform as part of its virtual maternity care platform\, enabling clinicians to extend prenatal ultrasound monitoring beyond the clinic and into patients’ homes while maintaining continuous connection between expectant mothers and their care teams throughout pregnancy.  \nFor Pulsenmore\, the agreement represents a significant expansion of its presence in the U.S. maternal health market and an opportunity to integrate its home ultrasound platform into an established virtual care model serving expectant mothers nationwide.  \n“Maternal healthcare is undergoing a fundamental transformation toward more connected\, patient-centered care models\,” said Dr. Elazar Sonnenschein\, Founder and CEO of Pulsenmore. “By partnering with Ouma Health\, we have an opportunity to bring ultrasound beyond the walls of the clinic and into established virtual maternity care pathways\, helping healthcare professionals expand access to prenatal monitoring while keeping patients at the center of care. With 35% of U.S. counties classified as maternal care deserts\, virtual care models combined with home ultrasound technology will play an important role in closing critical access gaps for expectant mothers.”  \n“At Ouma\, we care for patients who often face significant geographic and logistical barriers to prenatal care\, including those living in maternity deserts and underserved communities\,” said Dr. Sina Haeri\, CEO of Ouma Health. “Pulsenmore’s technology gives us a way to bring more of the prenatal monitoring experience into the home\, while keeping patients connected to a clinical team that can review the information and guide next steps. This partnership helps us make virtual maternity care more clinically complete\, especially for patients who cannot easily access specialty care in person.  \nMaternal health remains one of the most critical areas of healthcare delivery in the United States. As healthcare organizations look for ways to improve access\, patient engagement\, and care coordination\, home ultrasound is emerging as a meaningful component of virtual and hybrid prenatal care models.  \nThe collaboration aims to deliver transformative care for the most underserved patients and establish insights and experience to support future expansion opportunities with healthcare systems\, maternity care providers\, and payer organizations seeking innovative approaches for maternal health delivery. Home ultrasound has the potential to become an important part of the next generation of prenatal care\, helping healthcare providers expand access\, improve patient engagement\, and deliver more connected pregnancy care beyond traditional clinical settings.  \nAbout Pulsenmore  \nPulsenmore Ltd. is dedicated to revolutionizing maternal health through home-use ultrasound technology that connects mothers and healthcare providers remotely. By leveraging advanced imaging and telemedicine\, Pulsenmore makes prenatal care patient-centric\, expanding access and improving continuity of care. For more information\, visit www.pulsenmore.com  \n  \nAbout Ouma Health  \nOuma Health is the nation’s largest independent maternity telemedicine company\, providing comprehensive care from preconception through postpartum. Founded and run by maternal-fetal medicine specialists\, Ouma is committed to equity\, innovation\, and outcomes\, serving patients in all 50 states through partnerships with major payors\, health systems\, OB groups\, FQHCs\, reproductive agencies\, and employers. For more information\, visit www.oumahealth.com.  \n  \nThis press release contains forward-looking statements. In particular\, statements using words such as “may\,” “seek\,” “will\,” “consider\,” “likely\,” “assume\,” “estimate\,” “expect\,” “anticipate\,” “intend\,” “believe\,” “contemplate\,” “do not believe\,” “aim\,” “goal\,” “due\,” “predict\,” “plan\,” “project\,” “continue\,” “potential\,” “positioned\,” “guidance\,” “objective\,” “outlook\,” “trends\,” “future\,” “could\,” “would\,” “should\,” “target\,” “on track” or their negatives or variations\, and similar terminology and words of similar import\, generally involve future or forward-looking statements. Such forward-looking statements include\, but are not limited to\, statements relating to the expected outcome of Pulsenmore’s engagement with OUMA. Forward-looking statements reflect Pulsenmore’s current views\, plans\, or expectations with respect to future events or financial performance. They are inherently subject to significant business\, economic\, competitive\, and other risks\, uncertainties\, and contingencies. Forward-looking statements are based on Pulsenmore’s current expectations and are subject to inherent uncertainties\, risks and assumptions that are difficult to predict\, including\, but not limited to\, the following: the Company’s lack of operating history; the Company’s current and future capital requirements and the Company’s belief that its existing cash will be sufficient to fund its operations for more than one year from the date that the financial statements are issued; the Company’s ability to manufacture\, market and sell its products and to generate revenues; the Company’s ability to maintain its relationships with key partners and grow relationships with new partners; the Company’s ability to maintain or protect the validity of its U.S. and other patents and other intellectual property; the Company’s ability to launch and penetrate markets in new locations and new market segments; the Company’s ability to retain key executive members and hire additional personnel; the Company’s ability to maintain and expand intellectual property rights; interpretations of current laws and the passages of future laws; the Company’s ability to achieve greater regulatory compliance needed in existing and new markets; the Company’s ability to achieve key performance milestones in its planned operational testing; the Company’s ability to establish adequate sales\, marketing and distribution channels; security\, political and economic instability in the Middle East that could harm its business; and acceptance of the Company’s business model by investors. Further\, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. For a more detailed description of the risks and uncertainties affecting the Company\, reference is made to the Company’s reports filed from time to time with the SEC\, including\, but not limited to\, the risks\, uncertainties and other factors included in the Company’s Form 20-F (SEC File No. 001-43033)\, filed with the SEC on December 29\, 2025. The inclusion of forward-looking statements in this or any other communication should not be considered as a representation by Pulsenmore or any other person that current plans or expectations will be achieved. Forward-looking statements speak only as of the date on which they are made\, and Pulsenmore undertakes no obligation to publicly update or revise any forward-looking statement\, whether as a result of new information\, future developments\, or otherwise\, except as otherwise required by law.  \n  \nInvestor Contact:  \n  \nMiri Segal-Scharia  \nMS-IR LLC  \nmsegal@ms-ir.com 
URL:https://pulsenmore.com/event/cmo-santa-joana/
ATTACH;FMTTYPE=image/png:https://pulsenmore.com/wp-content/uploads/2025/11/Screenshot-2025-11-26-132244.png
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20251114
DTEND;VALUE=DATE:20251116
DTSTAMP:20260625T173200
CREATED:20251026T092153Z
LAST-MODIFIED:20251026T092153Z
UID:48144-1763078400-1763251199@pulsenmore.com
SUMMARY:Mid Atlantic ultrasound symposium in OBGYN
DESCRIPTION:Pulsenmore Announces Strategic Partnership with Ouma Health to Expand Access to Remote Prenatal Care Across the United States  \nFDA-authorized home ultrasound technology to be integrated into Ouma Health’s virtual maternity care model\, creating a scalable pathway to expand the adoption of home ultrasound in prenatal care across the United States  \nRamat Gan\, Israel\, June 24\, 2026 /PRNewswire/ Pulsenmore Ltd. (NASDAQ\, TASE: PLSM)\, a pioneer in home ultrasound technology\, today announced a strategic partnership with Ouma Health\, a leading provider of virtual maternity care solutions in the United States.  \nThrough the collaboration\, Ouma Health will incorporate Pulsenmore’s FDA-authorized home ultrasound platform as part of its virtual maternity care platform\, enabling clinicians to extend prenatal ultrasound monitoring beyond the clinic and into patients’ homes while maintaining continuous connection between expectant mothers and their care teams throughout pregnancy.  \nFor Pulsenmore\, the agreement represents a significant expansion of its presence in the U.S. maternal health market and an opportunity to integrate its home ultrasound platform into an established virtual care model serving expectant mothers nationwide.  \n“Maternal healthcare is undergoing a fundamental transformation toward more connected\, patient-centered care models\,” said Dr. Elazar Sonnenschein\, Founder and CEO of Pulsenmore. “By partnering with Ouma Health\, we have an opportunity to bring ultrasound beyond the walls of the clinic and into established virtual maternity care pathways\, helping healthcare professionals expand access to prenatal monitoring while keeping patients at the center of care. With 35% of U.S. counties classified as maternal care deserts\, virtual care models combined with home ultrasound technology will play an important role in closing critical access gaps for expectant mothers.”  \n“At Ouma\, we care for patients who often face significant geographic and logistical barriers to prenatal care\, including those living in maternity deserts and underserved communities\,” said Dr. Sina Haeri\, CEO of Ouma Health. “Pulsenmore’s technology gives us a way to bring more of the prenatal monitoring experience into the home\, while keeping patients connected to a clinical team that can review the information and guide next steps. This partnership helps us make virtual maternity care more clinically complete\, especially for patients who cannot easily access specialty care in person.  \nMaternal health remains one of the most critical areas of healthcare delivery in the United States. As healthcare organizations look for ways to improve access\, patient engagement\, and care coordination\, home ultrasound is emerging as a meaningful component of virtual and hybrid prenatal care models.  \nThe collaboration aims to deliver transformative care for the most underserved patients and establish insights and experience to support future expansion opportunities with healthcare systems\, maternity care providers\, and payer organizations seeking innovative approaches for maternal health delivery. Home ultrasound has the potential to become an important part of the next generation of prenatal care\, helping healthcare providers expand access\, improve patient engagement\, and deliver more connected pregnancy care beyond traditional clinical settings.  \nAbout Pulsenmore  \nPulsenmore Ltd. is dedicated to revolutionizing maternal health through home-use ultrasound technology that connects mothers and healthcare providers remotely. By leveraging advanced imaging and telemedicine\, Pulsenmore makes prenatal care patient-centric\, expanding access and improving continuity of care. For more information\, visit www.pulsenmore.com  \n  \nAbout Ouma Health  \nOuma Health is the nation’s largest independent maternity telemedicine company\, providing comprehensive care from preconception through postpartum. Founded and run by maternal-fetal medicine specialists\, Ouma is committed to equity\, innovation\, and outcomes\, serving patients in all 50 states through partnerships with major payors\, health systems\, OB groups\, FQHCs\, reproductive agencies\, and employers. For more information\, visit www.oumahealth.com.  \n  \nThis press release contains forward-looking statements. In particular\, statements using words such as “may\,” “seek\,” “will\,” “consider\,” “likely\,” “assume\,” “estimate\,” “expect\,” “anticipate\,” “intend\,” “believe\,” “contemplate\,” “do not believe\,” “aim\,” “goal\,” “due\,” “predict\,” “plan\,” “project\,” “continue\,” “potential\,” “positioned\,” “guidance\,” “objective\,” “outlook\,” “trends\,” “future\,” “could\,” “would\,” “should\,” “target\,” “on track” or their negatives or variations\, and similar terminology and words of similar import\, generally involve future or forward-looking statements. Such forward-looking statements include\, but are not limited to\, statements relating to the expected outcome of Pulsenmore’s engagement with OUMA. Forward-looking statements reflect Pulsenmore’s current views\, plans\, or expectations with respect to future events or financial performance. They are inherently subject to significant business\, economic\, competitive\, and other risks\, uncertainties\, and contingencies. Forward-looking statements are based on Pulsenmore’s current expectations and are subject to inherent uncertainties\, risks and assumptions that are difficult to predict\, including\, but not limited to\, the following: the Company’s lack of operating history; the Company’s current and future capital requirements and the Company’s belief that its existing cash will be sufficient to fund its operations for more than one year from the date that the financial statements are issued; the Company’s ability to manufacture\, market and sell its products and to generate revenues; the Company’s ability to maintain its relationships with key partners and grow relationships with new partners; the Company’s ability to maintain or protect the validity of its U.S. and other patents and other intellectual property; the Company’s ability to launch and penetrate markets in new locations and new market segments; the Company’s ability to retain key executive members and hire additional personnel; the Company’s ability to maintain and expand intellectual property rights; interpretations of current laws and the passages of future laws; the Company’s ability to achieve greater regulatory compliance needed in existing and new markets; the Company’s ability to achieve key performance milestones in its planned operational testing; the Company’s ability to establish adequate sales\, marketing and distribution channels; security\, political and economic instability in the Middle East that could harm its business; and acceptance of the Company’s business model by investors. Further\, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. For a more detailed description of the risks and uncertainties affecting the Company\, reference is made to the Company’s reports filed from time to time with the SEC\, including\, but not limited to\, the risks\, uncertainties and other factors included in the Company’s Form 20-F (SEC File No. 001-43033)\, filed with the SEC on December 29\, 2025. The inclusion of forward-looking statements in this or any other communication should not be considered as a representation by Pulsenmore or any other person that current plans or expectations will be achieved. Forward-looking statements speak only as of the date on which they are made\, and Pulsenmore undertakes no obligation to publicly update or revise any forward-looking statement\, whether as a result of new information\, future developments\, or otherwise\, except as otherwise required by law.  \n  \nInvestor Contact:  \n  \nMiri Segal-Scharia  \nMS-IR LLC  \nmsegal@ms-ir.com 
URL:https://pulsenmore.com/event/mid-atlantic-ultrasound-symposium-in-obgyn/
ATTACH;FMTTYPE=image/png:https://pulsenmore.com/wp-content/uploads/2025/10/Screenshot-2025-10-23-094453.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Asia/Jerusalem:20251029T180000
DTEND;TZID=Asia/Jerusalem:20251029T190000
DTSTAMP:20260625T173200
CREATED:20251012T135033Z
LAST-MODIFIED:20251021T075508Z
UID:47855-1761760800-1761764400@pulsenmore.com
SUMMARY:Webinar - The lasting Effects of Prenatal Anxiety
DESCRIPTION:Pulsenmore Announces Strategic Partnership with Ouma Health to Expand Access to Remote Prenatal Care Across the United States  \nFDA-authorized home ultrasound technology to be integrated into Ouma Health’s virtual maternity care model\, creating a scalable pathway to expand the adoption of home ultrasound in prenatal care across the United States  \nRamat Gan\, Israel\, June 24\, 2026 /PRNewswire/ Pulsenmore Ltd. (NASDAQ\, TASE: PLSM)\, a pioneer in home ultrasound technology\, today announced a strategic partnership with Ouma Health\, a leading provider of virtual maternity care solutions in the United States.  \nThrough the collaboration\, Ouma Health will incorporate Pulsenmore’s FDA-authorized home ultrasound platform as part of its virtual maternity care platform\, enabling clinicians to extend prenatal ultrasound monitoring beyond the clinic and into patients’ homes while maintaining continuous connection between expectant mothers and their care teams throughout pregnancy.  \nFor Pulsenmore\, the agreement represents a significant expansion of its presence in the U.S. maternal health market and an opportunity to integrate its home ultrasound platform into an established virtual care model serving expectant mothers nationwide.  \n“Maternal healthcare is undergoing a fundamental transformation toward more connected\, patient-centered care models\,” said Dr. Elazar Sonnenschein\, Founder and CEO of Pulsenmore. “By partnering with Ouma Health\, we have an opportunity to bring ultrasound beyond the walls of the clinic and into established virtual maternity care pathways\, helping healthcare professionals expand access to prenatal monitoring while keeping patients at the center of care. With 35% of U.S. counties classified as maternal care deserts\, virtual care models combined with home ultrasound technology will play an important role in closing critical access gaps for expectant mothers.”  \n“At Ouma\, we care for patients who often face significant geographic and logistical barriers to prenatal care\, including those living in maternity deserts and underserved communities\,” said Dr. Sina Haeri\, CEO of Ouma Health. “Pulsenmore’s technology gives us a way to bring more of the prenatal monitoring experience into the home\, while keeping patients connected to a clinical team that can review the information and guide next steps. This partnership helps us make virtual maternity care more clinically complete\, especially for patients who cannot easily access specialty care in person.  \nMaternal health remains one of the most critical areas of healthcare delivery in the United States. As healthcare organizations look for ways to improve access\, patient engagement\, and care coordination\, home ultrasound is emerging as a meaningful component of virtual and hybrid prenatal care models.  \nThe collaboration aims to deliver transformative care for the most underserved patients and establish insights and experience to support future expansion opportunities with healthcare systems\, maternity care providers\, and payer organizations seeking innovative approaches for maternal health delivery. Home ultrasound has the potential to become an important part of the next generation of prenatal care\, helping healthcare providers expand access\, improve patient engagement\, and deliver more connected pregnancy care beyond traditional clinical settings.  \nAbout Pulsenmore  \nPulsenmore Ltd. is dedicated to revolutionizing maternal health through home-use ultrasound technology that connects mothers and healthcare providers remotely. By leveraging advanced imaging and telemedicine\, Pulsenmore makes prenatal care patient-centric\, expanding access and improving continuity of care. For more information\, visit www.pulsenmore.com  \n  \nAbout Ouma Health  \nOuma Health is the nation’s largest independent maternity telemedicine company\, providing comprehensive care from preconception through postpartum. Founded and run by maternal-fetal medicine specialists\, Ouma is committed to equity\, innovation\, and outcomes\, serving patients in all 50 states through partnerships with major payors\, health systems\, OB groups\, FQHCs\, reproductive agencies\, and employers. For more information\, visit www.oumahealth.com.  \n  \nThis press release contains forward-looking statements. In particular\, statements using words such as “may\,” “seek\,” “will\,” “consider\,” “likely\,” “assume\,” “estimate\,” “expect\,” “anticipate\,” “intend\,” “believe\,” “contemplate\,” “do not believe\,” “aim\,” “goal\,” “due\,” “predict\,” “plan\,” “project\,” “continue\,” “potential\,” “positioned\,” “guidance\,” “objective\,” “outlook\,” “trends\,” “future\,” “could\,” “would\,” “should\,” “target\,” “on track” or their negatives or variations\, and similar terminology and words of similar import\, generally involve future or forward-looking statements. Such forward-looking statements include\, but are not limited to\, statements relating to the expected outcome of Pulsenmore’s engagement with OUMA. Forward-looking statements reflect Pulsenmore’s current views\, plans\, or expectations with respect to future events or financial performance. They are inherently subject to significant business\, economic\, competitive\, and other risks\, uncertainties\, and contingencies. Forward-looking statements are based on Pulsenmore’s current expectations and are subject to inherent uncertainties\, risks and assumptions that are difficult to predict\, including\, but not limited to\, the following: the Company’s lack of operating history; the Company’s current and future capital requirements and the Company’s belief that its existing cash will be sufficient to fund its operations for more than one year from the date that the financial statements are issued; the Company’s ability to manufacture\, market and sell its products and to generate revenues; the Company’s ability to maintain its relationships with key partners and grow relationships with new partners; the Company’s ability to maintain or protect the validity of its U.S. and other patents and other intellectual property; the Company’s ability to launch and penetrate markets in new locations and new market segments; the Company’s ability to retain key executive members and hire additional personnel; the Company’s ability to maintain and expand intellectual property rights; interpretations of current laws and the passages of future laws; the Company’s ability to achieve greater regulatory compliance needed in existing and new markets; the Company’s ability to achieve key performance milestones in its planned operational testing; the Company’s ability to establish adequate sales\, marketing and distribution channels; security\, political and economic instability in the Middle East that could harm its business; and acceptance of the Company’s business model by investors. Further\, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. For a more detailed description of the risks and uncertainties affecting the Company\, reference is made to the Company’s reports filed from time to time with the SEC\, including\, but not limited to\, the risks\, uncertainties and other factors included in the Company’s Form 20-F (SEC File No. 001-43033)\, filed with the SEC on December 29\, 2025. The inclusion of forward-looking statements in this or any other communication should not be considered as a representation by Pulsenmore or any other person that current plans or expectations will be achieved. Forward-looking statements speak only as of the date on which they are made\, and Pulsenmore undertakes no obligation to publicly update or revise any forward-looking statement\, whether as a result of new information\, future developments\, or otherwise\, except as otherwise required by law.  \n  \nInvestor Contact:  \n  \nMiri Segal-Scharia  \nMS-IR LLC  \nmsegal@ms-ir.com 
URL:https://pulsenmore.com/event/webinar-the-lasting-effects-of-prenatal-anxiety/
ATTACH;FMTTYPE=image/png:https://pulsenmore.com/wp-content/uploads/2025/10/The-LAsting-EFFECTS-OF-Prenatal-Anxiety-1.png
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20251018
DTEND;VALUE=DATE:20251023
DTSTAMP:20260625T173200
CREATED:20250916T084624Z
LAST-MODIFIED:20250916T084624Z
UID:47628-1760745600-1761177599@pulsenmore.com
SUMMARY:RANZCOG 2025
DESCRIPTION:Pulsenmore Announces Strategic Partnership with Ouma Health to Expand Access to Remote Prenatal Care Across the United States  \nFDA-authorized home ultrasound technology to be integrated into Ouma Health’s virtual maternity care model\, creating a scalable pathway to expand the adoption of home ultrasound in prenatal care across the United States  \nRamat Gan\, Israel\, June 24\, 2026 /PRNewswire/ Pulsenmore Ltd. (NASDAQ\, TASE: PLSM)\, a pioneer in home ultrasound technology\, today announced a strategic partnership with Ouma Health\, a leading provider of virtual maternity care solutions in the United States.  \nThrough the collaboration\, Ouma Health will incorporate Pulsenmore’s FDA-authorized home ultrasound platform as part of its virtual maternity care platform\, enabling clinicians to extend prenatal ultrasound monitoring beyond the clinic and into patients’ homes while maintaining continuous connection between expectant mothers and their care teams throughout pregnancy.  \nFor Pulsenmore\, the agreement represents a significant expansion of its presence in the U.S. maternal health market and an opportunity to integrate its home ultrasound platform into an established virtual care model serving expectant mothers nationwide.  \n“Maternal healthcare is undergoing a fundamental transformation toward more connected\, patient-centered care models\,” said Dr. Elazar Sonnenschein\, Founder and CEO of Pulsenmore. “By partnering with Ouma Health\, we have an opportunity to bring ultrasound beyond the walls of the clinic and into established virtual maternity care pathways\, helping healthcare professionals expand access to prenatal monitoring while keeping patients at the center of care. With 35% of U.S. counties classified as maternal care deserts\, virtual care models combined with home ultrasound technology will play an important role in closing critical access gaps for expectant mothers.”  \n“At Ouma\, we care for patients who often face significant geographic and logistical barriers to prenatal care\, including those living in maternity deserts and underserved communities\,” said Dr. Sina Haeri\, CEO of Ouma Health. “Pulsenmore’s technology gives us a way to bring more of the prenatal monitoring experience into the home\, while keeping patients connected to a clinical team that can review the information and guide next steps. This partnership helps us make virtual maternity care more clinically complete\, especially for patients who cannot easily access specialty care in person.  \nMaternal health remains one of the most critical areas of healthcare delivery in the United States. As healthcare organizations look for ways to improve access\, patient engagement\, and care coordination\, home ultrasound is emerging as a meaningful component of virtual and hybrid prenatal care models.  \nThe collaboration aims to deliver transformative care for the most underserved patients and establish insights and experience to support future expansion opportunities with healthcare systems\, maternity care providers\, and payer organizations seeking innovative approaches for maternal health delivery. Home ultrasound has the potential to become an important part of the next generation of prenatal care\, helping healthcare providers expand access\, improve patient engagement\, and deliver more connected pregnancy care beyond traditional clinical settings.  \nAbout Pulsenmore  \nPulsenmore Ltd. is dedicated to revolutionizing maternal health through home-use ultrasound technology that connects mothers and healthcare providers remotely. By leveraging advanced imaging and telemedicine\, Pulsenmore makes prenatal care patient-centric\, expanding access and improving continuity of care. For more information\, visit www.pulsenmore.com  \n  \nAbout Ouma Health  \nOuma Health is the nation’s largest independent maternity telemedicine company\, providing comprehensive care from preconception through postpartum. Founded and run by maternal-fetal medicine specialists\, Ouma is committed to equity\, innovation\, and outcomes\, serving patients in all 50 states through partnerships with major payors\, health systems\, OB groups\, FQHCs\, reproductive agencies\, and employers. For more information\, visit www.oumahealth.com.  \n  \nThis press release contains forward-looking statements. In particular\, statements using words such as “may\,” “seek\,” “will\,” “consider\,” “likely\,” “assume\,” “estimate\,” “expect\,” “anticipate\,” “intend\,” “believe\,” “contemplate\,” “do not believe\,” “aim\,” “goal\,” “due\,” “predict\,” “plan\,” “project\,” “continue\,” “potential\,” “positioned\,” “guidance\,” “objective\,” “outlook\,” “trends\,” “future\,” “could\,” “would\,” “should\,” “target\,” “on track” or their negatives or variations\, and similar terminology and words of similar import\, generally involve future or forward-looking statements. Such forward-looking statements include\, but are not limited to\, statements relating to the expected outcome of Pulsenmore’s engagement with OUMA. Forward-looking statements reflect Pulsenmore’s current views\, plans\, or expectations with respect to future events or financial performance. They are inherently subject to significant business\, economic\, competitive\, and other risks\, uncertainties\, and contingencies. Forward-looking statements are based on Pulsenmore’s current expectations and are subject to inherent uncertainties\, risks and assumptions that are difficult to predict\, including\, but not limited to\, the following: the Company’s lack of operating history; the Company’s current and future capital requirements and the Company’s belief that its existing cash will be sufficient to fund its operations for more than one year from the date that the financial statements are issued; the Company’s ability to manufacture\, market and sell its products and to generate revenues; the Company’s ability to maintain its relationships with key partners and grow relationships with new partners; the Company’s ability to maintain or protect the validity of its U.S. and other patents and other intellectual property; the Company’s ability to launch and penetrate markets in new locations and new market segments; the Company’s ability to retain key executive members and hire additional personnel; the Company’s ability to maintain and expand intellectual property rights; interpretations of current laws and the passages of future laws; the Company’s ability to achieve greater regulatory compliance needed in existing and new markets; the Company’s ability to achieve key performance milestones in its planned operational testing; the Company’s ability to establish adequate sales\, marketing and distribution channels; security\, political and economic instability in the Middle East that could harm its business; and acceptance of the Company’s business model by investors. Further\, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. For a more detailed description of the risks and uncertainties affecting the Company\, reference is made to the Company’s reports filed from time to time with the SEC\, including\, but not limited to\, the risks\, uncertainties and other factors included in the Company’s Form 20-F (SEC File No. 001-43033)\, filed with the SEC on December 29\, 2025. The inclusion of forward-looking statements in this or any other communication should not be considered as a representation by Pulsenmore or any other person that current plans or expectations will be achieved. Forward-looking statements speak only as of the date on which they are made\, and Pulsenmore undertakes no obligation to publicly update or revise any forward-looking statement\, whether as a result of new information\, future developments\, or otherwise\, except as otherwise required by law.  \n  \nInvestor Contact:  \n  \nMiri Segal-Scharia  \nMS-IR LLC  \nmsegal@ms-ir.com 
URL:https://pulsenmore.com/event/ranzcog-2025/
ATTACH;FMTTYPE=image/png:https://pulsenmore.com/wp-content/uploads/2025/09/Screenshot-2025-09-16-114308.png
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20250914
DTEND;VALUE=DATE:20250918
DTSTAMP:20260625T173200
CREATED:20250914T143456Z
LAST-MODIFIED:20250916T084026Z
UID:47619-1757808000-1758153599@pulsenmore.com
SUMMARY:ISOUG 2025
DESCRIPTION:Pulsenmore Announces Strategic Partnership with Ouma Health to Expand Access to Remote Prenatal Care Across the United States  \nFDA-authorized home ultrasound technology to be integrated into Ouma Health’s virtual maternity care model\, creating a scalable pathway to expand the adoption of home ultrasound in prenatal care across the United States  \nRamat Gan\, Israel\, June 24\, 2026 /PRNewswire/ Pulsenmore Ltd. (NASDAQ\, TASE: PLSM)\, a pioneer in home ultrasound technology\, today announced a strategic partnership with Ouma Health\, a leading provider of virtual maternity care solutions in the United States.  \nThrough the collaboration\, Ouma Health will incorporate Pulsenmore’s FDA-authorized home ultrasound platform as part of its virtual maternity care platform\, enabling clinicians to extend prenatal ultrasound monitoring beyond the clinic and into patients’ homes while maintaining continuous connection between expectant mothers and their care teams throughout pregnancy.  \nFor Pulsenmore\, the agreement represents a significant expansion of its presence in the U.S. maternal health market and an opportunity to integrate its home ultrasound platform into an established virtual care model serving expectant mothers nationwide.  \n“Maternal healthcare is undergoing a fundamental transformation toward more connected\, patient-centered care models\,” said Dr. Elazar Sonnenschein\, Founder and CEO of Pulsenmore. “By partnering with Ouma Health\, we have an opportunity to bring ultrasound beyond the walls of the clinic and into established virtual maternity care pathways\, helping healthcare professionals expand access to prenatal monitoring while keeping patients at the center of care. With 35% of U.S. counties classified as maternal care deserts\, virtual care models combined with home ultrasound technology will play an important role in closing critical access gaps for expectant mothers.”  \n“At Ouma\, we care for patients who often face significant geographic and logistical barriers to prenatal care\, including those living in maternity deserts and underserved communities\,” said Dr. Sina Haeri\, CEO of Ouma Health. “Pulsenmore’s technology gives us a way to bring more of the prenatal monitoring experience into the home\, while keeping patients connected to a clinical team that can review the information and guide next steps. This partnership helps us make virtual maternity care more clinically complete\, especially for patients who cannot easily access specialty care in person.  \nMaternal health remains one of the most critical areas of healthcare delivery in the United States. As healthcare organizations look for ways to improve access\, patient engagement\, and care coordination\, home ultrasound is emerging as a meaningful component of virtual and hybrid prenatal care models.  \nThe collaboration aims to deliver transformative care for the most underserved patients and establish insights and experience to support future expansion opportunities with healthcare systems\, maternity care providers\, and payer organizations seeking innovative approaches for maternal health delivery. Home ultrasound has the potential to become an important part of the next generation of prenatal care\, helping healthcare providers expand access\, improve patient engagement\, and deliver more connected pregnancy care beyond traditional clinical settings.  \nAbout Pulsenmore  \nPulsenmore Ltd. is dedicated to revolutionizing maternal health through home-use ultrasound technology that connects mothers and healthcare providers remotely. By leveraging advanced imaging and telemedicine\, Pulsenmore makes prenatal care patient-centric\, expanding access and improving continuity of care. For more information\, visit www.pulsenmore.com  \n  \nAbout Ouma Health  \nOuma Health is the nation’s largest independent maternity telemedicine company\, providing comprehensive care from preconception through postpartum. Founded and run by maternal-fetal medicine specialists\, Ouma is committed to equity\, innovation\, and outcomes\, serving patients in all 50 states through partnerships with major payors\, health systems\, OB groups\, FQHCs\, reproductive agencies\, and employers. For more information\, visit www.oumahealth.com.  \n  \nThis press release contains forward-looking statements. In particular\, statements using words such as “may\,” “seek\,” “will\,” “consider\,” “likely\,” “assume\,” “estimate\,” “expect\,” “anticipate\,” “intend\,” “believe\,” “contemplate\,” “do not believe\,” “aim\,” “goal\,” “due\,” “predict\,” “plan\,” “project\,” “continue\,” “potential\,” “positioned\,” “guidance\,” “objective\,” “outlook\,” “trends\,” “future\,” “could\,” “would\,” “should\,” “target\,” “on track” or their negatives or variations\, and similar terminology and words of similar import\, generally involve future or forward-looking statements. Such forward-looking statements include\, but are not limited to\, statements relating to the expected outcome of Pulsenmore’s engagement with OUMA. Forward-looking statements reflect Pulsenmore’s current views\, plans\, or expectations with respect to future events or financial performance. They are inherently subject to significant business\, economic\, competitive\, and other risks\, uncertainties\, and contingencies. Forward-looking statements are based on Pulsenmore’s current expectations and are subject to inherent uncertainties\, risks and assumptions that are difficult to predict\, including\, but not limited to\, the following: the Company’s lack of operating history; the Company’s current and future capital requirements and the Company’s belief that its existing cash will be sufficient to fund its operations for more than one year from the date that the financial statements are issued; the Company’s ability to manufacture\, market and sell its products and to generate revenues; the Company’s ability to maintain its relationships with key partners and grow relationships with new partners; the Company’s ability to maintain or protect the validity of its U.S. and other patents and other intellectual property; the Company’s ability to launch and penetrate markets in new locations and new market segments; the Company’s ability to retain key executive members and hire additional personnel; the Company’s ability to maintain and expand intellectual property rights; interpretations of current laws and the passages of future laws; the Company’s ability to achieve greater regulatory compliance needed in existing and new markets; the Company’s ability to achieve key performance milestones in its planned operational testing; the Company’s ability to establish adequate sales\, marketing and distribution channels; security\, political and economic instability in the Middle East that could harm its business; and acceptance of the Company’s business model by investors. Further\, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. For a more detailed description of the risks and uncertainties affecting the Company\, reference is made to the Company’s reports filed from time to time with the SEC\, including\, but not limited to\, the risks\, uncertainties and other factors included in the Company’s Form 20-F (SEC File No. 001-43033)\, filed with the SEC on December 29\, 2025. The inclusion of forward-looking statements in this or any other communication should not be considered as a representation by Pulsenmore or any other person that current plans or expectations will be achieved. Forward-looking statements speak only as of the date on which they are made\, and Pulsenmore undertakes no obligation to publicly update or revise any forward-looking statement\, whether as a result of new information\, future developments\, or otherwise\, except as otherwise required by law.  \n  \nInvestor Contact:  \n  \nMiri Segal-Scharia  \nMS-IR LLC  \nmsegal@ms-ir.com 
URL:https://pulsenmore.com/event/isoug-2025/
ATTACH;FMTTYPE=image/png:https://pulsenmore.com/wp-content/uploads/2025/09/Screenshot-2025-09-16-113900.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Asia/Jerusalem:20250824T080000
DTEND;TZID=Asia/Jerusalem:20250827T170000
DTSTAMP:20260625T173200
CREATED:20250320T134422Z
LAST-MODIFIED:20250320T134944Z
UID:40397-1756022400-1756314000@pulsenmore.com
SUMMARY:NFOG Congress 2025
DESCRIPTION:Pulsenmore Announces Strategic Partnership with Ouma Health to Expand Access to Remote Prenatal Care Across the United States  \nFDA-authorized home ultrasound technology to be integrated into Ouma Health’s virtual maternity care model\, creating a scalable pathway to expand the adoption of home ultrasound in prenatal care across the United States  \nRamat Gan\, Israel\, June 24\, 2026 /PRNewswire/ Pulsenmore Ltd. (NASDAQ\, TASE: PLSM)\, a pioneer in home ultrasound technology\, today announced a strategic partnership with Ouma Health\, a leading provider of virtual maternity care solutions in the United States.  \nThrough the collaboration\, Ouma Health will incorporate Pulsenmore’s FDA-authorized home ultrasound platform as part of its virtual maternity care platform\, enabling clinicians to extend prenatal ultrasound monitoring beyond the clinic and into patients’ homes while maintaining continuous connection between expectant mothers and their care teams throughout pregnancy.  \nFor Pulsenmore\, the agreement represents a significant expansion of its presence in the U.S. maternal health market and an opportunity to integrate its home ultrasound platform into an established virtual care model serving expectant mothers nationwide.  \n“Maternal healthcare is undergoing a fundamental transformation toward more connected\, patient-centered care models\,” said Dr. Elazar Sonnenschein\, Founder and CEO of Pulsenmore. “By partnering with Ouma Health\, we have an opportunity to bring ultrasound beyond the walls of the clinic and into established virtual maternity care pathways\, helping healthcare professionals expand access to prenatal monitoring while keeping patients at the center of care. With 35% of U.S. counties classified as maternal care deserts\, virtual care models combined with home ultrasound technology will play an important role in closing critical access gaps for expectant mothers.”  \n“At Ouma\, we care for patients who often face significant geographic and logistical barriers to prenatal care\, including those living in maternity deserts and underserved communities\,” said Dr. Sina Haeri\, CEO of Ouma Health. “Pulsenmore’s technology gives us a way to bring more of the prenatal monitoring experience into the home\, while keeping patients connected to a clinical team that can review the information and guide next steps. This partnership helps us make virtual maternity care more clinically complete\, especially for patients who cannot easily access specialty care in person.  \nMaternal health remains one of the most critical areas of healthcare delivery in the United States. As healthcare organizations look for ways to improve access\, patient engagement\, and care coordination\, home ultrasound is emerging as a meaningful component of virtual and hybrid prenatal care models.  \nThe collaboration aims to deliver transformative care for the most underserved patients and establish insights and experience to support future expansion opportunities with healthcare systems\, maternity care providers\, and payer organizations seeking innovative approaches for maternal health delivery. Home ultrasound has the potential to become an important part of the next generation of prenatal care\, helping healthcare providers expand access\, improve patient engagement\, and deliver more connected pregnancy care beyond traditional clinical settings.  \nAbout Pulsenmore  \nPulsenmore Ltd. is dedicated to revolutionizing maternal health through home-use ultrasound technology that connects mothers and healthcare providers remotely. By leveraging advanced imaging and telemedicine\, Pulsenmore makes prenatal care patient-centric\, expanding access and improving continuity of care. For more information\, visit www.pulsenmore.com  \n  \nAbout Ouma Health  \nOuma Health is the nation’s largest independent maternity telemedicine company\, providing comprehensive care from preconception through postpartum. Founded and run by maternal-fetal medicine specialists\, Ouma is committed to equity\, innovation\, and outcomes\, serving patients in all 50 states through partnerships with major payors\, health systems\, OB groups\, FQHCs\, reproductive agencies\, and employers. For more information\, visit www.oumahealth.com.  \n  \nThis press release contains forward-looking statements. In particular\, statements using words such as “may\,” “seek\,” “will\,” “consider\,” “likely\,” “assume\,” “estimate\,” “expect\,” “anticipate\,” “intend\,” “believe\,” “contemplate\,” “do not believe\,” “aim\,” “goal\,” “due\,” “predict\,” “plan\,” “project\,” “continue\,” “potential\,” “positioned\,” “guidance\,” “objective\,” “outlook\,” “trends\,” “future\,” “could\,” “would\,” “should\,” “target\,” “on track” or their negatives or variations\, and similar terminology and words of similar import\, generally involve future or forward-looking statements. Such forward-looking statements include\, but are not limited to\, statements relating to the expected outcome of Pulsenmore’s engagement with OUMA. Forward-looking statements reflect Pulsenmore’s current views\, plans\, or expectations with respect to future events or financial performance. They are inherently subject to significant business\, economic\, competitive\, and other risks\, uncertainties\, and contingencies. Forward-looking statements are based on Pulsenmore’s current expectations and are subject to inherent uncertainties\, risks and assumptions that are difficult to predict\, including\, but not limited to\, the following: the Company’s lack of operating history; the Company’s current and future capital requirements and the Company’s belief that its existing cash will be sufficient to fund its operations for more than one year from the date that the financial statements are issued; the Company’s ability to manufacture\, market and sell its products and to generate revenues; the Company’s ability to maintain its relationships with key partners and grow relationships with new partners; the Company’s ability to maintain or protect the validity of its U.S. and other patents and other intellectual property; the Company’s ability to launch and penetrate markets in new locations and new market segments; the Company’s ability to retain key executive members and hire additional personnel; the Company’s ability to maintain and expand intellectual property rights; interpretations of current laws and the passages of future laws; the Company’s ability to achieve greater regulatory compliance needed in existing and new markets; the Company’s ability to achieve key performance milestones in its planned operational testing; the Company’s ability to establish adequate sales\, marketing and distribution channels; security\, political and economic instability in the Middle East that could harm its business; and acceptance of the Company’s business model by investors. Further\, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. For a more detailed description of the risks and uncertainties affecting the Company\, reference is made to the Company’s reports filed from time to time with the SEC\, including\, but not limited to\, the risks\, uncertainties and other factors included in the Company’s Form 20-F (SEC File No. 001-43033)\, filed with the SEC on December 29\, 2025. The inclusion of forward-looking statements in this or any other communication should not be considered as a representation by Pulsenmore or any other person that current plans or expectations will be achieved. Forward-looking statements speak only as of the date on which they are made\, and Pulsenmore undertakes no obligation to publicly update or revise any forward-looking statement\, whether as a result of new information\, future developments\, or otherwise\, except as otherwise required by law.  \n  \nInvestor Contact:  \n  \nMiri Segal-Scharia  \nMS-IR LLC  \nmsegal@ms-ir.com 
URL:https://pulsenmore.com/event/nfog-congress-2025/
ATTACH;FMTTYPE=image/png:https://pulsenmore.com/wp-content/uploads/2025/03/18.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Asia/Jerusalem:20250629T080000
DTEND;TZID=Asia/Jerusalem:20250703T170000
DTSTAMP:20260625T173200
CREATED:20250320T133404Z
LAST-MODIFIED:20250320T134852Z
UID:40383-1751184000-1751562000@pulsenmore.com
SUMMARY:FMF World Congress
DESCRIPTION:Pulsenmore Announces Strategic Partnership with Ouma Health to Expand Access to Remote Prenatal Care Across the United States  \nFDA-authorized home ultrasound technology to be integrated into Ouma Health’s virtual maternity care model\, creating a scalable pathway to expand the adoption of home ultrasound in prenatal care across the United States  \nRamat Gan\, Israel\, June 24\, 2026 /PRNewswire/ Pulsenmore Ltd. (NASDAQ\, TASE: PLSM)\, a pioneer in home ultrasound technology\, today announced a strategic partnership with Ouma Health\, a leading provider of virtual maternity care solutions in the United States.  \nThrough the collaboration\, Ouma Health will incorporate Pulsenmore’s FDA-authorized home ultrasound platform as part of its virtual maternity care platform\, enabling clinicians to extend prenatal ultrasound monitoring beyond the clinic and into patients’ homes while maintaining continuous connection between expectant mothers and their care teams throughout pregnancy.  \nFor Pulsenmore\, the agreement represents a significant expansion of its presence in the U.S. maternal health market and an opportunity to integrate its home ultrasound platform into an established virtual care model serving expectant mothers nationwide.  \n“Maternal healthcare is undergoing a fundamental transformation toward more connected\, patient-centered care models\,” said Dr. Elazar Sonnenschein\, Founder and CEO of Pulsenmore. “By partnering with Ouma Health\, we have an opportunity to bring ultrasound beyond the walls of the clinic and into established virtual maternity care pathways\, helping healthcare professionals expand access to prenatal monitoring while keeping patients at the center of care. With 35% of U.S. counties classified as maternal care deserts\, virtual care models combined with home ultrasound technology will play an important role in closing critical access gaps for expectant mothers.”  \n“At Ouma\, we care for patients who often face significant geographic and logistical barriers to prenatal care\, including those living in maternity deserts and underserved communities\,” said Dr. Sina Haeri\, CEO of Ouma Health. “Pulsenmore’s technology gives us a way to bring more of the prenatal monitoring experience into the home\, while keeping patients connected to a clinical team that can review the information and guide next steps. This partnership helps us make virtual maternity care more clinically complete\, especially for patients who cannot easily access specialty care in person.  \nMaternal health remains one of the most critical areas of healthcare delivery in the United States. As healthcare organizations look for ways to improve access\, patient engagement\, and care coordination\, home ultrasound is emerging as a meaningful component of virtual and hybrid prenatal care models.  \nThe collaboration aims to deliver transformative care for the most underserved patients and establish insights and experience to support future expansion opportunities with healthcare systems\, maternity care providers\, and payer organizations seeking innovative approaches for maternal health delivery. Home ultrasound has the potential to become an important part of the next generation of prenatal care\, helping healthcare providers expand access\, improve patient engagement\, and deliver more connected pregnancy care beyond traditional clinical settings.  \nAbout Pulsenmore  \nPulsenmore Ltd. is dedicated to revolutionizing maternal health through home-use ultrasound technology that connects mothers and healthcare providers remotely. By leveraging advanced imaging and telemedicine\, Pulsenmore makes prenatal care patient-centric\, expanding access and improving continuity of care. For more information\, visit www.pulsenmore.com  \n  \nAbout Ouma Health  \nOuma Health is the nation’s largest independent maternity telemedicine company\, providing comprehensive care from preconception through postpartum. Founded and run by maternal-fetal medicine specialists\, Ouma is committed to equity\, innovation\, and outcomes\, serving patients in all 50 states through partnerships with major payors\, health systems\, OB groups\, FQHCs\, reproductive agencies\, and employers. For more information\, visit www.oumahealth.com.  \n  \nThis press release contains forward-looking statements. In particular\, statements using words such as “may\,” “seek\,” “will\,” “consider\,” “likely\,” “assume\,” “estimate\,” “expect\,” “anticipate\,” “intend\,” “believe\,” “contemplate\,” “do not believe\,” “aim\,” “goal\,” “due\,” “predict\,” “plan\,” “project\,” “continue\,” “potential\,” “positioned\,” “guidance\,” “objective\,” “outlook\,” “trends\,” “future\,” “could\,” “would\,” “should\,” “target\,” “on track” or their negatives or variations\, and similar terminology and words of similar import\, generally involve future or forward-looking statements. Such forward-looking statements include\, but are not limited to\, statements relating to the expected outcome of Pulsenmore’s engagement with OUMA. Forward-looking statements reflect Pulsenmore’s current views\, plans\, or expectations with respect to future events or financial performance. They are inherently subject to significant business\, economic\, competitive\, and other risks\, uncertainties\, and contingencies. Forward-looking statements are based on Pulsenmore’s current expectations and are subject to inherent uncertainties\, risks and assumptions that are difficult to predict\, including\, but not limited to\, the following: the Company’s lack of operating history; the Company’s current and future capital requirements and the Company’s belief that its existing cash will be sufficient to fund its operations for more than one year from the date that the financial statements are issued; the Company’s ability to manufacture\, market and sell its products and to generate revenues; the Company’s ability to maintain its relationships with key partners and grow relationships with new partners; the Company’s ability to maintain or protect the validity of its U.S. and other patents and other intellectual property; the Company’s ability to launch and penetrate markets in new locations and new market segments; the Company’s ability to retain key executive members and hire additional personnel; the Company’s ability to maintain and expand intellectual property rights; interpretations of current laws and the passages of future laws; the Company’s ability to achieve greater regulatory compliance needed in existing and new markets; the Company’s ability to achieve key performance milestones in its planned operational testing; the Company’s ability to establish adequate sales\, marketing and distribution channels; security\, political and economic instability in the Middle East that could harm its business; and acceptance of the Company’s business model by investors. Further\, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. For a more detailed description of the risks and uncertainties affecting the Company\, reference is made to the Company’s reports filed from time to time with the SEC\, including\, but not limited to\, the risks\, uncertainties and other factors included in the Company’s Form 20-F (SEC File No. 001-43033)\, filed with the SEC on December 29\, 2025. The inclusion of forward-looking statements in this or any other communication should not be considered as a representation by Pulsenmore or any other person that current plans or expectations will be achieved. Forward-looking statements speak only as of the date on which they are made\, and Pulsenmore undertakes no obligation to publicly update or revise any forward-looking statement\, whether as a result of new information\, future developments\, or otherwise\, except as otherwise required by law.  \n  \nInvestor Contact:  \n  \nMiri Segal-Scharia  \nMS-IR LLC  \nmsegal@ms-ir.com 
URL:https://pulsenmore.com/event/fmf-world-congress/
ATTACH;FMTTYPE=image/png:https://pulsenmore.com/wp-content/uploads/2025/03/17.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Asia/Jerusalem:20250623T080000
DTEND;TZID=Asia/Jerusalem:20250625T170000
DTSTAMP:20260625T173200
CREATED:20250320T133306Z
LAST-MODIFIED:20250320T134735Z
UID:40381-1750665600-1750870800@pulsenmore.com
SUMMARY:RCOG World Congress 2025
DESCRIPTION:Pulsenmore Announces Strategic Partnership with Ouma Health to Expand Access to Remote Prenatal Care Across the United States  \nFDA-authorized home ultrasound technology to be integrated into Ouma Health’s virtual maternity care model\, creating a scalable pathway to expand the adoption of home ultrasound in prenatal care across the United States  \nRamat Gan\, Israel\, June 24\, 2026 /PRNewswire/ Pulsenmore Ltd. (NASDAQ\, TASE: PLSM)\, a pioneer in home ultrasound technology\, today announced a strategic partnership with Ouma Health\, a leading provider of virtual maternity care solutions in the United States.  \nThrough the collaboration\, Ouma Health will incorporate Pulsenmore’s FDA-authorized home ultrasound platform as part of its virtual maternity care platform\, enabling clinicians to extend prenatal ultrasound monitoring beyond the clinic and into patients’ homes while maintaining continuous connection between expectant mothers and their care teams throughout pregnancy.  \nFor Pulsenmore\, the agreement represents a significant expansion of its presence in the U.S. maternal health market and an opportunity to integrate its home ultrasound platform into an established virtual care model serving expectant mothers nationwide.  \n“Maternal healthcare is undergoing a fundamental transformation toward more connected\, patient-centered care models\,” said Dr. Elazar Sonnenschein\, Founder and CEO of Pulsenmore. “By partnering with Ouma Health\, we have an opportunity to bring ultrasound beyond the walls of the clinic and into established virtual maternity care pathways\, helping healthcare professionals expand access to prenatal monitoring while keeping patients at the center of care. With 35% of U.S. counties classified as maternal care deserts\, virtual care models combined with home ultrasound technology will play an important role in closing critical access gaps for expectant mothers.”  \n“At Ouma\, we care for patients who often face significant geographic and logistical barriers to prenatal care\, including those living in maternity deserts and underserved communities\,” said Dr. Sina Haeri\, CEO of Ouma Health. “Pulsenmore’s technology gives us a way to bring more of the prenatal monitoring experience into the home\, while keeping patients connected to a clinical team that can review the information and guide next steps. This partnership helps us make virtual maternity care more clinically complete\, especially for patients who cannot easily access specialty care in person.  \nMaternal health remains one of the most critical areas of healthcare delivery in the United States. As healthcare organizations look for ways to improve access\, patient engagement\, and care coordination\, home ultrasound is emerging as a meaningful component of virtual and hybrid prenatal care models.  \nThe collaboration aims to deliver transformative care for the most underserved patients and establish insights and experience to support future expansion opportunities with healthcare systems\, maternity care providers\, and payer organizations seeking innovative approaches for maternal health delivery. Home ultrasound has the potential to become an important part of the next generation of prenatal care\, helping healthcare providers expand access\, improve patient engagement\, and deliver more connected pregnancy care beyond traditional clinical settings.  \nAbout Pulsenmore  \nPulsenmore Ltd. is dedicated to revolutionizing maternal health through home-use ultrasound technology that connects mothers and healthcare providers remotely. By leveraging advanced imaging and telemedicine\, Pulsenmore makes prenatal care patient-centric\, expanding access and improving continuity of care. For more information\, visit www.pulsenmore.com  \n  \nAbout Ouma Health  \nOuma Health is the nation’s largest independent maternity telemedicine company\, providing comprehensive care from preconception through postpartum. Founded and run by maternal-fetal medicine specialists\, Ouma is committed to equity\, innovation\, and outcomes\, serving patients in all 50 states through partnerships with major payors\, health systems\, OB groups\, FQHCs\, reproductive agencies\, and employers. For more information\, visit www.oumahealth.com.  \n  \nThis press release contains forward-looking statements. In particular\, statements using words such as “may\,” “seek\,” “will\,” “consider\,” “likely\,” “assume\,” “estimate\,” “expect\,” “anticipate\,” “intend\,” “believe\,” “contemplate\,” “do not believe\,” “aim\,” “goal\,” “due\,” “predict\,” “plan\,” “project\,” “continue\,” “potential\,” “positioned\,” “guidance\,” “objective\,” “outlook\,” “trends\,” “future\,” “could\,” “would\,” “should\,” “target\,” “on track” or their negatives or variations\, and similar terminology and words of similar import\, generally involve future or forward-looking statements. Such forward-looking statements include\, but are not limited to\, statements relating to the expected outcome of Pulsenmore’s engagement with OUMA. Forward-looking statements reflect Pulsenmore’s current views\, plans\, or expectations with respect to future events or financial performance. They are inherently subject to significant business\, economic\, competitive\, and other risks\, uncertainties\, and contingencies. Forward-looking statements are based on Pulsenmore’s current expectations and are subject to inherent uncertainties\, risks and assumptions that are difficult to predict\, including\, but not limited to\, the following: the Company’s lack of operating history; the Company’s current and future capital requirements and the Company’s belief that its existing cash will be sufficient to fund its operations for more than one year from the date that the financial statements are issued; the Company’s ability to manufacture\, market and sell its products and to generate revenues; the Company’s ability to maintain its relationships with key partners and grow relationships with new partners; the Company’s ability to maintain or protect the validity of its U.S. and other patents and other intellectual property; the Company’s ability to launch and penetrate markets in new locations and new market segments; the Company’s ability to retain key executive members and hire additional personnel; the Company’s ability to maintain and expand intellectual property rights; interpretations of current laws and the passages of future laws; the Company’s ability to achieve greater regulatory compliance needed in existing and new markets; the Company’s ability to achieve key performance milestones in its planned operational testing; the Company’s ability to establish adequate sales\, marketing and distribution channels; security\, political and economic instability in the Middle East that could harm its business; and acceptance of the Company’s business model by investors. Further\, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. For a more detailed description of the risks and uncertainties affecting the Company\, reference is made to the Company’s reports filed from time to time with the SEC\, including\, but not limited to\, the risks\, uncertainties and other factors included in the Company’s Form 20-F (SEC File No. 001-43033)\, filed with the SEC on December 29\, 2025. The inclusion of forward-looking statements in this or any other communication should not be considered as a representation by Pulsenmore or any other person that current plans or expectations will be achieved. Forward-looking statements speak only as of the date on which they are made\, and Pulsenmore undertakes no obligation to publicly update or revise any forward-looking statement\, whether as a result of new information\, future developments\, or otherwise\, except as otherwise required by law.  \n  \nInvestor Contact:  \n  \nMiri Segal-Scharia  \nMS-IR LLC  \nmsegal@ms-ir.com 
URL:https://pulsenmore.com/event/rcog-world-congress-2025/
ATTACH;FMTTYPE=image/png:https://pulsenmore.com/wp-content/uploads/2025/03/16.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Asia/Jerusalem:20250616T080000
DTEND;TZID=Asia/Jerusalem:20250619T170000
DTSTAMP:20260625T173200
CREATED:20250320T133208Z
LAST-MODIFIED:20250320T134630Z
UID:40379-1750060800-1750352400@pulsenmore.com
SUMMARY:HLTH EU 2025
DESCRIPTION:Pulsenmore Announces Strategic Partnership with Ouma Health to Expand Access to Remote Prenatal Care Across the United States  \nFDA-authorized home ultrasound technology to be integrated into Ouma Health’s virtual maternity care model\, creating a scalable pathway to expand the adoption of home ultrasound in prenatal care across the United States  \nRamat Gan\, Israel\, June 24\, 2026 /PRNewswire/ Pulsenmore Ltd. (NASDAQ\, TASE: PLSM)\, a pioneer in home ultrasound technology\, today announced a strategic partnership with Ouma Health\, a leading provider of virtual maternity care solutions in the United States.  \nThrough the collaboration\, Ouma Health will incorporate Pulsenmore’s FDA-authorized home ultrasound platform as part of its virtual maternity care platform\, enabling clinicians to extend prenatal ultrasound monitoring beyond the clinic and into patients’ homes while maintaining continuous connection between expectant mothers and their care teams throughout pregnancy.  \nFor Pulsenmore\, the agreement represents a significant expansion of its presence in the U.S. maternal health market and an opportunity to integrate its home ultrasound platform into an established virtual care model serving expectant mothers nationwide.  \n“Maternal healthcare is undergoing a fundamental transformation toward more connected\, patient-centered care models\,” said Dr. Elazar Sonnenschein\, Founder and CEO of Pulsenmore. “By partnering with Ouma Health\, we have an opportunity to bring ultrasound beyond the walls of the clinic and into established virtual maternity care pathways\, helping healthcare professionals expand access to prenatal monitoring while keeping patients at the center of care. With 35% of U.S. counties classified as maternal care deserts\, virtual care models combined with home ultrasound technology will play an important role in closing critical access gaps for expectant mothers.”  \n“At Ouma\, we care for patients who often face significant geographic and logistical barriers to prenatal care\, including those living in maternity deserts and underserved communities\,” said Dr. Sina Haeri\, CEO of Ouma Health. “Pulsenmore’s technology gives us a way to bring more of the prenatal monitoring experience into the home\, while keeping patients connected to a clinical team that can review the information and guide next steps. This partnership helps us make virtual maternity care more clinically complete\, especially for patients who cannot easily access specialty care in person.  \nMaternal health remains one of the most critical areas of healthcare delivery in the United States. As healthcare organizations look for ways to improve access\, patient engagement\, and care coordination\, home ultrasound is emerging as a meaningful component of virtual and hybrid prenatal care models.  \nThe collaboration aims to deliver transformative care for the most underserved patients and establish insights and experience to support future expansion opportunities with healthcare systems\, maternity care providers\, and payer organizations seeking innovative approaches for maternal health delivery. Home ultrasound has the potential to become an important part of the next generation of prenatal care\, helping healthcare providers expand access\, improve patient engagement\, and deliver more connected pregnancy care beyond traditional clinical settings.  \nAbout Pulsenmore  \nPulsenmore Ltd. is dedicated to revolutionizing maternal health through home-use ultrasound technology that connects mothers and healthcare providers remotely. By leveraging advanced imaging and telemedicine\, Pulsenmore makes prenatal care patient-centric\, expanding access and improving continuity of care. For more information\, visit www.pulsenmore.com  \n  \nAbout Ouma Health  \nOuma Health is the nation’s largest independent maternity telemedicine company\, providing comprehensive care from preconception through postpartum. Founded and run by maternal-fetal medicine specialists\, Ouma is committed to equity\, innovation\, and outcomes\, serving patients in all 50 states through partnerships with major payors\, health systems\, OB groups\, FQHCs\, reproductive agencies\, and employers. For more information\, visit www.oumahealth.com.  \n  \nThis press release contains forward-looking statements. In particular\, statements using words such as “may\,” “seek\,” “will\,” “consider\,” “likely\,” “assume\,” “estimate\,” “expect\,” “anticipate\,” “intend\,” “believe\,” “contemplate\,” “do not believe\,” “aim\,” “goal\,” “due\,” “predict\,” “plan\,” “project\,” “continue\,” “potential\,” “positioned\,” “guidance\,” “objective\,” “outlook\,” “trends\,” “future\,” “could\,” “would\,” “should\,” “target\,” “on track” or their negatives or variations\, and similar terminology and words of similar import\, generally involve future or forward-looking statements. Such forward-looking statements include\, but are not limited to\, statements relating to the expected outcome of Pulsenmore’s engagement with OUMA. Forward-looking statements reflect Pulsenmore’s current views\, plans\, or expectations with respect to future events or financial performance. They are inherently subject to significant business\, economic\, competitive\, and other risks\, uncertainties\, and contingencies. Forward-looking statements are based on Pulsenmore’s current expectations and are subject to inherent uncertainties\, risks and assumptions that are difficult to predict\, including\, but not limited to\, the following: the Company’s lack of operating history; the Company’s current and future capital requirements and the Company’s belief that its existing cash will be sufficient to fund its operations for more than one year from the date that the financial statements are issued; the Company’s ability to manufacture\, market and sell its products and to generate revenues; the Company’s ability to maintain its relationships with key partners and grow relationships with new partners; the Company’s ability to maintain or protect the validity of its U.S. and other patents and other intellectual property; the Company’s ability to launch and penetrate markets in new locations and new market segments; the Company’s ability to retain key executive members and hire additional personnel; the Company’s ability to maintain and expand intellectual property rights; interpretations of current laws and the passages of future laws; the Company’s ability to achieve greater regulatory compliance needed in existing and new markets; the Company’s ability to achieve key performance milestones in its planned operational testing; the Company’s ability to establish adequate sales\, marketing and distribution channels; security\, political and economic instability in the Middle East that could harm its business; and acceptance of the Company’s business model by investors. Further\, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. For a more detailed description of the risks and uncertainties affecting the Company\, reference is made to the Company’s reports filed from time to time with the SEC\, including\, but not limited to\, the risks\, uncertainties and other factors included in the Company’s Form 20-F (SEC File No. 001-43033)\, filed with the SEC on December 29\, 2025. The inclusion of forward-looking statements in this or any other communication should not be considered as a representation by Pulsenmore or any other person that current plans or expectations will be achieved. Forward-looking statements speak only as of the date on which they are made\, and Pulsenmore undertakes no obligation to publicly update or revise any forward-looking statement\, whether as a result of new information\, future developments\, or otherwise\, except as otherwise required by law.  \n  \nInvestor Contact:  \n  \nMiri Segal-Scharia  \nMS-IR LLC  \nmsegal@ms-ir.com 
URL:https://pulsenmore.com/event/hlth-eu-2025/
ATTACH;FMTTYPE=image/png:https://pulsenmore.com/wp-content/uploads/2025/03/15.png
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20250607
DTEND;VALUE=DATE:20250611
DTSTAMP:20260625T173200
CREATED:20250318T085323Z
LAST-MODIFIED:20250318T090540Z
UID:40136-1749254400-1749599999@pulsenmore.com
SUMMARY:ARM 2025 - Jun 7-10\, Minneapolis\, MN
DESCRIPTION:Pulsenmore Announces Strategic Partnership with Ouma Health to Expand Access to Remote Prenatal Care Across the United States  \nFDA-authorized home ultrasound technology to be integrated into Ouma Health’s virtual maternity care model\, creating a scalable pathway to expand the adoption of home ultrasound in prenatal care across the United States  \nRamat Gan\, Israel\, June 24\, 2026 /PRNewswire/ Pulsenmore Ltd. (NASDAQ\, TASE: PLSM)\, a pioneer in home ultrasound technology\, today announced a strategic partnership with Ouma Health\, a leading provider of virtual maternity care solutions in the United States.  \nThrough the collaboration\, Ouma Health will incorporate Pulsenmore’s FDA-authorized home ultrasound platform as part of its virtual maternity care platform\, enabling clinicians to extend prenatal ultrasound monitoring beyond the clinic and into patients’ homes while maintaining continuous connection between expectant mothers and their care teams throughout pregnancy.  \nFor Pulsenmore\, the agreement represents a significant expansion of its presence in the U.S. maternal health market and an opportunity to integrate its home ultrasound platform into an established virtual care model serving expectant mothers nationwide.  \n“Maternal healthcare is undergoing a fundamental transformation toward more connected\, patient-centered care models\,” said Dr. Elazar Sonnenschein\, Founder and CEO of Pulsenmore. “By partnering with Ouma Health\, we have an opportunity to bring ultrasound beyond the walls of the clinic and into established virtual maternity care pathways\, helping healthcare professionals expand access to prenatal monitoring while keeping patients at the center of care. With 35% of U.S. counties classified as maternal care deserts\, virtual care models combined with home ultrasound technology will play an important role in closing critical access gaps for expectant mothers.”  \n“At Ouma\, we care for patients who often face significant geographic and logistical barriers to prenatal care\, including those living in maternity deserts and underserved communities\,” said Dr. Sina Haeri\, CEO of Ouma Health. “Pulsenmore’s technology gives us a way to bring more of the prenatal monitoring experience into the home\, while keeping patients connected to a clinical team that can review the information and guide next steps. This partnership helps us make virtual maternity care more clinically complete\, especially for patients who cannot easily access specialty care in person.  \nMaternal health remains one of the most critical areas of healthcare delivery in the United States. As healthcare organizations look for ways to improve access\, patient engagement\, and care coordination\, home ultrasound is emerging as a meaningful component of virtual and hybrid prenatal care models.  \nThe collaboration aims to deliver transformative care for the most underserved patients and establish insights and experience to support future expansion opportunities with healthcare systems\, maternity care providers\, and payer organizations seeking innovative approaches for maternal health delivery. Home ultrasound has the potential to become an important part of the next generation of prenatal care\, helping healthcare providers expand access\, improve patient engagement\, and deliver more connected pregnancy care beyond traditional clinical settings.  \nAbout Pulsenmore  \nPulsenmore Ltd. is dedicated to revolutionizing maternal health through home-use ultrasound technology that connects mothers and healthcare providers remotely. By leveraging advanced imaging and telemedicine\, Pulsenmore makes prenatal care patient-centric\, expanding access and improving continuity of care. For more information\, visit www.pulsenmore.com  \n  \nAbout Ouma Health  \nOuma Health is the nation’s largest independent maternity telemedicine company\, providing comprehensive care from preconception through postpartum. Founded and run by maternal-fetal medicine specialists\, Ouma is committed to equity\, innovation\, and outcomes\, serving patients in all 50 states through partnerships with major payors\, health systems\, OB groups\, FQHCs\, reproductive agencies\, and employers. For more information\, visit www.oumahealth.com.  \n  \nThis press release contains forward-looking statements. In particular\, statements using words such as “may\,” “seek\,” “will\,” “consider\,” “likely\,” “assume\,” “estimate\,” “expect\,” “anticipate\,” “intend\,” “believe\,” “contemplate\,” “do not believe\,” “aim\,” “goal\,” “due\,” “predict\,” “plan\,” “project\,” “continue\,” “potential\,” “positioned\,” “guidance\,” “objective\,” “outlook\,” “trends\,” “future\,” “could\,” “would\,” “should\,” “target\,” “on track” or their negatives or variations\, and similar terminology and words of similar import\, generally involve future or forward-looking statements. Such forward-looking statements include\, but are not limited to\, statements relating to the expected outcome of Pulsenmore’s engagement with OUMA. Forward-looking statements reflect Pulsenmore’s current views\, plans\, or expectations with respect to future events or financial performance. They are inherently subject to significant business\, economic\, competitive\, and other risks\, uncertainties\, and contingencies. Forward-looking statements are based on Pulsenmore’s current expectations and are subject to inherent uncertainties\, risks and assumptions that are difficult to predict\, including\, but not limited to\, the following: the Company’s lack of operating history; the Company’s current and future capital requirements and the Company’s belief that its existing cash will be sufficient to fund its operations for more than one year from the date that the financial statements are issued; the Company’s ability to manufacture\, market and sell its products and to generate revenues; the Company’s ability to maintain its relationships with key partners and grow relationships with new partners; the Company’s ability to maintain or protect the validity of its U.S. and other patents and other intellectual property; the Company’s ability to launch and penetrate markets in new locations and new market segments; the Company’s ability to retain key executive members and hire additional personnel; the Company’s ability to maintain and expand intellectual property rights; interpretations of current laws and the passages of future laws; the Company’s ability to achieve greater regulatory compliance needed in existing and new markets; the Company’s ability to achieve key performance milestones in its planned operational testing; the Company’s ability to establish adequate sales\, marketing and distribution channels; security\, political and economic instability in the Middle East that could harm its business; and acceptance of the Company’s business model by investors. Further\, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. For a more detailed description of the risks and uncertainties affecting the Company\, reference is made to the Company’s reports filed from time to time with the SEC\, including\, but not limited to\, the risks\, uncertainties and other factors included in the Company’s Form 20-F (SEC File No. 001-43033)\, filed with the SEC on December 29\, 2025. The inclusion of forward-looking statements in this or any other communication should not be considered as a representation by Pulsenmore or any other person that current plans or expectations will be achieved. Forward-looking statements speak only as of the date on which they are made\, and Pulsenmore undertakes no obligation to publicly update or revise any forward-looking statement\, whether as a result of new information\, future developments\, or otherwise\, except as otherwise required by law.  \n  \nInvestor Contact:  \n  \nMiri Segal-Scharia  \nMS-IR LLC  \nmsegal@ms-ir.com 
URL:https://pulsenmore.com/event/arm-2025-jun-7-10-minneapolis-mn/
ATTACH;FMTTYPE=image/jpeg:https://pulsenmore.com/wp-content/uploads/2025/03/ARM-2025.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Asia/Jerusalem:20250528T080000
DTEND;TZID=Asia/Jerusalem:20250530T170000
DTSTAMP:20260625T173200
CREATED:20250506T075912Z
LAST-MODIFIED:20250506T075912Z
UID:41853-1748419200-1748624400@pulsenmore.com
SUMMARY:WCPM 2025
DESCRIPTION:Pulsenmore Announces Strategic Partnership with Ouma Health to Expand Access to Remote Prenatal Care Across the United States  \nFDA-authorized home ultrasound technology to be integrated into Ouma Health’s virtual maternity care model\, creating a scalable pathway to expand the adoption of home ultrasound in prenatal care across the United States  \nRamat Gan\, Israel\, June 24\, 2026 /PRNewswire/ Pulsenmore Ltd. (NASDAQ\, TASE: PLSM)\, a pioneer in home ultrasound technology\, today announced a strategic partnership with Ouma Health\, a leading provider of virtual maternity care solutions in the United States.  \nThrough the collaboration\, Ouma Health will incorporate Pulsenmore’s FDA-authorized home ultrasound platform as part of its virtual maternity care platform\, enabling clinicians to extend prenatal ultrasound monitoring beyond the clinic and into patients’ homes while maintaining continuous connection between expectant mothers and their care teams throughout pregnancy.  \nFor Pulsenmore\, the agreement represents a significant expansion of its presence in the U.S. maternal health market and an opportunity to integrate its home ultrasound platform into an established virtual care model serving expectant mothers nationwide.  \n“Maternal healthcare is undergoing a fundamental transformation toward more connected\, patient-centered care models\,” said Dr. Elazar Sonnenschein\, Founder and CEO of Pulsenmore. “By partnering with Ouma Health\, we have an opportunity to bring ultrasound beyond the walls of the clinic and into established virtual maternity care pathways\, helping healthcare professionals expand access to prenatal monitoring while keeping patients at the center of care. With 35% of U.S. counties classified as maternal care deserts\, virtual care models combined with home ultrasound technology will play an important role in closing critical access gaps for expectant mothers.”  \n“At Ouma\, we care for patients who often face significant geographic and logistical barriers to prenatal care\, including those living in maternity deserts and underserved communities\,” said Dr. Sina Haeri\, CEO of Ouma Health. “Pulsenmore’s technology gives us a way to bring more of the prenatal monitoring experience into the home\, while keeping patients connected to a clinical team that can review the information and guide next steps. This partnership helps us make virtual maternity care more clinically complete\, especially for patients who cannot easily access specialty care in person.  \nMaternal health remains one of the most critical areas of healthcare delivery in the United States. As healthcare organizations look for ways to improve access\, patient engagement\, and care coordination\, home ultrasound is emerging as a meaningful component of virtual and hybrid prenatal care models.  \nThe collaboration aims to deliver transformative care for the most underserved patients and establish insights and experience to support future expansion opportunities with healthcare systems\, maternity care providers\, and payer organizations seeking innovative approaches for maternal health delivery. Home ultrasound has the potential to become an important part of the next generation of prenatal care\, helping healthcare providers expand access\, improve patient engagement\, and deliver more connected pregnancy care beyond traditional clinical settings.  \nAbout Pulsenmore  \nPulsenmore Ltd. is dedicated to revolutionizing maternal health through home-use ultrasound technology that connects mothers and healthcare providers remotely. By leveraging advanced imaging and telemedicine\, Pulsenmore makes prenatal care patient-centric\, expanding access and improving continuity of care. For more information\, visit www.pulsenmore.com  \n  \nAbout Ouma Health  \nOuma Health is the nation’s largest independent maternity telemedicine company\, providing comprehensive care from preconception through postpartum. Founded and run by maternal-fetal medicine specialists\, Ouma is committed to equity\, innovation\, and outcomes\, serving patients in all 50 states through partnerships with major payors\, health systems\, OB groups\, FQHCs\, reproductive agencies\, and employers. For more information\, visit www.oumahealth.com.  \n  \nThis press release contains forward-looking statements. In particular\, statements using words such as “may\,” “seek\,” “will\,” “consider\,” “likely\,” “assume\,” “estimate\,” “expect\,” “anticipate\,” “intend\,” “believe\,” “contemplate\,” “do not believe\,” “aim\,” “goal\,” “due\,” “predict\,” “plan\,” “project\,” “continue\,” “potential\,” “positioned\,” “guidance\,” “objective\,” “outlook\,” “trends\,” “future\,” “could\,” “would\,” “should\,” “target\,” “on track” or their negatives or variations\, and similar terminology and words of similar import\, generally involve future or forward-looking statements. Such forward-looking statements include\, but are not limited to\, statements relating to the expected outcome of Pulsenmore’s engagement with OUMA. Forward-looking statements reflect Pulsenmore’s current views\, plans\, or expectations with respect to future events or financial performance. They are inherently subject to significant business\, economic\, competitive\, and other risks\, uncertainties\, and contingencies. Forward-looking statements are based on Pulsenmore’s current expectations and are subject to inherent uncertainties\, risks and assumptions that are difficult to predict\, including\, but not limited to\, the following: the Company’s lack of operating history; the Company’s current and future capital requirements and the Company’s belief that its existing cash will be sufficient to fund its operations for more than one year from the date that the financial statements are issued; the Company’s ability to manufacture\, market and sell its products and to generate revenues; the Company’s ability to maintain its relationships with key partners and grow relationships with new partners; the Company’s ability to maintain or protect the validity of its U.S. and other patents and other intellectual property; the Company’s ability to launch and penetrate markets in new locations and new market segments; the Company’s ability to retain key executive members and hire additional personnel; the Company’s ability to maintain and expand intellectual property rights; interpretations of current laws and the passages of future laws; the Company’s ability to achieve greater regulatory compliance needed in existing and new markets; the Company’s ability to achieve key performance milestones in its planned operational testing; the Company’s ability to establish adequate sales\, marketing and distribution channels; security\, political and economic instability in the Middle East that could harm its business; and acceptance of the Company’s business model by investors. Further\, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. For a more detailed description of the risks and uncertainties affecting the Company\, reference is made to the Company’s reports filed from time to time with the SEC\, including\, but not limited to\, the risks\, uncertainties and other factors included in the Company’s Form 20-F (SEC File No. 001-43033)\, filed with the SEC on December 29\, 2025. The inclusion of forward-looking statements in this or any other communication should not be considered as a representation by Pulsenmore or any other person that current plans or expectations will be achieved. Forward-looking statements speak only as of the date on which they are made\, and Pulsenmore undertakes no obligation to publicly update or revise any forward-looking statement\, whether as a result of new information\, future developments\, or otherwise\, except as otherwise required by law.  \n  \nInvestor Contact:  \n  \nMiri Segal-Scharia  \nMS-IR LLC  \nmsegal@ms-ir.com 
URL:https://pulsenmore.com/event/wcpm-2025/
ATTACH;FMTTYPE=image/png:https://pulsenmore.com/wp-content/uploads/2024/12/WCPM-2025.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Asia/Jerusalem:20250520T080000
DTEND;TZID=Asia/Jerusalem:20250523T170000
DTSTAMP:20260625T173200
CREATED:20250506T075600Z
LAST-MODIFIED:20250506T075600Z
UID:41845-1747728000-1748019600@pulsenmore.com
SUMMARY:Hospitalar 2025
DESCRIPTION:Pulsenmore Announces Strategic Partnership with Ouma Health to Expand Access to Remote Prenatal Care Across the United States  \nFDA-authorized home ultrasound technology to be integrated into Ouma Health’s virtual maternity care model\, creating a scalable pathway to expand the adoption of home ultrasound in prenatal care across the United States  \nRamat Gan\, Israel\, June 24\, 2026 /PRNewswire/ Pulsenmore Ltd. (NASDAQ\, TASE: PLSM)\, a pioneer in home ultrasound technology\, today announced a strategic partnership with Ouma Health\, a leading provider of virtual maternity care solutions in the United States.  \nThrough the collaboration\, Ouma Health will incorporate Pulsenmore’s FDA-authorized home ultrasound platform as part of its virtual maternity care platform\, enabling clinicians to extend prenatal ultrasound monitoring beyond the clinic and into patients’ homes while maintaining continuous connection between expectant mothers and their care teams throughout pregnancy.  \nFor Pulsenmore\, the agreement represents a significant expansion of its presence in the U.S. maternal health market and an opportunity to integrate its home ultrasound platform into an established virtual care model serving expectant mothers nationwide.  \n“Maternal healthcare is undergoing a fundamental transformation toward more connected\, patient-centered care models\,” said Dr. Elazar Sonnenschein\, Founder and CEO of Pulsenmore. “By partnering with Ouma Health\, we have an opportunity to bring ultrasound beyond the walls of the clinic and into established virtual maternity care pathways\, helping healthcare professionals expand access to prenatal monitoring while keeping patients at the center of care. With 35% of U.S. counties classified as maternal care deserts\, virtual care models combined with home ultrasound technology will play an important role in closing critical access gaps for expectant mothers.”  \n“At Ouma\, we care for patients who often face significant geographic and logistical barriers to prenatal care\, including those living in maternity deserts and underserved communities\,” said Dr. Sina Haeri\, CEO of Ouma Health. “Pulsenmore’s technology gives us a way to bring more of the prenatal monitoring experience into the home\, while keeping patients connected to a clinical team that can review the information and guide next steps. This partnership helps us make virtual maternity care more clinically complete\, especially for patients who cannot easily access specialty care in person.  \nMaternal health remains one of the most critical areas of healthcare delivery in the United States. As healthcare organizations look for ways to improve access\, patient engagement\, and care coordination\, home ultrasound is emerging as a meaningful component of virtual and hybrid prenatal care models.  \nThe collaboration aims to deliver transformative care for the most underserved patients and establish insights and experience to support future expansion opportunities with healthcare systems\, maternity care providers\, and payer organizations seeking innovative approaches for maternal health delivery. Home ultrasound has the potential to become an important part of the next generation of prenatal care\, helping healthcare providers expand access\, improve patient engagement\, and deliver more connected pregnancy care beyond traditional clinical settings.  \nAbout Pulsenmore  \nPulsenmore Ltd. is dedicated to revolutionizing maternal health through home-use ultrasound technology that connects mothers and healthcare providers remotely. By leveraging advanced imaging and telemedicine\, Pulsenmore makes prenatal care patient-centric\, expanding access and improving continuity of care. For more information\, visit www.pulsenmore.com  \n  \nAbout Ouma Health  \nOuma Health is the nation’s largest independent maternity telemedicine company\, providing comprehensive care from preconception through postpartum. Founded and run by maternal-fetal medicine specialists\, Ouma is committed to equity\, innovation\, and outcomes\, serving patients in all 50 states through partnerships with major payors\, health systems\, OB groups\, FQHCs\, reproductive agencies\, and employers. For more information\, visit www.oumahealth.com.  \n  \nThis press release contains forward-looking statements. In particular\, statements using words such as “may\,” “seek\,” “will\,” “consider\,” “likely\,” “assume\,” “estimate\,” “expect\,” “anticipate\,” “intend\,” “believe\,” “contemplate\,” “do not believe\,” “aim\,” “goal\,” “due\,” “predict\,” “plan\,” “project\,” “continue\,” “potential\,” “positioned\,” “guidance\,” “objective\,” “outlook\,” “trends\,” “future\,” “could\,” “would\,” “should\,” “target\,” “on track” or their negatives or variations\, and similar terminology and words of similar import\, generally involve future or forward-looking statements. Such forward-looking statements include\, but are not limited to\, statements relating to the expected outcome of Pulsenmore’s engagement with OUMA. Forward-looking statements reflect Pulsenmore’s current views\, plans\, or expectations with respect to future events or financial performance. They are inherently subject to significant business\, economic\, competitive\, and other risks\, uncertainties\, and contingencies. Forward-looking statements are based on Pulsenmore’s current expectations and are subject to inherent uncertainties\, risks and assumptions that are difficult to predict\, including\, but not limited to\, the following: the Company’s lack of operating history; the Company’s current and future capital requirements and the Company’s belief that its existing cash will be sufficient to fund its operations for more than one year from the date that the financial statements are issued; the Company’s ability to manufacture\, market and sell its products and to generate revenues; the Company’s ability to maintain its relationships with key partners and grow relationships with new partners; the Company’s ability to maintain or protect the validity of its U.S. and other patents and other intellectual property; the Company’s ability to launch and penetrate markets in new locations and new market segments; the Company’s ability to retain key executive members and hire additional personnel; the Company’s ability to maintain and expand intellectual property rights; interpretations of current laws and the passages of future laws; the Company’s ability to achieve greater regulatory compliance needed in existing and new markets; the Company’s ability to achieve key performance milestones in its planned operational testing; the Company’s ability to establish adequate sales\, marketing and distribution channels; security\, political and economic instability in the Middle East that could harm its business; and acceptance of the Company’s business model by investors. Further\, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. For a more detailed description of the risks and uncertainties affecting the Company\, reference is made to the Company’s reports filed from time to time with the SEC\, including\, but not limited to\, the risks\, uncertainties and other factors included in the Company’s Form 20-F (SEC File No. 001-43033)\, filed with the SEC on December 29\, 2025. The inclusion of forward-looking statements in this or any other communication should not be considered as a representation by Pulsenmore or any other person that current plans or expectations will be achieved. Forward-looking statements speak only as of the date on which they are made\, and Pulsenmore undertakes no obligation to publicly update or revise any forward-looking statement\, whether as a result of new information\, future developments\, or otherwise\, except as otherwise required by law.  \n  \nInvestor Contact:  \n  \nMiri Segal-Scharia  \nMS-IR LLC  \nmsegal@ms-ir.com 
URL:https://pulsenmore.com/event/hospitalar-2025/
ATTACH;FMTTYPE=image/png:https://pulsenmore.com/wp-content/uploads/2025/05/Screenshot-2025-05-06-105429.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Asia/Jerusalem:20250520T080000
DTEND;TZID=Asia/Jerusalem:20250522T170000
DTSTAMP:20260625T173200
CREATED:20250320T132848Z
LAST-MODIFIED:20250320T132848Z
UID:40377-1747728000-1747933200@pulsenmore.com
SUMMARY:BIOMED Israel 2025
DESCRIPTION:Pulsenmore Announces Strategic Partnership with Ouma Health to Expand Access to Remote Prenatal Care Across the United States  \nFDA-authorized home ultrasound technology to be integrated into Ouma Health’s virtual maternity care model\, creating a scalable pathway to expand the adoption of home ultrasound in prenatal care across the United States  \nRamat Gan\, Israel\, June 24\, 2026 /PRNewswire/ Pulsenmore Ltd. (NASDAQ\, TASE: PLSM)\, a pioneer in home ultrasound technology\, today announced a strategic partnership with Ouma Health\, a leading provider of virtual maternity care solutions in the United States.  \nThrough the collaboration\, Ouma Health will incorporate Pulsenmore’s FDA-authorized home ultrasound platform as part of its virtual maternity care platform\, enabling clinicians to extend prenatal ultrasound monitoring beyond the clinic and into patients’ homes while maintaining continuous connection between expectant mothers and their care teams throughout pregnancy.  \nFor Pulsenmore\, the agreement represents a significant expansion of its presence in the U.S. maternal health market and an opportunity to integrate its home ultrasound platform into an established virtual care model serving expectant mothers nationwide.  \n“Maternal healthcare is undergoing a fundamental transformation toward more connected\, patient-centered care models\,” said Dr. Elazar Sonnenschein\, Founder and CEO of Pulsenmore. “By partnering with Ouma Health\, we have an opportunity to bring ultrasound beyond the walls of the clinic and into established virtual maternity care pathways\, helping healthcare professionals expand access to prenatal monitoring while keeping patients at the center of care. With 35% of U.S. counties classified as maternal care deserts\, virtual care models combined with home ultrasound technology will play an important role in closing critical access gaps for expectant mothers.”  \n“At Ouma\, we care for patients who often face significant geographic and logistical barriers to prenatal care\, including those living in maternity deserts and underserved communities\,” said Dr. Sina Haeri\, CEO of Ouma Health. “Pulsenmore’s technology gives us a way to bring more of the prenatal monitoring experience into the home\, while keeping patients connected to a clinical team that can review the information and guide next steps. This partnership helps us make virtual maternity care more clinically complete\, especially for patients who cannot easily access specialty care in person.  \nMaternal health remains one of the most critical areas of healthcare delivery in the United States. As healthcare organizations look for ways to improve access\, patient engagement\, and care coordination\, home ultrasound is emerging as a meaningful component of virtual and hybrid prenatal care models.  \nThe collaboration aims to deliver transformative care for the most underserved patients and establish insights and experience to support future expansion opportunities with healthcare systems\, maternity care providers\, and payer organizations seeking innovative approaches for maternal health delivery. Home ultrasound has the potential to become an important part of the next generation of prenatal care\, helping healthcare providers expand access\, improve patient engagement\, and deliver more connected pregnancy care beyond traditional clinical settings.  \nAbout Pulsenmore  \nPulsenmore Ltd. is dedicated to revolutionizing maternal health through home-use ultrasound technology that connects mothers and healthcare providers remotely. By leveraging advanced imaging and telemedicine\, Pulsenmore makes prenatal care patient-centric\, expanding access and improving continuity of care. For more information\, visit www.pulsenmore.com  \n  \nAbout Ouma Health  \nOuma Health is the nation’s largest independent maternity telemedicine company\, providing comprehensive care from preconception through postpartum. Founded and run by maternal-fetal medicine specialists\, Ouma is committed to equity\, innovation\, and outcomes\, serving patients in all 50 states through partnerships with major payors\, health systems\, OB groups\, FQHCs\, reproductive agencies\, and employers. For more information\, visit www.oumahealth.com.  \n  \nThis press release contains forward-looking statements. In particular\, statements using words such as “may\,” “seek\,” “will\,” “consider\,” “likely\,” “assume\,” “estimate\,” “expect\,” “anticipate\,” “intend\,” “believe\,” “contemplate\,” “do not believe\,” “aim\,” “goal\,” “due\,” “predict\,” “plan\,” “project\,” “continue\,” “potential\,” “positioned\,” “guidance\,” “objective\,” “outlook\,” “trends\,” “future\,” “could\,” “would\,” “should\,” “target\,” “on track” or their negatives or variations\, and similar terminology and words of similar import\, generally involve future or forward-looking statements. Such forward-looking statements include\, but are not limited to\, statements relating to the expected outcome of Pulsenmore’s engagement with OUMA. Forward-looking statements reflect Pulsenmore’s current views\, plans\, or expectations with respect to future events or financial performance. They are inherently subject to significant business\, economic\, competitive\, and other risks\, uncertainties\, and contingencies. Forward-looking statements are based on Pulsenmore’s current expectations and are subject to inherent uncertainties\, risks and assumptions that are difficult to predict\, including\, but not limited to\, the following: the Company’s lack of operating history; the Company’s current and future capital requirements and the Company’s belief that its existing cash will be sufficient to fund its operations for more than one year from the date that the financial statements are issued; the Company’s ability to manufacture\, market and sell its products and to generate revenues; the Company’s ability to maintain its relationships with key partners and grow relationships with new partners; the Company’s ability to maintain or protect the validity of its U.S. and other patents and other intellectual property; the Company’s ability to launch and penetrate markets in new locations and new market segments; the Company’s ability to retain key executive members and hire additional personnel; the Company’s ability to maintain and expand intellectual property rights; interpretations of current laws and the passages of future laws; the Company’s ability to achieve greater regulatory compliance needed in existing and new markets; the Company’s ability to achieve key performance milestones in its planned operational testing; the Company’s ability to establish adequate sales\, marketing and distribution channels; security\, political and economic instability in the Middle East that could harm its business; and acceptance of the Company’s business model by investors. Further\, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. For a more detailed description of the risks and uncertainties affecting the Company\, reference is made to the Company’s reports filed from time to time with the SEC\, including\, but not limited to\, the risks\, uncertainties and other factors included in the Company’s Form 20-F (SEC File No. 001-43033)\, filed with the SEC on December 29\, 2025. The inclusion of forward-looking statements in this or any other communication should not be considered as a representation by Pulsenmore or any other person that current plans or expectations will be achieved. Forward-looking statements speak only as of the date on which they are made\, and Pulsenmore undertakes no obligation to publicly update or revise any forward-looking statement\, whether as a result of new information\, future developments\, or otherwise\, except as otherwise required by law.  \n  \nInvestor Contact:  \n  \nMiri Segal-Scharia  \nMS-IR LLC  \nmsegal@ms-ir.com 
URL:https://pulsenmore.com/event/biomed-israel-2025/
ATTACH;FMTTYPE=image/png:https://pulsenmore.com/wp-content/uploads/2025/03/14.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Asia/Jerusalem:20250516T080000
DTEND;TZID=Asia/Jerusalem:20250518T170000
DTSTAMP:20260625T173200
CREATED:20250320T125817Z
LAST-MODIFIED:20250320T125817Z
UID:40375-1747382400-1747587600@pulsenmore.com
SUMMARY:ACOG Annual Clinical & Scientific Meeting
DESCRIPTION:Pulsenmore Announces Strategic Partnership with Ouma Health to Expand Access to Remote Prenatal Care Across the United States  \nFDA-authorized home ultrasound technology to be integrated into Ouma Health’s virtual maternity care model\, creating a scalable pathway to expand the adoption of home ultrasound in prenatal care across the United States  \nRamat Gan\, Israel\, June 24\, 2026 /PRNewswire/ Pulsenmore Ltd. (NASDAQ\, TASE: PLSM)\, a pioneer in home ultrasound technology\, today announced a strategic partnership with Ouma Health\, a leading provider of virtual maternity care solutions in the United States.  \nThrough the collaboration\, Ouma Health will incorporate Pulsenmore’s FDA-authorized home ultrasound platform as part of its virtual maternity care platform\, enabling clinicians to extend prenatal ultrasound monitoring beyond the clinic and into patients’ homes while maintaining continuous connection between expectant mothers and their care teams throughout pregnancy.  \nFor Pulsenmore\, the agreement represents a significant expansion of its presence in the U.S. maternal health market and an opportunity to integrate its home ultrasound platform into an established virtual care model serving expectant mothers nationwide.  \n“Maternal healthcare is undergoing a fundamental transformation toward more connected\, patient-centered care models\,” said Dr. Elazar Sonnenschein\, Founder and CEO of Pulsenmore. “By partnering with Ouma Health\, we have an opportunity to bring ultrasound beyond the walls of the clinic and into established virtual maternity care pathways\, helping healthcare professionals expand access to prenatal monitoring while keeping patients at the center of care. With 35% of U.S. counties classified as maternal care deserts\, virtual care models combined with home ultrasound technology will play an important role in closing critical access gaps for expectant mothers.”  \n“At Ouma\, we care for patients who often face significant geographic and logistical barriers to prenatal care\, including those living in maternity deserts and underserved communities\,” said Dr. Sina Haeri\, CEO of Ouma Health. “Pulsenmore’s technology gives us a way to bring more of the prenatal monitoring experience into the home\, while keeping patients connected to a clinical team that can review the information and guide next steps. This partnership helps us make virtual maternity care more clinically complete\, especially for patients who cannot easily access specialty care in person.  \nMaternal health remains one of the most critical areas of healthcare delivery in the United States. As healthcare organizations look for ways to improve access\, patient engagement\, and care coordination\, home ultrasound is emerging as a meaningful component of virtual and hybrid prenatal care models.  \nThe collaboration aims to deliver transformative care for the most underserved patients and establish insights and experience to support future expansion opportunities with healthcare systems\, maternity care providers\, and payer organizations seeking innovative approaches for maternal health delivery. Home ultrasound has the potential to become an important part of the next generation of prenatal care\, helping healthcare providers expand access\, improve patient engagement\, and deliver more connected pregnancy care beyond traditional clinical settings.  \nAbout Pulsenmore  \nPulsenmore Ltd. is dedicated to revolutionizing maternal health through home-use ultrasound technology that connects mothers and healthcare providers remotely. By leveraging advanced imaging and telemedicine\, Pulsenmore makes prenatal care patient-centric\, expanding access and improving continuity of care. For more information\, visit www.pulsenmore.com  \n  \nAbout Ouma Health  \nOuma Health is the nation’s largest independent maternity telemedicine company\, providing comprehensive care from preconception through postpartum. Founded and run by maternal-fetal medicine specialists\, Ouma is committed to equity\, innovation\, and outcomes\, serving patients in all 50 states through partnerships with major payors\, health systems\, OB groups\, FQHCs\, reproductive agencies\, and employers. For more information\, visit www.oumahealth.com.  \n  \nThis press release contains forward-looking statements. In particular\, statements using words such as “may\,” “seek\,” “will\,” “consider\,” “likely\,” “assume\,” “estimate\,” “expect\,” “anticipate\,” “intend\,” “believe\,” “contemplate\,” “do not believe\,” “aim\,” “goal\,” “due\,” “predict\,” “plan\,” “project\,” “continue\,” “potential\,” “positioned\,” “guidance\,” “objective\,” “outlook\,” “trends\,” “future\,” “could\,” “would\,” “should\,” “target\,” “on track” or their negatives or variations\, and similar terminology and words of similar import\, generally involve future or forward-looking statements. Such forward-looking statements include\, but are not limited to\, statements relating to the expected outcome of Pulsenmore’s engagement with OUMA. Forward-looking statements reflect Pulsenmore’s current views\, plans\, or expectations with respect to future events or financial performance. They are inherently subject to significant business\, economic\, competitive\, and other risks\, uncertainties\, and contingencies. Forward-looking statements are based on Pulsenmore’s current expectations and are subject to inherent uncertainties\, risks and assumptions that are difficult to predict\, including\, but not limited to\, the following: the Company’s lack of operating history; the Company’s current and future capital requirements and the Company’s belief that its existing cash will be sufficient to fund its operations for more than one year from the date that the financial statements are issued; the Company’s ability to manufacture\, market and sell its products and to generate revenues; the Company’s ability to maintain its relationships with key partners and grow relationships with new partners; the Company’s ability to maintain or protect the validity of its U.S. and other patents and other intellectual property; the Company’s ability to launch and penetrate markets in new locations and new market segments; the Company’s ability to retain key executive members and hire additional personnel; the Company’s ability to maintain and expand intellectual property rights; interpretations of current laws and the passages of future laws; the Company’s ability to achieve greater regulatory compliance needed in existing and new markets; the Company’s ability to achieve key performance milestones in its planned operational testing; the Company’s ability to establish adequate sales\, marketing and distribution channels; security\, political and economic instability in the Middle East that could harm its business; and acceptance of the Company’s business model by investors. Further\, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. For a more detailed description of the risks and uncertainties affecting the Company\, reference is made to the Company’s reports filed from time to time with the SEC\, including\, but not limited to\, the risks\, uncertainties and other factors included in the Company’s Form 20-F (SEC File No. 001-43033)\, filed with the SEC on December 29\, 2025. The inclusion of forward-looking statements in this or any other communication should not be considered as a representation by Pulsenmore or any other person that current plans or expectations will be achieved. Forward-looking statements speak only as of the date on which they are made\, and Pulsenmore undertakes no obligation to publicly update or revise any forward-looking statement\, whether as a result of new information\, future developments\, or otherwise\, except as otherwise required by law.  \n  \nInvestor Contact:  \n  \nMiri Segal-Scharia  \nMS-IR LLC  \nmsegal@ms-ir.com 
URL:https://pulsenmore.com/event/acog-annual-clinical-scientific-meeting/
ATTACH;FMTTYPE=image/png:https://pulsenmore.com/wp-content/uploads/2025/03/13.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Asia/Jerusalem:20250513T080000
DTEND;TZID=Asia/Jerusalem:20250514T170000
DTSTAMP:20260625T173200
CREATED:20250506T074807Z
LAST-MODIFIED:20250506T074807Z
UID:41834-1747123200-1747242000@pulsenmore.com
SUMMARY:DHF 2025
DESCRIPTION:Pulsenmore Announces Strategic Partnership with Ouma Health to Expand Access to Remote Prenatal Care Across the United States  \nFDA-authorized home ultrasound technology to be integrated into Ouma Health’s virtual maternity care model\, creating a scalable pathway to expand the adoption of home ultrasound in prenatal care across the United States  \nRamat Gan\, Israel\, June 24\, 2026 /PRNewswire/ Pulsenmore Ltd. (NASDAQ\, TASE: PLSM)\, a pioneer in home ultrasound technology\, today announced a strategic partnership with Ouma Health\, a leading provider of virtual maternity care solutions in the United States.  \nThrough the collaboration\, Ouma Health will incorporate Pulsenmore’s FDA-authorized home ultrasound platform as part of its virtual maternity care platform\, enabling clinicians to extend prenatal ultrasound monitoring beyond the clinic and into patients’ homes while maintaining continuous connection between expectant mothers and their care teams throughout pregnancy.  \nFor Pulsenmore\, the agreement represents a significant expansion of its presence in the U.S. maternal health market and an opportunity to integrate its home ultrasound platform into an established virtual care model serving expectant mothers nationwide.  \n“Maternal healthcare is undergoing a fundamental transformation toward more connected\, patient-centered care models\,” said Dr. Elazar Sonnenschein\, Founder and CEO of Pulsenmore. “By partnering with Ouma Health\, we have an opportunity to bring ultrasound beyond the walls of the clinic and into established virtual maternity care pathways\, helping healthcare professionals expand access to prenatal monitoring while keeping patients at the center of care. With 35% of U.S. counties classified as maternal care deserts\, virtual care models combined with home ultrasound technology will play an important role in closing critical access gaps for expectant mothers.”  \n“At Ouma\, we care for patients who often face significant geographic and logistical barriers to prenatal care\, including those living in maternity deserts and underserved communities\,” said Dr. Sina Haeri\, CEO of Ouma Health. “Pulsenmore’s technology gives us a way to bring more of the prenatal monitoring experience into the home\, while keeping patients connected to a clinical team that can review the information and guide next steps. This partnership helps us make virtual maternity care more clinically complete\, especially for patients who cannot easily access specialty care in person.  \nMaternal health remains one of the most critical areas of healthcare delivery in the United States. As healthcare organizations look for ways to improve access\, patient engagement\, and care coordination\, home ultrasound is emerging as a meaningful component of virtual and hybrid prenatal care models.  \nThe collaboration aims to deliver transformative care for the most underserved patients and establish insights and experience to support future expansion opportunities with healthcare systems\, maternity care providers\, and payer organizations seeking innovative approaches for maternal health delivery. Home ultrasound has the potential to become an important part of the next generation of prenatal care\, helping healthcare providers expand access\, improve patient engagement\, and deliver more connected pregnancy care beyond traditional clinical settings.  \nAbout Pulsenmore  \nPulsenmore Ltd. is dedicated to revolutionizing maternal health through home-use ultrasound technology that connects mothers and healthcare providers remotely. By leveraging advanced imaging and telemedicine\, Pulsenmore makes prenatal care patient-centric\, expanding access and improving continuity of care. For more information\, visit www.pulsenmore.com  \n  \nAbout Ouma Health  \nOuma Health is the nation’s largest independent maternity telemedicine company\, providing comprehensive care from preconception through postpartum. Founded and run by maternal-fetal medicine specialists\, Ouma is committed to equity\, innovation\, and outcomes\, serving patients in all 50 states through partnerships with major payors\, health systems\, OB groups\, FQHCs\, reproductive agencies\, and employers. For more information\, visit www.oumahealth.com.  \n  \nThis press release contains forward-looking statements. In particular\, statements using words such as “may\,” “seek\,” “will\,” “consider\,” “likely\,” “assume\,” “estimate\,” “expect\,” “anticipate\,” “intend\,” “believe\,” “contemplate\,” “do not believe\,” “aim\,” “goal\,” “due\,” “predict\,” “plan\,” “project\,” “continue\,” “potential\,” “positioned\,” “guidance\,” “objective\,” “outlook\,” “trends\,” “future\,” “could\,” “would\,” “should\,” “target\,” “on track” or their negatives or variations\, and similar terminology and words of similar import\, generally involve future or forward-looking statements. Such forward-looking statements include\, but are not limited to\, statements relating to the expected outcome of Pulsenmore’s engagement with OUMA. Forward-looking statements reflect Pulsenmore’s current views\, plans\, or expectations with respect to future events or financial performance. They are inherently subject to significant business\, economic\, competitive\, and other risks\, uncertainties\, and contingencies. Forward-looking statements are based on Pulsenmore’s current expectations and are subject to inherent uncertainties\, risks and assumptions that are difficult to predict\, including\, but not limited to\, the following: the Company’s lack of operating history; the Company’s current and future capital requirements and the Company’s belief that its existing cash will be sufficient to fund its operations for more than one year from the date that the financial statements are issued; the Company’s ability to manufacture\, market and sell its products and to generate revenues; the Company’s ability to maintain its relationships with key partners and grow relationships with new partners; the Company’s ability to maintain or protect the validity of its U.S. and other patents and other intellectual property; the Company’s ability to launch and penetrate markets in new locations and new market segments; the Company’s ability to retain key executive members and hire additional personnel; the Company’s ability to maintain and expand intellectual property rights; interpretations of current laws and the passages of future laws; the Company’s ability to achieve greater regulatory compliance needed in existing and new markets; the Company’s ability to achieve key performance milestones in its planned operational testing; the Company’s ability to establish adequate sales\, marketing and distribution channels; security\, political and economic instability in the Middle East that could harm its business; and acceptance of the Company’s business model by investors. Further\, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. For a more detailed description of the risks and uncertainties affecting the Company\, reference is made to the Company’s reports filed from time to time with the SEC\, including\, but not limited to\, the risks\, uncertainties and other factors included in the Company’s Form 20-F (SEC File No. 001-43033)\, filed with the SEC on December 29\, 2025. The inclusion of forward-looking statements in this or any other communication should not be considered as a representation by Pulsenmore or any other person that current plans or expectations will be achieved. Forward-looking statements speak only as of the date on which they are made\, and Pulsenmore undertakes no obligation to publicly update or revise any forward-looking statement\, whether as a result of new information\, future developments\, or otherwise\, except as otherwise required by law.  \n  \nInvestor Contact:  \n  \nMiri Segal-Scharia  \nMS-IR LLC  \nmsegal@ms-ir.com 
URL:https://pulsenmore.com/event/dhf-2025/
ATTACH;FMTTYPE=image/jpeg:https://pulsenmore.com/wp-content/uploads/2025/03/DHF-2025.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Asia/Jerusalem:20250512T080000
DTEND;TZID=Asia/Jerusalem:20250517T170000
DTSTAMP:20260625T173200
CREATED:20250506T075232Z
LAST-MODIFIED:20250506T075232Z
UID:41836-1747036800-1747501200@pulsenmore.com
SUMMARY:CBGO 2025
DESCRIPTION:Pulsenmore Announces Strategic Partnership with Ouma Health to Expand Access to Remote Prenatal Care Across the United States  \nFDA-authorized home ultrasound technology to be integrated into Ouma Health’s virtual maternity care model\, creating a scalable pathway to expand the adoption of home ultrasound in prenatal care across the United States  \nRamat Gan\, Israel\, June 24\, 2026 /PRNewswire/ Pulsenmore Ltd. (NASDAQ\, TASE: PLSM)\, a pioneer in home ultrasound technology\, today announced a strategic partnership with Ouma Health\, a leading provider of virtual maternity care solutions in the United States.  \nThrough the collaboration\, Ouma Health will incorporate Pulsenmore’s FDA-authorized home ultrasound platform as part of its virtual maternity care platform\, enabling clinicians to extend prenatal ultrasound monitoring beyond the clinic and into patients’ homes while maintaining continuous connection between expectant mothers and their care teams throughout pregnancy.  \nFor Pulsenmore\, the agreement represents a significant expansion of its presence in the U.S. maternal health market and an opportunity to integrate its home ultrasound platform into an established virtual care model serving expectant mothers nationwide.  \n“Maternal healthcare is undergoing a fundamental transformation toward more connected\, patient-centered care models\,” said Dr. Elazar Sonnenschein\, Founder and CEO of Pulsenmore. “By partnering with Ouma Health\, we have an opportunity to bring ultrasound beyond the walls of the clinic and into established virtual maternity care pathways\, helping healthcare professionals expand access to prenatal monitoring while keeping patients at the center of care. With 35% of U.S. counties classified as maternal care deserts\, virtual care models combined with home ultrasound technology will play an important role in closing critical access gaps for expectant mothers.”  \n“At Ouma\, we care for patients who often face significant geographic and logistical barriers to prenatal care\, including those living in maternity deserts and underserved communities\,” said Dr. Sina Haeri\, CEO of Ouma Health. “Pulsenmore’s technology gives us a way to bring more of the prenatal monitoring experience into the home\, while keeping patients connected to a clinical team that can review the information and guide next steps. This partnership helps us make virtual maternity care more clinically complete\, especially for patients who cannot easily access specialty care in person.  \nMaternal health remains one of the most critical areas of healthcare delivery in the United States. As healthcare organizations look for ways to improve access\, patient engagement\, and care coordination\, home ultrasound is emerging as a meaningful component of virtual and hybrid prenatal care models.  \nThe collaboration aims to deliver transformative care for the most underserved patients and establish insights and experience to support future expansion opportunities with healthcare systems\, maternity care providers\, and payer organizations seeking innovative approaches for maternal health delivery. Home ultrasound has the potential to become an important part of the next generation of prenatal care\, helping healthcare providers expand access\, improve patient engagement\, and deliver more connected pregnancy care beyond traditional clinical settings.  \nAbout Pulsenmore  \nPulsenmore Ltd. is dedicated to revolutionizing maternal health through home-use ultrasound technology that connects mothers and healthcare providers remotely. By leveraging advanced imaging and telemedicine\, Pulsenmore makes prenatal care patient-centric\, expanding access and improving continuity of care. For more information\, visit www.pulsenmore.com  \n  \nAbout Ouma Health  \nOuma Health is the nation’s largest independent maternity telemedicine company\, providing comprehensive care from preconception through postpartum. Founded and run by maternal-fetal medicine specialists\, Ouma is committed to equity\, innovation\, and outcomes\, serving patients in all 50 states through partnerships with major payors\, health systems\, OB groups\, FQHCs\, reproductive agencies\, and employers. For more information\, visit www.oumahealth.com.  \n  \nThis press release contains forward-looking statements. In particular\, statements using words such as “may\,” “seek\,” “will\,” “consider\,” “likely\,” “assume\,” “estimate\,” “expect\,” “anticipate\,” “intend\,” “believe\,” “contemplate\,” “do not believe\,” “aim\,” “goal\,” “due\,” “predict\,” “plan\,” “project\,” “continue\,” “potential\,” “positioned\,” “guidance\,” “objective\,” “outlook\,” “trends\,” “future\,” “could\,” “would\,” “should\,” “target\,” “on track” or their negatives or variations\, and similar terminology and words of similar import\, generally involve future or forward-looking statements. Such forward-looking statements include\, but are not limited to\, statements relating to the expected outcome of Pulsenmore’s engagement with OUMA. Forward-looking statements reflect Pulsenmore’s current views\, plans\, or expectations with respect to future events or financial performance. They are inherently subject to significant business\, economic\, competitive\, and other risks\, uncertainties\, and contingencies. Forward-looking statements are based on Pulsenmore’s current expectations and are subject to inherent uncertainties\, risks and assumptions that are difficult to predict\, including\, but not limited to\, the following: the Company’s lack of operating history; the Company’s current and future capital requirements and the Company’s belief that its existing cash will be sufficient to fund its operations for more than one year from the date that the financial statements are issued; the Company’s ability to manufacture\, market and sell its products and to generate revenues; the Company’s ability to maintain its relationships with key partners and grow relationships with new partners; the Company’s ability to maintain or protect the validity of its U.S. and other patents and other intellectual property; the Company’s ability to launch and penetrate markets in new locations and new market segments; the Company’s ability to retain key executive members and hire additional personnel; the Company’s ability to maintain and expand intellectual property rights; interpretations of current laws and the passages of future laws; the Company’s ability to achieve greater regulatory compliance needed in existing and new markets; the Company’s ability to achieve key performance milestones in its planned operational testing; the Company’s ability to establish adequate sales\, marketing and distribution channels; security\, political and economic instability in the Middle East that could harm its business; and acceptance of the Company’s business model by investors. Further\, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. For a more detailed description of the risks and uncertainties affecting the Company\, reference is made to the Company’s reports filed from time to time with the SEC\, including\, but not limited to\, the risks\, uncertainties and other factors included in the Company’s Form 20-F (SEC File No. 001-43033)\, filed with the SEC on December 29\, 2025. The inclusion of forward-looking statements in this or any other communication should not be considered as a representation by Pulsenmore or any other person that current plans or expectations will be achieved. Forward-looking statements speak only as of the date on which they are made\, and Pulsenmore undertakes no obligation to publicly update or revise any forward-looking statement\, whether as a result of new information\, future developments\, or otherwise\, except as otherwise required by law.  \n  \nInvestor Contact:  \n  \nMiri Segal-Scharia  \nMS-IR LLC  \nmsegal@ms-ir.com 
URL:https://pulsenmore.com/event/cbgo-2025/
ATTACH;FMTTYPE=image/png:https://pulsenmore.com/wp-content/uploads/2025/05/Screenshot-2025-05-06-104918.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Asia/Jerusalem:20250508T080000
DTEND;TZID=Asia/Jerusalem:20250509T170000
DTSTAMP:20260625T173200
CREATED:20250506T074109Z
LAST-MODIFIED:20250506T074334Z
UID:41830-1746691200-1746810000@pulsenmore.com
SUMMARY:BMFMS
DESCRIPTION:Pulsenmore Announces Strategic Partnership with Ouma Health to Expand Access to Remote Prenatal Care Across the United States  \nFDA-authorized home ultrasound technology to be integrated into Ouma Health’s virtual maternity care model\, creating a scalable pathway to expand the adoption of home ultrasound in prenatal care across the United States  \nRamat Gan\, Israel\, June 24\, 2026 /PRNewswire/ Pulsenmore Ltd. (NASDAQ\, TASE: PLSM)\, a pioneer in home ultrasound technology\, today announced a strategic partnership with Ouma Health\, a leading provider of virtual maternity care solutions in the United States.  \nThrough the collaboration\, Ouma Health will incorporate Pulsenmore’s FDA-authorized home ultrasound platform as part of its virtual maternity care platform\, enabling clinicians to extend prenatal ultrasound monitoring beyond the clinic and into patients’ homes while maintaining continuous connection between expectant mothers and their care teams throughout pregnancy.  \nFor Pulsenmore\, the agreement represents a significant expansion of its presence in the U.S. maternal health market and an opportunity to integrate its home ultrasound platform into an established virtual care model serving expectant mothers nationwide.  \n“Maternal healthcare is undergoing a fundamental transformation toward more connected\, patient-centered care models\,” said Dr. Elazar Sonnenschein\, Founder and CEO of Pulsenmore. “By partnering with Ouma Health\, we have an opportunity to bring ultrasound beyond the walls of the clinic and into established virtual maternity care pathways\, helping healthcare professionals expand access to prenatal monitoring while keeping patients at the center of care. With 35% of U.S. counties classified as maternal care deserts\, virtual care models combined with home ultrasound technology will play an important role in closing critical access gaps for expectant mothers.”  \n“At Ouma\, we care for patients who often face significant geographic and logistical barriers to prenatal care\, including those living in maternity deserts and underserved communities\,” said Dr. Sina Haeri\, CEO of Ouma Health. “Pulsenmore’s technology gives us a way to bring more of the prenatal monitoring experience into the home\, while keeping patients connected to a clinical team that can review the information and guide next steps. This partnership helps us make virtual maternity care more clinically complete\, especially for patients who cannot easily access specialty care in person.  \nMaternal health remains one of the most critical areas of healthcare delivery in the United States. As healthcare organizations look for ways to improve access\, patient engagement\, and care coordination\, home ultrasound is emerging as a meaningful component of virtual and hybrid prenatal care models.  \nThe collaboration aims to deliver transformative care for the most underserved patients and establish insights and experience to support future expansion opportunities with healthcare systems\, maternity care providers\, and payer organizations seeking innovative approaches for maternal health delivery. Home ultrasound has the potential to become an important part of the next generation of prenatal care\, helping healthcare providers expand access\, improve patient engagement\, and deliver more connected pregnancy care beyond traditional clinical settings.  \nAbout Pulsenmore  \nPulsenmore Ltd. is dedicated to revolutionizing maternal health through home-use ultrasound technology that connects mothers and healthcare providers remotely. By leveraging advanced imaging and telemedicine\, Pulsenmore makes prenatal care patient-centric\, expanding access and improving continuity of care. For more information\, visit www.pulsenmore.com  \n  \nAbout Ouma Health  \nOuma Health is the nation’s largest independent maternity telemedicine company\, providing comprehensive care from preconception through postpartum. Founded and run by maternal-fetal medicine specialists\, Ouma is committed to equity\, innovation\, and outcomes\, serving patients in all 50 states through partnerships with major payors\, health systems\, OB groups\, FQHCs\, reproductive agencies\, and employers. For more information\, visit www.oumahealth.com.  \n  \nThis press release contains forward-looking statements. In particular\, statements using words such as “may\,” “seek\,” “will\,” “consider\,” “likely\,” “assume\,” “estimate\,” “expect\,” “anticipate\,” “intend\,” “believe\,” “contemplate\,” “do not believe\,” “aim\,” “goal\,” “due\,” “predict\,” “plan\,” “project\,” “continue\,” “potential\,” “positioned\,” “guidance\,” “objective\,” “outlook\,” “trends\,” “future\,” “could\,” “would\,” “should\,” “target\,” “on track” or their negatives or variations\, and similar terminology and words of similar import\, generally involve future or forward-looking statements. Such forward-looking statements include\, but are not limited to\, statements relating to the expected outcome of Pulsenmore’s engagement with OUMA. Forward-looking statements reflect Pulsenmore’s current views\, plans\, or expectations with respect to future events or financial performance. They are inherently subject to significant business\, economic\, competitive\, and other risks\, uncertainties\, and contingencies. Forward-looking statements are based on Pulsenmore’s current expectations and are subject to inherent uncertainties\, risks and assumptions that are difficult to predict\, including\, but not limited to\, the following: the Company’s lack of operating history; the Company’s current and future capital requirements and the Company’s belief that its existing cash will be sufficient to fund its operations for more than one year from the date that the financial statements are issued; the Company’s ability to manufacture\, market and sell its products and to generate revenues; the Company’s ability to maintain its relationships with key partners and grow relationships with new partners; the Company’s ability to maintain or protect the validity of its U.S. and other patents and other intellectual property; the Company’s ability to launch and penetrate markets in new locations and new market segments; the Company’s ability to retain key executive members and hire additional personnel; the Company’s ability to maintain and expand intellectual property rights; interpretations of current laws and the passages of future laws; the Company’s ability to achieve greater regulatory compliance needed in existing and new markets; the Company’s ability to achieve key performance milestones in its planned operational testing; the Company’s ability to establish adequate sales\, marketing and distribution channels; security\, political and economic instability in the Middle East that could harm its business; and acceptance of the Company’s business model by investors. Further\, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. For a more detailed description of the risks and uncertainties affecting the Company\, reference is made to the Company’s reports filed from time to time with the SEC\, including\, but not limited to\, the risks\, uncertainties and other factors included in the Company’s Form 20-F (SEC File No. 001-43033)\, filed with the SEC on December 29\, 2025. The inclusion of forward-looking statements in this or any other communication should not be considered as a representation by Pulsenmore or any other person that current plans or expectations will be achieved. Forward-looking statements speak only as of the date on which they are made\, and Pulsenmore undertakes no obligation to publicly update or revise any forward-looking statement\, whether as a result of new information\, future developments\, or otherwise\, except as otherwise required by law.  \n  \nInvestor Contact:  \n  \nMiri Segal-Scharia  \nMS-IR LLC  \nmsegal@ms-ir.com 
URL:https://pulsenmore.com/event/bmfms/
ATTACH;FMTTYPE=image/png:https://pulsenmore.com/wp-content/uploads/2025/03/12.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Asia/Jerusalem:20250501T080000
DTEND;TZID=Asia/Jerusalem:20250504T170000
DTSTAMP:20260625T173200
CREATED:20250320T125601Z
LAST-MODIFIED:20250320T125601Z
UID:40319-1746086400-1746378000@pulsenmore.com
SUMMARY:JPR 2025 55th Journada Paulista de Radiologia
DESCRIPTION:Pulsenmore Announces Strategic Partnership with Ouma Health to Expand Access to Remote Prenatal Care Across the United States  \nFDA-authorized home ultrasound technology to be integrated into Ouma Health’s virtual maternity care model\, creating a scalable pathway to expand the adoption of home ultrasound in prenatal care across the United States  \nRamat Gan\, Israel\, June 24\, 2026 /PRNewswire/ Pulsenmore Ltd. (NASDAQ\, TASE: PLSM)\, a pioneer in home ultrasound technology\, today announced a strategic partnership with Ouma Health\, a leading provider of virtual maternity care solutions in the United States.  \nThrough the collaboration\, Ouma Health will incorporate Pulsenmore’s FDA-authorized home ultrasound platform as part of its virtual maternity care platform\, enabling clinicians to extend prenatal ultrasound monitoring beyond the clinic and into patients’ homes while maintaining continuous connection between expectant mothers and their care teams throughout pregnancy.  \nFor Pulsenmore\, the agreement represents a significant expansion of its presence in the U.S. maternal health market and an opportunity to integrate its home ultrasound platform into an established virtual care model serving expectant mothers nationwide.  \n“Maternal healthcare is undergoing a fundamental transformation toward more connected\, patient-centered care models\,” said Dr. Elazar Sonnenschein\, Founder and CEO of Pulsenmore. “By partnering with Ouma Health\, we have an opportunity to bring ultrasound beyond the walls of the clinic and into established virtual maternity care pathways\, helping healthcare professionals expand access to prenatal monitoring while keeping patients at the center of care. With 35% of U.S. counties classified as maternal care deserts\, virtual care models combined with home ultrasound technology will play an important role in closing critical access gaps for expectant mothers.”  \n“At Ouma\, we care for patients who often face significant geographic and logistical barriers to prenatal care\, including those living in maternity deserts and underserved communities\,” said Dr. Sina Haeri\, CEO of Ouma Health. “Pulsenmore’s technology gives us a way to bring more of the prenatal monitoring experience into the home\, while keeping patients connected to a clinical team that can review the information and guide next steps. This partnership helps us make virtual maternity care more clinically complete\, especially for patients who cannot easily access specialty care in person.  \nMaternal health remains one of the most critical areas of healthcare delivery in the United States. As healthcare organizations look for ways to improve access\, patient engagement\, and care coordination\, home ultrasound is emerging as a meaningful component of virtual and hybrid prenatal care models.  \nThe collaboration aims to deliver transformative care for the most underserved patients and establish insights and experience to support future expansion opportunities with healthcare systems\, maternity care providers\, and payer organizations seeking innovative approaches for maternal health delivery. Home ultrasound has the potential to become an important part of the next generation of prenatal care\, helping healthcare providers expand access\, improve patient engagement\, and deliver more connected pregnancy care beyond traditional clinical settings.  \nAbout Pulsenmore  \nPulsenmore Ltd. is dedicated to revolutionizing maternal health through home-use ultrasound technology that connects mothers and healthcare providers remotely. By leveraging advanced imaging and telemedicine\, Pulsenmore makes prenatal care patient-centric\, expanding access and improving continuity of care. For more information\, visit www.pulsenmore.com  \n  \nAbout Ouma Health  \nOuma Health is the nation’s largest independent maternity telemedicine company\, providing comprehensive care from preconception through postpartum. Founded and run by maternal-fetal medicine specialists\, Ouma is committed to equity\, innovation\, and outcomes\, serving patients in all 50 states through partnerships with major payors\, health systems\, OB groups\, FQHCs\, reproductive agencies\, and employers. For more information\, visit www.oumahealth.com.  \n  \nThis press release contains forward-looking statements. In particular\, statements using words such as “may\,” “seek\,” “will\,” “consider\,” “likely\,” “assume\,” “estimate\,” “expect\,” “anticipate\,” “intend\,” “believe\,” “contemplate\,” “do not believe\,” “aim\,” “goal\,” “due\,” “predict\,” “plan\,” “project\,” “continue\,” “potential\,” “positioned\,” “guidance\,” “objective\,” “outlook\,” “trends\,” “future\,” “could\,” “would\,” “should\,” “target\,” “on track” or their negatives or variations\, and similar terminology and words of similar import\, generally involve future or forward-looking statements. Such forward-looking statements include\, but are not limited to\, statements relating to the expected outcome of Pulsenmore’s engagement with OUMA. Forward-looking statements reflect Pulsenmore’s current views\, plans\, or expectations with respect to future events or financial performance. They are inherently subject to significant business\, economic\, competitive\, and other risks\, uncertainties\, and contingencies. Forward-looking statements are based on Pulsenmore’s current expectations and are subject to inherent uncertainties\, risks and assumptions that are difficult to predict\, including\, but not limited to\, the following: the Company’s lack of operating history; the Company’s current and future capital requirements and the Company’s belief that its existing cash will be sufficient to fund its operations for more than one year from the date that the financial statements are issued; the Company’s ability to manufacture\, market and sell its products and to generate revenues; the Company’s ability to maintain its relationships with key partners and grow relationships with new partners; the Company’s ability to maintain or protect the validity of its U.S. and other patents and other intellectual property; the Company’s ability to launch and penetrate markets in new locations and new market segments; the Company’s ability to retain key executive members and hire additional personnel; the Company’s ability to maintain and expand intellectual property rights; interpretations of current laws and the passages of future laws; the Company’s ability to achieve greater regulatory compliance needed in existing and new markets; the Company’s ability to achieve key performance milestones in its planned operational testing; the Company’s ability to establish adequate sales\, marketing and distribution channels; security\, political and economic instability in the Middle East that could harm its business; and acceptance of the Company’s business model by investors. Further\, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. For a more detailed description of the risks and uncertainties affecting the Company\, reference is made to the Company’s reports filed from time to time with the SEC\, including\, but not limited to\, the risks\, uncertainties and other factors included in the Company’s Form 20-F (SEC File No. 001-43033)\, filed with the SEC on December 29\, 2025. The inclusion of forward-looking statements in this or any other communication should not be considered as a representation by Pulsenmore or any other person that current plans or expectations will be achieved. Forward-looking statements speak only as of the date on which they are made\, and Pulsenmore undertakes no obligation to publicly update or revise any forward-looking statement\, whether as a result of new information\, future developments\, or otherwise\, except as otherwise required by law.  \n  \nInvestor Contact:  \n  \nMiri Segal-Scharia  \nMS-IR LLC  \nmsegal@ms-ir.com 
URL:https://pulsenmore.com/event/jpr-2025-55th-journada-paulista-de-radiologia/
ATTACH;FMTTYPE=image/png:https://pulsenmore.com/wp-content/uploads/2025/03/11.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Asia/Jerusalem:20250418T080000
DTEND;TZID=Asia/Jerusalem:20250422T170000
DTSTAMP:20260625T173200
CREATED:20250320T134007Z
LAST-MODIFIED:20250320T134042Z
UID:40385-1744963200-1745341200@pulsenmore.com
SUMMARY:RANZCOG Annual Scientific Meeting 2025
DESCRIPTION:Pulsenmore Announces Strategic Partnership with Ouma Health to Expand Access to Remote Prenatal Care Across the United States  \nFDA-authorized home ultrasound technology to be integrated into Ouma Health’s virtual maternity care model\, creating a scalable pathway to expand the adoption of home ultrasound in prenatal care across the United States  \nRamat Gan\, Israel\, June 24\, 2026 /PRNewswire/ Pulsenmore Ltd. (NASDAQ\, TASE: PLSM)\, a pioneer in home ultrasound technology\, today announced a strategic partnership with Ouma Health\, a leading provider of virtual maternity care solutions in the United States.  \nThrough the collaboration\, Ouma Health will incorporate Pulsenmore’s FDA-authorized home ultrasound platform as part of its virtual maternity care platform\, enabling clinicians to extend prenatal ultrasound monitoring beyond the clinic and into patients’ homes while maintaining continuous connection between expectant mothers and their care teams throughout pregnancy.  \nFor Pulsenmore\, the agreement represents a significant expansion of its presence in the U.S. maternal health market and an opportunity to integrate its home ultrasound platform into an established virtual care model serving expectant mothers nationwide.  \n“Maternal healthcare is undergoing a fundamental transformation toward more connected\, patient-centered care models\,” said Dr. Elazar Sonnenschein\, Founder and CEO of Pulsenmore. “By partnering with Ouma Health\, we have an opportunity to bring ultrasound beyond the walls of the clinic and into established virtual maternity care pathways\, helping healthcare professionals expand access to prenatal monitoring while keeping patients at the center of care. With 35% of U.S. counties classified as maternal care deserts\, virtual care models combined with home ultrasound technology will play an important role in closing critical access gaps for expectant mothers.”  \n“At Ouma\, we care for patients who often face significant geographic and logistical barriers to prenatal care\, including those living in maternity deserts and underserved communities\,” said Dr. Sina Haeri\, CEO of Ouma Health. “Pulsenmore’s technology gives us a way to bring more of the prenatal monitoring experience into the home\, while keeping patients connected to a clinical team that can review the information and guide next steps. This partnership helps us make virtual maternity care more clinically complete\, especially for patients who cannot easily access specialty care in person.  \nMaternal health remains one of the most critical areas of healthcare delivery in the United States. As healthcare organizations look for ways to improve access\, patient engagement\, and care coordination\, home ultrasound is emerging as a meaningful component of virtual and hybrid prenatal care models.  \nThe collaboration aims to deliver transformative care for the most underserved patients and establish insights and experience to support future expansion opportunities with healthcare systems\, maternity care providers\, and payer organizations seeking innovative approaches for maternal health delivery. Home ultrasound has the potential to become an important part of the next generation of prenatal care\, helping healthcare providers expand access\, improve patient engagement\, and deliver more connected pregnancy care beyond traditional clinical settings.  \nAbout Pulsenmore  \nPulsenmore Ltd. is dedicated to revolutionizing maternal health through home-use ultrasound technology that connects mothers and healthcare providers remotely. By leveraging advanced imaging and telemedicine\, Pulsenmore makes prenatal care patient-centric\, expanding access and improving continuity of care. For more information\, visit www.pulsenmore.com  \n  \nAbout Ouma Health  \nOuma Health is the nation’s largest independent maternity telemedicine company\, providing comprehensive care from preconception through postpartum. Founded and run by maternal-fetal medicine specialists\, Ouma is committed to equity\, innovation\, and outcomes\, serving patients in all 50 states through partnerships with major payors\, health systems\, OB groups\, FQHCs\, reproductive agencies\, and employers. For more information\, visit www.oumahealth.com.  \n  \nThis press release contains forward-looking statements. In particular\, statements using words such as “may\,” “seek\,” “will\,” “consider\,” “likely\,” “assume\,” “estimate\,” “expect\,” “anticipate\,” “intend\,” “believe\,” “contemplate\,” “do not believe\,” “aim\,” “goal\,” “due\,” “predict\,” “plan\,” “project\,” “continue\,” “potential\,” “positioned\,” “guidance\,” “objective\,” “outlook\,” “trends\,” “future\,” “could\,” “would\,” “should\,” “target\,” “on track” or their negatives or variations\, and similar terminology and words of similar import\, generally involve future or forward-looking statements. Such forward-looking statements include\, but are not limited to\, statements relating to the expected outcome of Pulsenmore’s engagement with OUMA. Forward-looking statements reflect Pulsenmore’s current views\, plans\, or expectations with respect to future events or financial performance. They are inherently subject to significant business\, economic\, competitive\, and other risks\, uncertainties\, and contingencies. Forward-looking statements are based on Pulsenmore’s current expectations and are subject to inherent uncertainties\, risks and assumptions that are difficult to predict\, including\, but not limited to\, the following: the Company’s lack of operating history; the Company’s current and future capital requirements and the Company’s belief that its existing cash will be sufficient to fund its operations for more than one year from the date that the financial statements are issued; the Company’s ability to manufacture\, market and sell its products and to generate revenues; the Company’s ability to maintain its relationships with key partners and grow relationships with new partners; the Company’s ability to maintain or protect the validity of its U.S. and other patents and other intellectual property; the Company’s ability to launch and penetrate markets in new locations and new market segments; the Company’s ability to retain key executive members and hire additional personnel; the Company’s ability to maintain and expand intellectual property rights; interpretations of current laws and the passages of future laws; the Company’s ability to achieve greater regulatory compliance needed in existing and new markets; the Company’s ability to achieve key performance milestones in its planned operational testing; the Company’s ability to establish adequate sales\, marketing and distribution channels; security\, political and economic instability in the Middle East that could harm its business; and acceptance of the Company’s business model by investors. Further\, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. For a more detailed description of the risks and uncertainties affecting the Company\, reference is made to the Company’s reports filed from time to time with the SEC\, including\, but not limited to\, the risks\, uncertainties and other factors included in the Company’s Form 20-F (SEC File No. 001-43033)\, filed with the SEC on December 29\, 2025. The inclusion of forward-looking statements in this or any other communication should not be considered as a representation by Pulsenmore or any other person that current plans or expectations will be achieved. Forward-looking statements speak only as of the date on which they are made\, and Pulsenmore undertakes no obligation to publicly update or revise any forward-looking statement\, whether as a result of new information\, future developments\, or otherwise\, except as otherwise required by law.  \n  \nInvestor Contact:  \n  \nMiri Segal-Scharia  \nMS-IR LLC  \nmsegal@ms-ir.com 
URL:https://pulsenmore.com/event/ranzcog-annual-scientific-meeting-2025/
ATTACH;FMTTYPE=image/png:https://pulsenmore.com/wp-content/uploads/2025/03/19.png
END:VEVENT
END:VCALENDAR